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ePIDemIOlOGy aND aeTIOlOGy Of HumaN PaPIllOmaVIruS aND 
CerVICal CaNCer
Human papillomavirus is a common sexually transmitted infection. Estimates show that 
a majority of sexually active women are likely to acquire an HPV infection at some time 
in their lives (estimates ranging from 53% to 95%, depending on assumptions).1 HPV 
infections are associated with a range of both benign and malignant conditions, includ-
ing genital warts and premalignant lesions and cancers of the uterine cervix, anus, vulva, 
vagina, penis and oropharynx. There are more than 200 HPV types that infect humans 
registered by the International HPV Reference Center,2 with only some of these types 
being oncogenic. Twelve types of HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) 
are classified by the International Agency for Research on Cancer (IARC) as carcinogenic 
to humans.3 These types are referred to as high-risk HPV (hrHPV) in this thesis. HPV 16 
and 18 are responsible for the majority of cervical cancers, in the range of 70%.4
While hrHPV infection is responsible for almost all cervical cancers,5 6 not every 
person who is infected with hrHPV goes on to develop cervical dysplasia. HPV infects 
the epithelial layer of cells in the cervix.7 Most individuals infected with hrHPV have a 
transient infection that clear without the need for treatment. However, if an infection is 
not cleared, it can cause changes to the squamous and/or glandular cells of the uterine 
cervix; these are persistent and transforming infections. Transforming infections can 
cause progression to cervical intraepithelial neoplasia (CIN; see Figure 1). Changes to the 
cervix can be detected by cytological or histological examination. Low-grade squamous 
intraepithelial neoplasia (LSIL) refers to the first stage of changes to the cervix that can 
be observed on cytological material. The corresponding histological diagnosis is CIN 
1, with dysplasia limited to the lower third of the epithelium (Figure 1).8 High-grade 
intraepithelial neoplasia (HSIL) is a more serious type of lesion, with cell changes af-
fected more layers of the epithelium of the cervix. HSIL encompasses both CIN 2 and 
CIN 3 histological diagnoses, with CIN 3 is diagnosed when undifferentiated cells have 
replaced the full thickness of the epithelium.8 Cervical cancer occurs when the dysplastic 
cells break through the basement membrane and dermis of the cervix.
The risk of persistence, or of progression to CIN or cervical cancer, is influenced by 
a number of factors. Firstly, the type of HPV is the most important risk factor for trans-
formation. Infections with higher viral loads are more likely to be persistent.9 Women 
who are HIV positive have an increased risk of CIN and cervical cancer than women who 
are HIV negative.10 Higher parity and earlier age of first first-term pregnancy have been 
found to be associated with increased risk of cervical cancer.11 Behavioural risk factors 
include smoking,12 13 long-term oral contraceptive use,13 early age of sexual initiation 
and higher number of lifetime sexual partners.14
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Figure 1: Progression of disease from hrHPV infection to cervical cancer. Image modified from Crosbie et al.7
Of all the malignancies that hrHPV infections are associated with, cervical cancer has 
by far the highest global burden in terms of cancer incidence and mortality. Worldwide 
in 2018, cervical cancer had the third highest incidence (age standardised rate: 24.7 per 
100,000 women) and mortality (age standardised rate: 12.6 per 100,000 women) of all 
cancer types amongst women aged 25 to 74 years.15 Low- and middle-income countries 
bare the greatest burden of cervical cancer incidence and mortality.16 Incidence and 
mortality rates were much lower for the Netherlands (10.8 and 2.4 per 100,000 women, 
respectively).15 Although these numbers are favourable, this still translates per year to 
approximately 735 incident cervical cancer cases and 210 cervical cancer deaths, based 
on an average of data from the Netherlands Cancer Registry from 2010 to 2017.17
INTerVeNTIONS TO PreVeNT hrHPV INfeCTIONS aND CerVICal DySPlaSIa
Public health interventions for the prevention and control of cervical cancer are classified 
by the World Health Organisation (WHO) as either primary, secondary or tertiary18 (see 
Figure 2). Primary prevention strategies generally aim to reducing the incidence of new 
hrHPV infections. The most effective primary prevention strategy is vaccination of girls 
and boys against hrHPV prior to sexual debut, typically between ages 9 and 13 years. 
There are currently several hrHPV vaccines on the market that cover different hrHPV 
types, ranging from bivalent vaccines that provide protection against hrHPV 16 and 18 to 
nonavalent vaccines that provide protection against hrHPV 6, 11, 16, 18, 31, 33, 45, 52 and 
58. In several high-income countries, hrHPV vaccination of girls have been implemented 
for over a decade and reductions in the prevalence of HPV 16/1819 20 and CIN 2+ lesions21 
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have already been shown amongst partly vaccinated cohorts. A reduction in HPV preva-
lence in unvaccinated, heterosexual males has also been shown,22 suggesting that some 
level of cross-protection is provided to heterosexual males following the implementation 
of female-only vaccination programmes.23 Other primary interventions have also been 
shown to be somewhat effective in reducing hrHPV infections, such as consistent condom 
use,24 but results are mixed and consistent condom usage has been shown to be low.25
Secondary prevention strategies involve identifying women at risk of developing 
cervical cancer and treating lesions as appropriate. This can be achieved by screening 
of asymptomatic women. Treatments for cervical cancer are classified by the WHO as 
tertiary strategies. The remainder of this thesis will focus on secondary prevention of 
cervical cancer through screening.
Figure 2: Primary, secondary and tertiary cervical cancer prevention strategies and the impact by age. Image 
from World Health Organisation18
Screening for cervical cancer
The goal of cervical cancer screening programmes is to reduce morbidity and mortality 
from cervical cancer within the population. In order to reach this goal, programmes are 
designed to detect clinically significant premalignant lesions or early-stage cancers of the 
uterine cervix, and refer women with these lesions for treatment prior to progression to in-
vasive cervical cancer. For the purposes of monitoring and evaluation, clinically significant 
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lesions are either defined as CIN 2+ or CIN 3+, as the likelihood of these lesions persisting 
or progressing are higher than the likelihood of these lesions regressing (Table 1).26 27
Table 1: Suggested likelihoods of regression, persistence and progression of CIN lesions. Adapted from Arbyn et 
al.26 and Östör27
lesion grade regression Persistence Progression to CIN 3 Progression to invasive cancer
CIN 1 60% 30% 10% 1%
CIN 2 40% 40% 20% 5%
CIN 3 33% <55% – >12%
Screening can either be organised or opportunistic. An organised cervical cancer 
screening programme is characterised by the following qualities:28-30
•	 A	defined	programme	structure	driven	by	policies	that	specify	the	target	population,	
method and interval for screening and the screening pathway;




allow for monitoring and evaluation.
Juxtaposed to this, opportunistic screening involves ad hoc testing of women, rather 
than participation following invitation through a structured call-recall system.29 30 The 
European Guidelines for Quality Assurance for Cervical Cancer Screening recommend 
population-based, organised programmes are implemented and discourage opportu-
nistic screening.26
Prior to the implementation of organised cancer screening programmes, trials are 
usually conducted to estimate the impact of screening on morbidity and mortality 
and whether the benefit of screening outweigh the risks on a population level. Trials of 
cytology-based cervical cancer screening were not conducted prior to implementation, 
so there are no trial estimates available for the impact of cervical cancer screening on 
the incidence of, and mortality from, cervical cancer. However, results from observa-
tional studies conducted in Europe suggest that organised cervical cancer screening 
programmes are associated with reduced mortality from cervical cancer.31
While all cervical cancer screening programmes have the same goal, the combination 
of different factors used to define a programme, such as test type, screening interval, start 
and end age and triage algorithms, differs widely between countries. How a particular 
country or region decides which combination of strategies to use depends on the priori-
ties, available budgets, capacity and infrastructure as well as different acceptability of risk.
Chapter 1 15
General introduction
THe DuTCH CerVICal CaNCer SCreeNING PrOGramme
History of screening in the Netherlands
Organised cervical cancer screening began in the Netherlands in 1976 with a wide-
spread pilot of cytology screening. Nationwide screening began in the 1980’s, off ering 
cytology-based screening to women aged 35 to 53 years every three years.32 Over 
time, the age range and screening interval were changed based on cost-eff ectiveness 
research, with screening of women aged 30 to 60 years every fi ve years becoming the 
standard protocol.33 Several changes were implemented over the years to the cytology-
based screening programme including the introduction of liquid-based cytology34-36 
and hrHPV co-testing for women who were triaged.37 By 2016, most screening was 
conducted using either SurePath and ThinPrep liquid-based cytology mediums and 84% 
of triaged women were co-tested for hrHPV at their control cytology six months after 
Figure 3: Referral pathways in the Dutch Cervical Screening Programme from 1996 to 2016
NB. Pathways including hrHPV triage were introduced later than 1996.
NILM: Negative for intraepithelial lesion or malignancy




primary screening.38 The referral and triage algorithm for the cytology-based screening 
programme can be found in Figure 3.
Transition to hrHPV-based screening
In 2017, the Netherlands became the first country in the world to introduce a nationwide 
hrHPV-based cervical cancer screening programme. The switch to hrHPV-based screen-
ing was based on advice from the Dutch Health Council, published in 2011.39 HrHPV 
screening has been shown to provide better protection against cervical cancer, due to 
higher sensitivity for CIN 2+ lesions,40 thus making it a suitable alternative to primary 
cytology-based screening. Primary hrHPV-based screening had been extensively studied 
in the Netherlands, with various studies and trials conducted to assess the performance 
of hrHPV testing in the Dutch screening-eligible population. The POBASCAM trial found 
that, compared to cytology-based screening, primary hrHPV-based screening resulted 
in earlier detection of CIN 3+ lesions,41 better protection against CIN 3+ lesions in sub-
sequent screening rounds42 and found that a negative hrHPV primary screening result 
was followed by a lower cumulative risk of CIN 3+ lesions over 14 years.43 These findings 
supported the implementation of primary hrHPV-based screening in the Netherlands, 
with an extension of the screening interval for hrHPV negative women at age 40 and 50 
years. Results from POBASCAM were also in line with other international trials.44 The pos-
sibility of including self-sampling in a hrHPV-based programme was also studied, with 
the IMPROVE trial showing that the self-sampling was non-inferior to clinician-collected 
sampling in terms of CIN 2+ sensitivity and specificity.45
Prior to implementation of the programme, cost-effectiveness analysis found that, 
in comparison to the cytology-based programme, hrHPV-based screening would be 
13–15% more effective and would reduce costs of both the screening programme (ap-
proximately 35% lower) and the total societal costs of screening, including diagnostic 
and treatment costs (approximately 20% lower).46
Transition to HPV-based cervical cancer screening involved the following changes to 





for women who test hrHPV-negative at age 40 and 50 years.
The triage and referral algorithm was also modified, with women with hrHPV positive, 
ASC-US or higher screen results being directly referred for colposcopy (Figure 4).
In addition to the recommended changes, there was a consolidation of pathology 
laboratories that perform testing of primary screening samples from approximately 40 
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labs in the old cytology-based programme to fi ve labs in the new hrHPV-based screen-
ing programme. There were several reasons for the reduction in the number of labora-
tories, including maintaining the quality of cytology interpretation. Consolidation of the 
processing of screening programme tests was also more effi  cient in terms of costs due 
to economies of scale. The implementation of the hrHPV-based programme provided 
an appropriate moment to consolidate these services to one laboratory per screening 
organisation (there are fi ve screening organisations across the country; see Figure 5).
Starting in January 2017, these changes were gradually rolled out by screening region 
over the fi rst quarter of 2017. By April 2017, all screening regions were sending invitations 
in the new programme. With the change from cytology-based to hrHPV-based screening, 
the policy for inviting women was changed, with the regional screening organisations 
sending all invitations in a standard manner; women were all invited after their birthday 
in the year they were eligible for invitation. In the cytology-based programme, invita-
tions were either sent by the regional screening organisation, general practices or using a 
combined approach. The timing of the invitation also varied depending on which organi-
sation sent the invitation; some invitations were sent at the start of the year that women 
would become eligible to participate and some were sent after the women’s birthdate.
Figure 4: Referral pathways within the Dutch Cervical Screening Programme from 2017
NILM: Negative for intraepithelial lesion or malignancy
ASC-US+: Atypical squamous cells of undetermined signifi cance or higher
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Primary HPV screening and self-testing
Women invited for screening in the Dutch programme are able to choose between hav-
ing a sample taken by their GP or by requesting a self-sampling device using their digital 
identification number (DigiD), which is linked to their social security number (burgerser-
vicenumber, BSN). All tests within the new screening programme were selected via a 
tendering process run by the Dutch Institute for Public Health and the Environment 
(Rijksinstituut voor Volksgezondheid en Milieu, RIVM).
Clinician-collected samples are collected in 20mL ThinPrep medium (Hologic, Marl-
borough, United States), transported and stored at room temperature until processed 
in the laboratory. The Evalyn® Brush (Rovers Medical Devices, Oss, the Netherlands) is 
used for self-sampling. The self-collected brushes are sent to the laboratories by regular 
mail. The brush of the self-sampling device is transferred into 20mL of ThinPrep medium 
prior to hrHPV testing. All laboratories used the Cobas® 4800 HPV test (Roche Molecular 
Systems, Inc, Branchburg, NJ, USA). The Cobas® 4800 HPV test is a CE in vitro diagnostic 
(IVD) certified kit (for clinician-collected cervical scraps only) for use in combination with 
the Cobas® 4800 system for nucleic acid extraction, PCR setup, real-time PCR amplifica-
tion and result analysis. As part of the assay procedure, each sample is also tested for the 
presence of human cells by amplification of the human beta-globin gene.
Reflex cytology is performed on hrHPV positive clinician-collected samples. For hrHPV 
positive self-samples, women are contacted and asked to make an appointment with 
their GP for reflex cytology. The results of reflex cytology determine whether a woman is 
directly referred for colposcopy or invited to return for a repeat cytology test six months 
after primary screening.
Classification of cytology tests within the programme
Since 1996, cytology smears in the Netherlands have been classified according to the 
CISOE-A system.47 This system requires pathologists to grade cytological findings on six 
domains to describe composition and morphology of the cytology slide: Composition, 
Inflammation, Squamous, Other and endometrium, endocervical cylindrical epithelium 
and adequacy. This information is then used to provide advice about potential follow-
up screening or referral from the programme, and can be used to inform gynaecologists 
about the origin and severity of dysplasia upon referral. Implementation of the CISOE-
A system led to a reduction in borderline smears,47 and consequently a reduction in 
the number of screens with repeat advice.48 The CISOE-A system can be converted to 
alternative grading systems, such as the Bethesda and Pap classification systems. The 
concordance between these systems is summarised in Table 2.
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Diagnosis and treatment of CIN following referral
Once referred from screening, women undergo colposcopy and possibly receive di-
agnostic or therapeutic interventions. Biopsies can be taken from the transformation 
zone, taking one or more samples to be analysed for a histological diagnosis. While there 
are multiple options for treatment of CIN lesions including excisional, destructive and 
medicinal interventions, large loop excision of the transformation zone (LLETZ) is most 
commonly used in the Netherlands. There are two main treatment strategies for women 
referred for colposcopy: expectant management or see-and-treat management. Women 
under expectant management receive diagnostic biopsy at the initial colposcopy. The 
results of the initial biopsy and visual inspection of the cervix help direct the manage-
ment plan for the patient. In see-and-treat management, women are provided curative 
treatment as part of the initial colposcopy. See-and-treatment management can provide 
several potential benefits, including reducing loss to follow up, convenience for women 
and lower costs. However, the higher risks of overtreatment mean that the use of see-
and-treat management should be limited to women with both high-grade cytology and 
high-grade colposcopic image.50
Consensus-based guidelines for the diagnosis and treatment of CIN following referral 
have been developed by experts in the field and are authorised by Dutch Professional 
Table 2: Concordance between CISOE-A, Pap and Bethesda grading systems. Adapted from Oncoline49
CISOe-a Papanicolaou (Pap) bethesda 2001
C0 Pap 0 Inadequate
S1, O1-2*, E1-2# Pap 1 Negative for intraepithelial lesion or malignancy (NILM)
# E2: no endocervical cells
* O2: atrophy
S2-3, O3 Pap 2 Atypical squamous cells of undetermined significance (ASC-US)
E3 Pap 2 Atypical glandular cells (AGC), endocervical origin
E4-5 Pap 3a1 AGC, endocervical origin
(E4 low grade, E5 intermediate grade)
S4 Pap 3a1 Low-grade squamous intraepithelial lesion (LSIL)
S5 Pap 3a2 High-grade squamous intraepithelial lesion (HSIL)
O4-5 Pap 3a2 AGC, endometrial origin
E6, O6 Pap 3b AGC, E6 high grade neoplasia
S6 Pap 3b HSIL (*ASC-H)
E7 Pap 4 Adenocarcinoma in situ (AIS).
(Used interchangeable with E6)
S7 Pap 4 Carcinoma in situ
(Used interchangeable with S6)
S9, O7-9, E9 Pap 5 Invasive carcinoma
S1, E1-5, O1-3 in 
combination with EX 15
Pap 3a2 Atypical squamous cells, HSIL cannot be ruled out (ASC-H)
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Associations for Obstetrics and Gynaecology, Pathology and Medical Microbiology, in 
cooperation with the Dutch Professional Association for General Practitioners and the 
Dutch Patient Federation. These guidelines were updated in 2015 and provide guidance 
to medical practitioners about prevention, screening, diagnosis and treatment of CIN 
and other HPV-associated lesions of the female genital tract (adenocarcinoma in situ 
and vaginal intraepithelial neoplasia).51 The guidelines provide the following advice 
about the treatment of CIN lesions:
•	 In	principle,	CIN 1 lesions should not be treated. In the case of persistent low-grade 
cytology outside of reproductive age, treatment options may be discussed with the 
patient.
•	 For	CIN 2 lesions, individual assessment is required, particularly in younger women, 
weighting up the risks and benefits of treatment. If treatment is offered, LLETZ is 
recommended.
•	 CIN 3 lesions should always be treated. Women with high-grade cytology (moder-
ate dyskaryosis/dysplasia or worse) and colposcopy are eligible for see-and-treat 
management. LLETZ is the recommended treatment modality.
The 2015 guidelines provided more stringent advice about the treatment of CIN 2 le-
sions than in the previous version of the guidelines.52 For women who wish to become 
pregnant, the harms of excisional treatments of pre-malignant lesions, including 
increased risk of pre-term birth, premature rupture of the membranes, low birth weight, 
and perinatal mortality,53-56 may outweigh the benefits of treatment of CIN 2 lesions.
Governance of the Dutch Cervical Cancer Screening Programme
The RIVM has responsibility for the governance and coordination of the national screen-
ing programme. The RIVM also provides all communication materials for the screening 
programme and is responsible for managing the monitoring and evaluation of the 
programme. In practice, monitoring and evaluation of the programme is conducted by 
independent researchers at external organisations. Regional screening organisations 
are responsible for the implementation of the screening programme in practice, includ-
ing sending invitations to eligible women and communicating results with them. Over 
the years, the number of regional screening organisations have been consolidated from 
12 organisations to five (Figure 5).
monitoring and evaluation of the Programme
Monitoring provides regular oversight and feedback about performance of the screen-
ing programme to stakeholders, based on a pre-specified list of indicators using rou-
tinely collected data.58 Evaluation serves a different purpose, using in-depth analysis on 
particular research questions to provide information about impact and effectiveness 
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of programme- or policy changes.59 Both monitoring and evaluation are needed for 
ensuring quality and safety in the screening programme. Monitoring and evaluation are 
commonly used in health services research to manage the quality and performance of 
health services, to identify areas for improvement and as a signalling tool for programme 
managers and policy makers when performance of a health service is not as optimal as 
it should be.
Data required for monitoring and evaluation
For eff ective monitoring and evaluation, high quality, timely and accessible data is 
required.60 The nationwide network and registry of histo- and cytopathology in the 
Netherlands (PALGA Foundation) has provided data for monitoring and evaluation of 
the Dutch cervical screening programme for more than 20 years. PALGA has complete 
coverage of all pathology laboratories in the Netherlands and compiles information 
from all cytological and histological examinations into a centralised databank.61 Moni-
toring of the programme is partly conducted using an extract of all cervical cytology and 
histology records from PALGA This extract is processed using a SAS program that has 
been specifi cally developed for the purposes of monitoring and evaluation (PALEBA). 
Figure 5: Regional screening organisations in the Netherlands. Image from Bevolkingsonderzoek Nederland57
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Screening histories from individual women can be followed in PALEBA thanks to a pseud-
onymised personal identifi er. This personal identifi er is created using the eight letters 
of a woman’s surname and their date of birth. For more detailed evaluation questions, 
other data sources are available for linkage with PALEBA, including information about 
cancer diagnoses from the Netherlands Cancer Registry, information about invitations 
from the regional screening organisations and information about socio-economic vari-
ables from Statistics Netherlands. In the hrHPV-based screening programme, monitor-
ing is also conducted using data extracts from ScreenIT, an ICT system which records all 
invitations, reminders and participation (amongst other information). The use of these 
datasets, including data from PALGA, is subject to approval of the data owners.
SCreeNING aS a PrOCeSS
Cervical cancer screening programmes operate as a process,62 involving the women 
invited for screening, screening organisations, the RIVM and clinical care providers, in-
cluding GPs (and in some practices, physician assistants), pathologists, cytotechnicians 
and gynaecologists (see Figure 6). From the perspective of the organisations involved, 
the delineation of responsibilities and funding is clear; the RIVM and regional screening 
organisations are responsible for the fi rst half of the screening process (blue section 
Figure 6) and at the point of referral, screening transitions to clinical care, with the 
management of care becoming the responsibility of the gynaecologists and costs being 
covered by health insurance companies (orange section Figure 6).
However, from the perspective of women participating in screening, the process 
of screening involves a continuous course of care, moving from the care of the GP to 
specialist care if required, without division between what is managed and funded by dif-
ferent parties. Without a national screening programme, many women who are referred 
to the gynaecologist would not have ended up in clinical care. Understanding outcomes 
for women across all stages of the screening programme is necessary to get a complete 
view of performance and cost-eff ectiveness of the programme.
Figure 6: Stages within cervical cancer screening programmes. Adapted from Anhang Price et al62 and the RIVM63
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aImS Of THIS THeSIS
This thesis aims to evaluate the Dutch cervical cancer screening programme as a whole 
(Part 2), as well as each stage of the screening process: attendance (Part 3), test and 
referral (Part 4) and clinical care (Part 5). In particular, this thesis will focus on the 
transition from cytology-based screening to hrHPV-based screening. The thesis aims to 
answer the following questions:
Part 2: Overall screening process
Following the initial implementation of the programme and monitoring of the overall 
process of screening, specific questions were raised about aspects of the new pro-
gramme that were not performing as expected or were not optimal. Specifically, it was 
critical to understand if the programme was performing as expected and how the new 
screening programme performed in comparison to the old cytology-based screening 
programme.
1. What was the impact of implementation of the hrHPV-based screening programme on 
short-time programme indicators? (Chapter 2.1)
Cost-effectiveness analyses that was performed prior to the implementation of the 
new programme found that hrHPV-based screening was more cost-effective than 
cytology-based screening. However, these estimates were based on assumptions from 
the literature. With information from the new programme now available, it was of inter-
est whether the hrHPV-based programme was still considered more cost-effective than 
cytology-based screening.
2. Is the new hrHPV programme still considered to be more cost-effective than the cytology-
based screening when using the results of the first year of the hrHPV-based screening 
programme to calculate cost-effectiveness? (Chapter 2.2)
Part 3: attendance
Short-term monitoring of the new hrHPV-based programme found that participation 
in the new programme was lower than the old cytology-based programme. This was 
unexpected, especially given the availability of self-sampling. It is unclear if the new 
programme was reaching a different population group than the old cytology-based pro-
gramme. Furthermore, the centralisation of the invitation system meant that changes 
were made to which organisations could send out invitations.
3. What factors (both personal and organisational) are related to attendance, and which 




Part 4: Test and referral
Test
In the new hrHPV-based screening programme, all cytology slides that are examined by 
cytotechnicians and pathologists are hrHPV positive. Previous research has indicated 
that, when the professional reading the slide is aware of its hrHPV status, there is a 
upward bias in the rating of the slide. Whether this was likely to happen in the Dutch 
setting was unknown.
4. Are ratings of cytology slides by cytotechnicians influenced by the knowledge of hrHPV 
status? (Chapter 4.1)
Referral
Given the high number of unnecessary referrals from the new hrHPV-based screening 
programme, optimisation of the triage algorithm may be required to minimise potential 
harms from unnecessary referrals. Any new triage algorithm would need to reduce these 
referrals with little to no impact on cervical cancer incidence and mortality and be easy 
to implement within the current laboratory procedures.
5. What are the options for optimising the triage algorithm of the hrHPV-based screening 
programme within the current parameters of the programme? (Chapter 4.2)
Atypical glandular cells (AGC) are a rare but high-risk cytological abnormality. Evidence 
suggests that women with AGC are at higher risk of cervical and other gynaecological 
cancers. In the old-cytology-based programme, depending on the severity of the abnor-
mality, some women with AGC smears were advised to have repeat cytology rather than 
a direct referral. The risk of a cancer diagnosis in these groups has not been investigated 
previously using Dutch data.
6. What is the risk of cervical and other gynaecological cancers following AGC on cervi-
cal cytology and is this higher than the risk following squamous cell abnormalities of 
comparable severity? (Chapter 4.3)
Part 5: Diagnosis and treatment
Despite the fact that women are referred as a direct consequence of the screening pro-
gramme and the risks associated with overtreatment following cervical screening, there 
is little evidence about adherence to the published CIN treatment guidelines. If there 
are gaps between the guidelines and current clinician practice, these could be used to 
identify areas for potential improvement.
7. What are the trends in CIN management and treatment following referral following the 




The final part of this thesis (Part 6) will summarise the findings from Parts 2 to 5 as well as 
propose potential changes to the Dutch cervical cancer screening programme (Chapter 
6.2). Potential improvements to the monitoring and evaluation of the programme by im-
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In January 2017, the Dutch cervical cancer screening programme transitioned from 
cytomorphological to primary high-risk HPV DNA (hrHPV) screening, including the in-
troduction of self-sampling, for women aged between 30 and 60 years. The Netherlands 
was the first country to switch to hrHPV screening at the national level. We investigated 
the health impact of this transition by comparing performance indicators from the new 
hrHPV-based programme with the previous cytology-based programme.
methods
We obtained data from the Dutch nationwide registry of histo- and cytopathology (PALGA) 
for 454,573 women eligible for screening in 2017 who participated in the hrHPV-based pro-
gramme between 1 January 2017 and 30 June 2018 (maximum follow-up of almost 21 months) 
and for 483,146 women eligible for screening in 2015 who participated in the cytology-based 
programme between 1 January 2015 and 31 March 2016 (maximum follow-up of 40 months). 
We compared indicators of participation (participation rate), referral (screen positivity; referral 
rate) and detection (CIN detection; number of referrals per detected CIN lesion).
results
Participation in the hrHPV-based programme was significantly lower than in the cytol-
ogy-based programme (61% vs. 64%). Screen positivity and direct referral rates were 
significantly higher in the hrHPV-based programme (positivity rate: 5% vs 9%; referral 
rate: 1% vs 3%). CIN2+ detection increased from 11 to 14 per 1,000 women screened. 
Overall, approximately 2.2 times more clinical irrelevant findings (i.e. ≤ CIN1) were found 
in the hrHPV-based programme, compared with approximately 1·3 times more clinically 
relevant findings (i.e. CIN2+); this difference was mostly due to a national policy change 
recommending colposcopy, rather than observation, of hrHPV-positive, ASC-US/LSIL 
results in the hrHPV-based programme.
Conclusions
This is the first time that comprehensive results of nationwide implementation of hrHPV-
based screening have been reported using high-quality data with a long follow-up. We 
have shown that both benefits and potential harms are higher in one screening round 
of a well-implemented hrHPV-based screening programme than in an established 
cytology-based programme. Lower participation in the new hrHPV programme may 
be due to factors such as invitation policy changes and the phased roll-out of the new 
programme. Our findings add further to evidence from trials and modelling studies on 
the effectiveness of hrHPV-based screening.
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baCKGrOuND
Primary hrHPV DNA screening, evaluated in clinical trials, has been shown to be more 
effective and cost-effective than cytology screening for the detection of pre-malignant 
and malignant cervical lesions.1,2 Following advice from the Dutch Health Council3 and 
a feasibility study by the Dutch National Institute for Public Health and the Environ-
ment (RIVM),4 primary high-risk HPV (hrHPV) screening replaced cytology screening in 
the Dutch national cervical cancer screening programme in January 2017. Each of the 
five regional screening organisations implemented hrHPV-based screening sequentially 
during the first quarter of 2017 and by April 2017, the national implementation was 
complete. Women can choose either to have a cervical smear taken by their general prac-
titioner (GP) or to use a self-sampling kit.5 Laboratory testing of screening programme 
samples is performed in five dedicated screening laboratories.
As part of the initial feasibility study, modelling analysis was conducted assessing the 
costs and effects of implementing primary hrHPV-based screening in the Netherlands.4 
Recent modelling estimated that nationwide implementation of primary hrHPV-based 
screening was expected to reduce cervical cancer diagnoses by 13% and related 
deaths by 15% compared with cytology-based screening, while also reducing overall 
programme costs.6
The success of a screening programme depends on the implementation of well-de-
fined protocols and guidelines.7 Screening programmes should be regularly monitored 
using high-quality data for quality assurance, to evaluate effectiveness and to identify 
potential harms.8 Although results from the implementation of primary hrHPV screening 
in Italy and Turkey have been published,9,10 these data lack robust results on detection 
of CIN lesions and do not compare the performance of hrHPV screening with cytology-
based screening. Results from the Italian programme were also limited to a number of 
regions. Comprehensive results from the implementation of a nationwide hrHPV screen-
ing programme have yet to be published.
Data from the nationwide network and registry of histo- and cytopathology (PALGA) 
has enabled regular, high-quality monitoring of organised cervical cancer screening in 
the Netherlands for many years. This comprehensive dataset has national coverage11 
enabling us to assess the impact of cervical cancer screening programme policies on 
a national level. In order to evaluate the performance of the new primary hrHPV-based 
screening programme, we aimed to compared outcomes of the first year of the new 





The cytology-based Dutch cervical screening programme
Until the end of 2016, the Dutch cervical cancer screening programme used cytology 
as the primary screening test. Women were invited to make an appointment for screen-
ing with their GP every five years from ages 30 to 60. Women could choose to opt-out 
of screening either temporarily (in the case of pregnancy, illness or other short-term 
reason) or indefinitely (in the case of hysterectomy or non-medical reasons such as 
conscientious objection).
There were various referral pathways in the cytology-based programme, depending 
on the result of primary cytology screening (Figure 1a). Direct referrals for colposcopy 
were given to women with high-grade cervical cytological abnormalities (high-grade 
squamous intraepithelial lesion (HSIL)) at primary screening. If women had low-grade 
cervical cytological abnormalities (atypical squamous cells of undetermined significance 
(ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at primary screening, they 
were advised to make an appointment with their GP after six months for a follow-up 
smear. For women advised to have a follow-up cytology at six months, hrHPV triage 
was used in some cases, depending on the policy of the laboratory performing the test. 
Referral advice was given to women at the six month screening who had the following 
result: a) ASC-US or higher (when no hrHPV triage was performed) or, in the case of 
hrHPV triage, b) ASC-US/LSIL and hrHPV-positive or c) HSIL. Further repeat testing at 
18 months was advised for women with cytology negative for intraepithelial lesion or 
malignancy (NILM) when no hrHPV triage was used or for NILM, hrHPV-positive results 
or ASC-US/LSIL, hrHPV negative results. When hrHPV triage testing at six months was 
used, women were referred back for routine screening if they were hrHPV-negative and 
cytology negative. All women with ASC-US+ cytology at 18 months were referred.
The hrHPV-based Dutch cervical screening programme
Primary hrHPV screening was implemented in the Netherlands on 1 January 2017 
(Figure 1b), replacing the cytology-based programme. Women are invited to participate 
by their regional screening organisation every five years between the ages of 30 and 
60, with some exceptions based on hrHPV positivity in the previous screening round; 
women with a negative hrHPV test result at age 40 or 50 are invited for screening after 
ten years instead of five and women who test hrHPV-positive at age 60 are invited for 
final screening at age 65. Women who do not wish to have a cervical sample taken at 
their GP can request a self-sampling kit. If requested at primary invitation, women were 
sent the self-sampling kit approximately four months after the initial invitation letter. 
Non-responders received a reminder letter four months after the initial invitation, which 
also contained information about how to request the self-sampling kit. Women who 
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requested the self-sampling kit after this reminder received it immediately. Refl ex cytol-
ogy was immediately performed on hrHPV-positive GP-collected samples. As cytology 
on self-sampled cervicovaginal material is unreliable,12,13 women with an hrHPV-positive 
result on self-sampling were invited to have a cytological smear taken by their GP.
The referral algorithm in the hrHPV-based programme was simplifi ed. HrHPV-positive 
women with cytological abnormalities (i.e. ASC-US or worse) were referred for colpos-
copy, while hrHPV-positive women with normal cytology were invited for repeat cytol-
ogy testing after six months.
Organisational and policy diff erences between the two programmes
In the Netherlands, there are fi ve regional screening organisations responsibility for the 
implementation of the screening programme. With the change from cytology-based to 
hrHPV-based screening, the policy for inviting women was changed, with the regional 
screening organisations sending all invitations in a standard manner; women were all 
Figure 1a: Screening protocol cytology-based screening programme
NILM: Negative for intraepithelial lesion or malignancy
ASC-US: Atypical squamous cells of undetermined signifi cance
LSIL: Low-grade squamous intraepithelial lesion
HSIL: High-grade squamous intraepithelial lesion
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invited after their birthday in the year they were eligible for invitation. In the cytology-
based programme, invitations were sent by the regional screening organisation, GP 
practices or using a combined approach. The timing of the invitation also varied depend-
ing on which organisation sent the invitation; some invitations were sent at the start of 
the year that women would become eligible to participate and some were sent after 
the women’s birthdate. The number of laboratories responsible for analysing primary 
screens from the programme was reduced from approximately 40 in the cytology-based 
programme to fi ve in the hrHPV-based programme (one per region).
hrHPV test in the new programme
Clinician-collected samples were collected in 20ml ThinPrep medium (Hologic, Marl-
borough, United States), transported and stored at room temperature until processed 
in the laboratory. The Evalyn® Brush (Rovers Medical Devices, Oss, the Netherlands) 
was used for self-sampling. The self-collected brushes were sent to the laboratories by 
regular mail. The brush of the self-sampling device was transferred into 20ml of ThinPrep 
medium prior to hrHPV testing. All laboratories used the Cobas® 4800 HPV test (Roche 
Diagnostics, Alameda CA, USA) to test the clinician-collected- and self-samples. The 
Cobas® 4800 HPV test is a CE in vitro diagnostic (IVD) certifi ed kit (for clinician-collected 
cervical scraps only) for use in combination with the Cobas® 4800 system for nucleic acid 
Figure 1b: Screening protocol HPV-based screening programme
NILM: Negative for intraepithelial lesion or malignancy
ASC-US: Atypical squamous cells of undetermined signifi cance
LSIL: Low-grade squamous intraepithelial lesion
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extraction, PCR setup, real-time PCR amplification and result analysis. As part of the assay 
procedure, each sample was also tested for the presence of human cells by amplification 
of the human beta-globin gene. The clinical performance of the Cobas® 4800 system has 
been validated using Dutch samples,14 and the Evalyn® Brush was compared with lavage 
self-sampling in a Dutch population and found to have equivalent performance.15 All 
tests used in the hrHPV-based programme were selected through a tendering process.
Study design and data source
This study is a longitudinal, retrospective population-based cohort study. We obtained 
results of primary screening tests and any associated follow-up from the Dutch nation-
wide registry of histo- and cytopathology (PALGA) for two cohorts. The cytology cohort 
consisted of women who participated in the cytology-based screening programme 
between 1 January 2015 and 31 March 2016 (maximum follow-up of 40 months). The 
hrHPV cohort consisted of women who participated between 1 January 2017 and 30 June 
2018 in the hrHPV screening programme (maximum follow-up of almost 21 months). An 
inclusion period of 18 months was used for the hrHPV cohort to compensate for the 
phased implementation of the new programme (see Additional file 1).
All pathology laboratories in the Netherlands are linked to PALGA.11 Identification of 
women is based on their birthdate and up to the first eight letters of their surname 
(maiden name is used for married women) and allows linkage of tests belonging to the 
same woman, enabling individual screening histories to be followed. For all primary 
and follow-up tests, the corresponding advice codes were analysed. Age was defined as 
the woman’s age at the time of the primary screening test, classified into five-year age 
groups. Given differences in invitation policies between the two programmes, slightly 
different age ranges have been used for the hrHPV cohort and the cytology cohort (see 
Additional file 1).
Data analysis
To compare the performance of the hrHPV-based screening programme with the 
cytology-based screening programme, we calculated indicators in three categories: 
participation (participation rate), referral (screen positivity rate, positive cytology among 
screen positive women, referral rate from primary screening (direct referral), referral 
rate from follow-up smear (indirect referral) and total referral rate (direct and indirect 
referrals combined)) and detection (findings after referral per 1,000 screened women, 
number of positive screen test results/number of referrals for colposcopy per detected 
CIN2+ or CIN3+ lesion).
The participation rate was defined by the number of primary screening tests divided 
by the number of women eligible for screening. The number of eligible women was esti-
mated from the number of women in the Dutch population who would reach screening 
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age in 2015 or 2017 (i.e. aged 29, 34, etc.) on 1 January 2015 for the cytology cohort and 
on 1 January 2017 for the hrHPV cohort. This data was obtained from Statistics Nether-
lands16 and adjusted for the risk of having their cervix removed by hysterectomy.17
Referrals were identified based on advice codes recorded in PALGA and could be di-
rect or indirect (see Additional file 1). Overdiagnosis and false positive screening results 
are recognised harms of screening.18 Screen positivity and referrals can lead to psycho-
logical distress19,20 and colposcopy itself can result in physical symptoms.21 As such, we 
considered screen positivity and referral to be proxies for potential harms. To estimate 
the harms-benefits ratio of screening, we calculated the number of screen positives and 
number of referrals per detected CIN2+ and CIN3+ case. Detailed information about 
data definitions can be found in Additional file 1.
All analyses were performed using IBM SPSS Statistics 24. Chi-squared tests were 




A total of 454,573 women eligible for screening invitation in 2017 participated in the 
hrHPV-based programme between 1 January 2017 and 30 June 2018 and 483,146 
women eligible for screening invitation in 2015 participated in the cytology-based 
programme between 1 January 2015 and 31 March 2016. Women ranged in age from 
29 to 61 years.
Figure 2 shows that the overall participation rate in 2017 in the hrHPV-based pro-
gramme was significantly lower than in the cytology-based screening programme in 
2015 (64% in 2015 compared with 61% in 2017; p < 0.001). The participation rate in the 
hrHPV-based programme was lower in all age groups. The biggest difference was found 
in age group 45-49 years (68% in 2015 compared with 63% in 2017; p < 0.001). Differ-
ences in participation rates were statistically significant for all age groups (p < 0.001).
The percentage of inadequate cytology smears recorded at primary screening as a 
proportion of all primary screening reduced from 1.6% in 2015 to 0.1% in 2017 (p < 
0.001).
Of all women participating in the hrHPV-based programme, 8% used the self-sampling 
kit (i.e. 36,295 self-sampled compared with 418,278 clinician-collected) (Figure 3).
referral
Figure 4 shows that the proportion of women with a positive screen test was signifi-
cantly higher in the hrHPV-based programme than in the cytology-based programme 
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(increased from 5% in 2015 to 9% in 2017; p < 0.001). Related to this, we found that the 
proportion of women referred to the gynaecologist also signifi cantly increased (from 
1% in the cytology-based programme to 3% in the hrHPV-based programme; p < 0.001). 
The increase in screen positive tests and in the referral rate were largest in women aged 
30-34 years, where the proportion of positive screen tests increased from 9% in the 
cytology-based programme to 21% in the hrHPV-based programme (p < 0.001) and the 
referral rate increased from 3% to 8% (p < 0.001).
In the hrHPV-based programme, we found a signifi cantly higher hrHPV positivity rate 
in clinician-collected than in self-collected samples (9.2% vs 7.6%; p < 0.001). In addition, 
amongst hrHPV-positive women, more women had a cytological abnormality after self-
sampling than clinician-collected sampling (37.2% vs 32.2%; p < 0.001) (Figure 3).
Detection
Figure 5 shows per 1,000 women screened, the total number of referrals (both direct and 
indirect) to the gynaecologist and the number of CIN2+ lesions detected after referral. 
Figure 2: Participation rate in hrHPV-based screening (2017) and in cytology-based screening (2015) by age.
454,573 women participated in hrHPV-based screening programme and 483,146 women participated in 
the cytology-based screening programme. NB. Please refer to Additional fi le 1 for a comprehensive expla-
nation of age group criteria.








































































































































































































































































































































































































































































































































































































































































































First results of hrHPV-based screening
The number of referrals increased from 20 to 39 per 1,000 women screened, and the 
CIN2+ detection rate increased from 11 to 14 per 1,000 women screened (p < 0.001). 
Overall, the referral rate doubled and the CIN2+ detection rate increased by 34% (p < 
0.001). For the youngest age group, the referral rate increased by 92% (p < 0.001) and the 
CIN2+ detection rate by 30% (p < 0.001).
Cytology or histology was performed in 77% of women directly referred to the 
gynaecologist in the hrHPV-based programme (Figure 3). In the remaining 23%, only 
colposcopy was performed after referral or women were lost to follow up. In case of 
indirect referrals, in 64.5% of clinician-collected or 56.0% of self-sampling (p = 0.974) 
cytology or histology was performed. The CIN2+ detection rate after cytology or histol-
ogy varied across the four diff erent groups in the hrHPV-based programme: from 35.7% 
Figure 4: Screen positivity and direct referral rates by screening programme and age.
Cytology-based screening results are based on the 2015 screening cohort and hrHPV-based screening re-
sults are based on the 2017 screening cohort. Screen positivity in the hrHPV-based screening programme is 
hrHPV-positive, irrespective of refl ex cytology results. 454,573 women participated in hrHPV-based screen-
ing programme and 483,146 women participated in the cytology-based screening programme. NB. Please 
refer to Additional fi le 1 for a comprehensive explanation of age group criteria.
* Pearson’s chi-square test signifi cantly diff erent for screen positivity rates between test types (p < 0.001).
† Pearson’s chi-square test signifi cantly diff erent for referral rates between test types (p < 0.001).
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in indirect referred women after a clinician collected sample to 57.1% in direct referred 
women after self-sampling (Figure 3).
Table 1 shows the diff erent fi ndings after direct and indirect referrals for the hrHPV-
based and cytology-based programmes. We found that in the hrHPV-based programme 
after referral, approximately 2.2 times more clinically irrelevant fi ndings were found (i.e. 
‘cytology only’, ‘no dysplasia’ or CIN1), compared with approximately 1.3 times more 
clinically relevant fi ndings (i.e. CIN2, CIN3 and cancer).
Harms versus benefi ts
Table 2 shows the number of positive screen test and number of referrals (i.e. ‘harms’) 
per CIN2+ and CIN3+ lesion detected (i.e. ‘benefi ts’) in one screening round, for both 
the hrHPV-based and cytology-based screening programme. We found that in the new 
programme, the harms per benefi t increased by approximately 45% in one screening 
round for CIN 2+ lesions and by 51% for CIN3+ lesions. For example, to detect one CIN3+ 
Figure 5: Total referral and CIN2+ detection rates in all screened women by screening programme and age.
Cytology-based screening results are based on the 2015 screening cohort and hrHPV-based screening 
results are based on the 2017 screening cohort. 454,573 women participated in hrHPV-based screening 
programme and 483,146 women participated in the cytology-based screening programme. Referral rates 
include direct and indirect referrals. NB. Please refer to Additional fi le 1 for a comprehensive explanation of 
age group criteria.
* Pearson’s chi-square test signifi cantly diff erent for referral rates between test types (p < 0.001).
† Pearson’s chi-square test signifi cantly diff erent for CIN2+ detection rates between test types (p < 0.001).
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lesion in the cytology-based programme, 3.0 women where referred, compared to 4.6 in 
the hrHPV-based programme. This difference was mostly due to the increase in referrals 
of hrHPV-positive screens with ASC-US/LSIL cytology in the hrHPV-based programme, 
which stemmed from a national policy change to refer, rather than observe, hrHPV-
positive screens with ASC-US/LSIL results.
DISCuSSION
main findings
The nationwide implementation of primary high-risk HPV DNA screening in the Neth-
erlands has been successful, with the programme now fully implemented and results 
generally as expected, apart from a lower than anticipated participation rate. In the first 
year, we observed a participation rate of 61%, which was lower than observed in the 
previous cytology-based programme (64%). Screen positivity was higher in the hrHPV-
based programme. The cytology programme recommended observation of ASC-US/
LSIL results, while the hrHPV-based programme recommended colposcopic referral for 
Table 2: Number of positive screen tests and number of referrals per detected CIN2+ or CIN3+ lesion.
Cytology HPV Difference per round (%)
POSITIVe SCreeNS
Total*
Number of positives 
needed to detect one:
CIN2+ 4.4 6.3 44
CIN3+ 7.2 10.8 50
referralS
Total*
Number of referrals 
needed to detect one:
CIN2+ 1.9 2.7 47
CIN3+ 3.0 4.6 53
HSIL
Number of referrals 
needed to detect one:
CIN2+ 1.3 1.3 -2
CIN3+ 1.8 1.8 -2
ASC-US/LSIL
Number of referrals 
needed to detect one:
CIN2+ 3.0 4.7 57
CIN3+ 7.5 12.0 60
NB. Triage algorithms for ASC-US/LSIL screens differ between the cytology-based and hrHPV-based pro-
grammes; in the hrHPV-based programme, all hrHPV-positive, ASC-US/LSIL screens are directly referred 
whereas, in the cytology-based programme, ASC-US/LSIL screens were triaged for repeat cytology after 
six months.
* Total include all positive hrHPV tests irrespective of the reflex cytology result (includes hrHPV-positive 
screens with reflex cytology of NILM, inadequate or missing).
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hrHPV-positive, ASC-US/LSIL results. As expected, this increased both the number of 
colposcopic referrals and CIN2+ lesions detected.
factors influencing participation rates
The introduction of self-sampling had been expected to increase participation, as a 
previous Dutch study (PROHTECT) found that screening non-attenders who were of-
fered self-sampling were more likely to be screened than non-attenders.22 While 8% of 
screened women used self-sampling, this did not increase overall participation, suggest-
ing that switching is occurring. Information about switching was not publicly reported in 
2017 official monitoring report,23 and further research is needed into the characteristics 
of women who choose for self-sampling to provide reliable estimates of this indicator. 
One important difference between PROHTECT and the real-world implementation was 
that women needed to opt-in to self-sampling in the screening programme. Secondly, 
the four-month waiting period for the self-sampling kit may have delayed uptake of 
screening amongst women who opted-in. The self-sampling kit may be used by women 
who find it more convenient than attending the GP; one of the main reasons identified 
in a Dutch study for using a self-sampling kit.24 Finally, although self-sampling is gener-
ally acceptable to women,12 23% of self-sampling kits requested by the 2017 cohort 
have not yet been returned (as of December 2018; personal communication, RIVM, 21 
December 2018). Although the return of these kits would not have a large effect on 
overall participation, the reasons for not returning them should be further investigated.
Organisational factors, such as the phased roll-out of the new programme and 
changes in the invitation process may also have resulted in lower participation. Due to 
the phased roll-out of the new programme over the first quarter of 2017, women had 
less time to take up their screening invitations compared with the cytology-based pro-
gramme, although we still observed a lower participation rate when calculating it based 
on 18 months of data. If the phased implementation is the cause of lower participation, 
we would expect participation to increase in coming months. In the cytology-based pro-
gramme, GP practices could invite patients for screening, rather than women receiving 
an invitation from the regional screening organisation. Women who received invitations 
sent from GP practices were more likely to participate in the cytology-based programme 
than women who received invitations from screening organisations.25 Discontinuing 
the involvement of GP practices in the invitation and reminder process may have led 
to a decline in participation, as invitations are now sent from organisations that may be 
unfamiliar to women; this needs further investigation.
Comparison with other studies
The hrHPV positivity rate was higher than anticipated at 9.1%, as a previous population-
based Dutch study (DuSC) found a hrHPV positivity rate of 8% amongst women of 
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screening age.26 This difference may be explained by differences in sociodemographic 
characteristics of women participating in the programme overall and the women in-
cluded in DuSC. It could also be that there has been an increase in the incidence of 
hrHPV infections over time. The higher than expected hrHPV positivity rate may explain 
differences between the estimated referral rate of 3.4% (based on modelling)6 and the 
observed referral rate of 3.9%. We found 48.2% CIN2+ detection in all women with 
histologically confirmed diagnosis, which was higher than the rate predicted by model-
ling (45%), which may be due to differences in the assumed test characteristics and the 
real-world performance of the hrHPV test.6
One surprising finding was that hrHPV positivity was lower in self-samples than in the 
clinician-collected samples, contrary to previous Dutch studies. One population-based 
study found higher hrHPV positivity in self-samples than in clinician-collected samples12 
and one randomised non-inferiority trial (IMPROVE) found equivalent hrHPV positiv-
ity between the two test types, although IMPROVE used a different clinician-collected 
test than is used in the screening programme.27 Despite this, we found higher CIN2+ 
detection in self-sampling than in clinician-collected sampling. This may indicate that 
the self-sampling test has a higher CIN2+ specificity than the clinician-collected test, in 
contrast to results from IMPROVE, which reported CIN2+ specificity of the self-test was 
non-inferior (relative accuracy of 1.00).27 Further analysis of the self-sampling kit within 
the screening programme is needed, controlling for background risk and population 
factors.
Triage of hrHPV-positive women
A higher CIN2+ detection rate was found in the hrHPV programme than in the cytology-
based programme. This was expected based on the results of four large randomised 
trials of HPV screening.1 However, in the new hrHPV screening programme, more re-
ferrals per screening round were needed to detect one CIN2+ lesion compared with 
cytology-based screening, mainly due to an increase in the number of referrals amongst 
women with ASC-US/LSIL cytology. This increase potentially leads to more harms for 
women, including anxiety for women unnecessarily referred19 or potential overtreat-
ment of low-grade lesions. Therefore, optimising triage to reduce unnecessary referrals 
should be a priority. Different triage strategies for hrHPV-positive screens have been 
proposed, including (but not limited to) p16/Ki67 dual staining, hrHPV genotyping, 
methylation, HPV E6 protein assays or combinations of these strategies.28 Risk-based 
management could also be explored, in which risk factors (such as a woman’s screening 
history) are taken into account when triaging hrHPV-positive, ASC-US primary screens.29 
The performance of additional triage tests in the Dutch setting, as well as the feasibility 
of implementation and any impacts on programme cost-effectiveness and the balance 
of harms versus benefits of the screening programme need to be considered prior 
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to changing the triage algorithm. The harms benefits ratio of the old cytology-based 
programme was considered acceptable in the Netherlands, and while in one round of 
screening the hrHPV-based screening programme had a more unfavourable balance, 
reducing the number of total screening rounds in the hrHPV-based programme (from 
seven to five for many woman) will result in similar overall life-time harms-benefits ratio 
to that of the cytology-based programme.
International comparisons
In several countries, hrHPV-based screening has been implemented, but published 
results are only available from Italy and Turkey. In Italy, HPV-based screening was imple-
mented in 2012 in 19 screening programmes across ten regions. The direct referral rate 
from the Italian programme was comparable with the Dutch programme at 2.9%.10 In 
2014, primary HPV screening was implemented in Turkey; however, direct comparison 
of results is difficult due to a low participation rate (36.5%) and incomplete histological 
follow-up data.9 Neither study compared hrHPV-based screening with cytology-based 
screening. In general, the quality of a cytology-based programme influences such 
a comparison. In the Netherlands, the quality of the cytology-based programme was 
consistently high, with low rates of unsatisfactory smears and a high positive predictive 
value for CIN2+ lesions compared with other European countries.30 In a country with 
a less highly-performing cytology programme, the incremental effects of HPV-based 
screening versus cytology-based screening would be different.
future implications for hrHPV in partly vaccinated cohorts
Given the increased sensitivity of hrHPV testing for CIN2+ lesions, detection rates 
are expected to be higher in the first round, as both prevalent and incident lesions 
are detected. As the programme reaches a steady state, and fewer prevalent lesions 
are detected, we expect that detection of CIN3+ lesions will decrease, as seen in the 
POBASCAM trial.31 Therefore, it will be necessary to compare results from the first and 
subsequent screening rounds. In the Netherlands, hrHPV vaccination was offered in a 
catch-up programme to girls aged 13 to 16 years in 2009, meaning the first cohort of 
partly vaccinated women will be eligible for screening in 2023. This may necessitate 
changes to the programme, due to an anticipated reduction in HPV16/18 infections. 
Modelling has shown that with herd immunity levels greater than 50%, a reduction in 
the number of screening rounds may need to be considered to maintain programme 
cost-effectiveness in the Netherlands.32 Finally, for full evaluation of the new screening 
programme, calculation of interval cancer incidence is essential to approximate the 
sensitivity of one screening round. Women are at highest risk of an interval cancer diag-
nosis four to six years after a negative screen,33 as the screening interval is five years. As 
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such, the first opportunity for comparison of this indicator will come five years after the 
implementation of hrHPV-based screening.
Strengths and limitations of this study
This is the first study to report the results of the nationwide implementation of a hrHPV-
based screening using prospectively-collected cyto- and histopathological data. We have 
been able to compare this reliably with the previous cytology-based programme due to 
the nationwide coverage of PALGA. The large number of screens included in our study 
has allowed us to make statistically robust comparisons between indicators of the two 
programmes. Our study has some limitations. The follow-up time included in our study 
was shorter for the hrHPV-based programme than the cytology-based programme, as 
the hrHPV-based programme was implemented more recently. We are unable to analyse 
characteristics of non-attenders to the programme, as characteristics of these women 
are not captured by PALGA. We are also unable to differentiate loss to follow-up after 
referral for colposcopy from cases where women attended colposcopy, but no cytology 
or histological diagnostic test was performed. This information is unavailable for both 
the hrHPV-based programme and the cytology-based programme. As such, we cannot 
investigate whether adherence to referral advice has changed over time. Furthermore, 
compliance to referral, used to differentiate cytology only and no follow-up with cytol-
ogy or histology in Table 1, may have been underestimated for hrHPV screening due 
to the shorter follow-up time for the hrHPV-based programme; however, without data 
on colposcopies, the extent of this underestimation is unknown. The identifier used in 
PALGA to link records is non-unique (based on the first eight letters of a woman’s surname 
and her date of birth). This means that records from multiple women could be linked to 
one identifier (called an administrative fusion). It is unlikely that there is a difference 
in the number of administrative fusions between the two programmes and therefore, 
we expect that this has not influenced our results. Finally, because the cytology-based 
programme recommended observation of ASC-US/LSIL results, while the hrHPV-based 
programme recommended colposcopic referral for hrHPV-positive, ASC-US/LSIL results, 
distinguishing the relative impact of the hrHPV test itself versus the lower threshold for 
referral on both unnecessary testing and CIN2+ detection is difficult.
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CONCluSIONS
This is the first time that results of nationwide implementation of hrHPV-based screen-
ing have been reported using high-quality data with extended follow-up. Our results 
show implementation of the hrHPV-based programme has been successful. However, 
the lower participation rate in the hrHPV-based programme needs to be investigated 
further to ensure that the screening programme remains effective and efficient. Detec-
tion of CIN2+ lesions was higher in the hrHPV-based programme at the cost of more 
unnecessary referrals. Careful consideration needs to be given to potentially changing 
triage of HPV-positive screens to reduce unnecessary referrals. Ongoing monitoring of 
the hrHPV-based programme is essential to ensure that a reasonable balance of benefits 




ASC-US – atypical squamous cells of undetermined significance
CIN – Cervical intraepithelial neoplasia
GP – general practitioner
hrHPV – high-risk human papillomavirus
HSIL – high-grade squamous intraepithelial lesion
LSIL – low-grade squamous intraepithelial lesion
PALGA – Nationwide network of cyto- and histopathology in the Netherlands
NILM – Negative for intraepithelial lesion or malignancy
RIVM – Rijksinstituut voor Volksgezondheid en Milieu (Dutch National Institute for Public 
Health and the Environment)
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aDDITIONal fIle 1: DeTaIleD DeSCrIPTION Of meTHODS fOr 
CalCulaTING reSulTS
Supplement to: Aitken CA, van Agt HME, Siebers AG et al. Introduction of primary screening 
using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a 
population-based cohort study
To calculate results for our study, we used extracts of all cervical cytology and histol-
ogy records from the nationwide network and registry of histo- and cytopathology in 
the Netherlands (PALGA). Primary screening tests were selected from 1 January 2015 
to 31 March 2016 for the cytology cohort and from 1 January 2017 to 30 June 2018 for 
the hrHPV cohort. We chose not to select 1 January 2016 to 31 March 2017 as the com-
parison period for cytology, due to an overlap with the new programme. The maximum 
follow-up time for the cytology cohort was 40 months and four days for screens taken on 
1 January 2015 (end date of dataset: 4 May 2018) and the maximum follow-up time for 
the hrHPV cohort was 20 months and 28 days for screens taken on 1 January 2017 (end 
date of dataset: 28 September 2018).
ages included in analysis
Due to changes in the organisation of invitations, grouping of age is slightly different 
between the old cytology-based programme and the new hrHPV-based programme. In 
the cytology-based programme, women could be invited at different dates in the year 
that they were eligible for screening; this could be at the start of the year they were 
eligible for screening, on their birth date or other time during the year that they were eli-
gible for screening. Invitations could also be sent by different organisations (the regional 
screening organisation, the woman’s GP or a combined approach). In the hrHPV-based 
programme, women are sent an invitation letter on their birth date from their regional 
screening organisation. Due to these differences, many women aged 29, 34, 39, 44, 49, 
54 and 59 had primary screening in the cytology cohort between 1 January 2015 and 
31 March 2016. The age categories outlined in Table A1 for the cytology cohort have 
been used for many years to categorise age in the annual screening programme Monitor 
published by the Dutch National Institute for Public Health and the Environment. For 
this reason, we have used these age groupings for the cytology cohort in our study.
Table A1 shows how age group was defined in our analysis. A very small number of 
29-year olds (36 in total) had a primary screening test recorded in the hrHPV-based 
programme between 1 January 2017 and 30 June 2018; these women were included in 




In the cytology-based programme, participants were defined by the number of screen-
ing test results from clinician-based sampling, performed between 1 January 2015 and 
31 March 2016. The eligible population was based on the number of women who would 
reach screening age in 2015 in the Dutch population on 1 January 2015 (i.e. aged 29, 34, 
etc.), adjusted for the risk of having their cervix removed by hysterectomy.
In the hrHPV-based programme, participants were defined by the number of screen-
ing test results from clinician-based sampling or self-sampling, performed between 1 
January 2017 and 30 June 2018. The eligible population was based on the number of 
women who would reach screening age in 2017 in the Dutch population on 1 Janu-
ary 2017 (i.e. aged 29, 34, etc.), adjusted for the risk of having their cervix removed by 
hysterectomy.
referral
Table A2 and Table A3 shows the definitions used to calculate the direct and indirect 
referral rates in the cytology-based programme and hrHPV-based programme.
In the cytology-based programme, there were two triages for repeat cytology (first 
indirect at 6 months and second indirect at 12 months; see Figure 1a). Therefore, the 
indirect referral rate combines first and second indirect referrals. This rate was calculated 
amongst women who complied to the advice for repeat cytology within 365 days from 
the primary screening test for 6 months repeat cytology, and within 630 days from the 6 
months cytology test for 12 months repeat cytology.
In the hrHPV-based programme, indirect referral rates were calculated in women who 
complied to the advice for repeat cytology within 365 days from of the date of primary 
screening.
Detection
Table A2 and Table A3 shows the definitions used to calculate the detection rates in the 
cytology-based programme and hrHPV-based programme.
Detection rates were calculated in women who were referred to the gynaecologist 
(due to their result on the screening test or their result from repeat cytology) and 
complied to the referral advice. In Figure 2, all detection rates are calculated amongst 
women who complied with referral advice within 150 days of a primary screening or 
follow-up test. In Tables 1 and 2, compliance within 150 days was only used to define the 
‘no follow-up with cytology or histology test’ and ‘cytology only’ groups.
Women who complied to referral (i.e. they had an examination after 150 days from the 
referral advice, either from screening test of repeat cytology) but did not have a histol-
ogy result were assumed to have had a cytology test only. The most severe histological 
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diagnosis that was recorded within the episode of screening was used to categorise 
histology results.
Colposcopies without a histology or cytology test were not registered in the PALGA 
database. Referred women who did not comply, according to the definition, may there-
fore consist of women who are lost to follow-up or women who had colposcopy without 
histology or cytology.
Harms vs. benefits
To estimate the harms-benefits ratio of screening, we calculated the number of screen 
positives per detected CIN2+ and CIN3+ case and number of referrals per detected 
CIN2+ and CIN3+ case.
Table A1: Age groupings used in analysis by programme type.
age groupings used in monitoring reporting
label used in this study Cytology-based programme hrHPV-based programme
30 years 29-33 years 29*-34 years
35 years 34-38 years 35-39 years
40 years 39-43 years 40-44 years
45 years 44-48 years 45-49 years
50 years 49-53 years 50-54 years
55 years 54-58 years 55-59 years
60 years 59-63 years** 60-64 years**
* 36 women aged 29 years had screening registered as part of the hrHPV-based screening programme in 
2017.
** The maximum age of women included in this study was 61 years, however, five-year age categories are 
used in the Monitoring reports for the cervical cancer screening programme.
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Table A2: Calculation of the indicators shown in Figure 2 for participation, referral and detection within the new 
hrHPV-based screening programme, 2017 cohort.
Indicator Numerator Denominator
Participation
Participation rate Participants, i.e. number of 
screening tests from clinician-
based sampling or self-sampling, 
performed between 1 January 2017 
and 30 June 2018.
Eligible population, i.e. number of 
women at screening ages in the 
Dutch population on 1 January 
2017, adjusted for the risk of 
having their cervix removed by 
hysterectomy.
referral
hrHPV positivity Screen positives, i.e. number of 
hrHPV positive screening tests
Participants
Cytology assessments amongst 
screen positives
Number of hrHPV positives with a 
cytology result
Screen positives
Referral rate from primary 
screening (direct referral)
Direct referrals, i.e. number of hrHPV 
positive screening tests with ASC-
US+ cytology result
Number of screen positives with 
cytology assessment
Advice for follow-up smear after 6 
months
Triage cytology advice, i.e. number 
of screen positives with NILM 
cytology
Number of screen positives with 
cytology assessment
Referral rate from follow-up smear 
(indirect referral)
Indirect referrals, i.e. number of 
follow-up smears with an ASC-US+ 
cytology result
Number of triage cytology 
performed within 365 days from 
the screening test.
Detection
Histology or cytology test 
performed amongst direct referrals
Histology or cytology test in direct 
referrals, i.e. number of screen 
positives with ASC-US+ cytology 
where an examination was 
performed within 150 days from 
the screening test
Direct referrals
CIN2+ detection from direct 
referrals
Number of histological confirmed 
CIN2+ lesions
Histology or cytology test in direct 
referrals
Histology or cytology test 
performed in indirect referrals
Histology or cytology test in indirect 
referrals, i.e. number of follow-up 
smears with an ASC-US+ cytology 
result where an examination was 
performed within 150 days from 
follow-up smear.
Indirect referrals
CIN2+ rate from indirect referrals Number of histological confirmed 
CIN2+ lesions
Histology or cytology test in 
indirect referrals
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Table A3: Calculation of the indicators for participation, referral and detection in the old cytology-based screen-
ing programme, cohort 2015, and within the new hrHPV-based screening programme, 2017 cohort.




Cytology cohort Participants, i.e. 
number of screening 
test results from 
clinician-based 
sampling, performed 
between 1 January 
2015 and 31 March 
2016.
Eligible population, i.e. number of 
women at screening ages in the Dutch 
population on 1 January 2015 and 
adjusted for the risk of having their 
cervix removed by hysterectomy.
hrHPV cohort Participants, i.e. 
number of screening 




between 1 January 
2017 and 30 June 
2018.
Eligible population, i.e. number of 
women at screening ages in the Dutch 
population on 1 January 2017 and 
adjusted for the risk of having their 




Cytology cohort Screen-positives, i.e. 
number of screening 
tests with ASC-US+ 
cytology
Participants
hrHPV cohort Screen positives, i.e. 
number of hrHPV 
positive screening tests
Participants
Referral rate from 
primary screening 
(direct referral)
Figure 3, Figure 5, Table 
1, Table 2
Cytology cohort Direct referrals, i.e. 
number of screen 
positive women with 
HSIL cytology result
Participants
hrHPV cohort Direct referrals, i.e. 
number of hrHPV 
positive screening tests 
with ASC-US+ cytology 
result
Participants
Referral rate from follow-
up smear (indirect 
referral)
Figure 5, Table 1, Table 2
Cytology cohort Indirect referrals, 
Number of follow-
up smears at first 
or second repeat 
cytology, with HSIL 
cytology result
Participants
hrHPV cohort Indirect referrals, 
Number of follow-up 






Table A3: Calculation of the indicators for participation, referral and detection in the old cytology-based screen-
ing programme, cohort 2015, and within the new hrHPV-based screening programme, 2017 cohort. (continued)
Indicator Cohort Numerator Denominator
CIN2+
Figure 5, Table 1, Table 2
Cytology cohort Number of CIN2+ 
lesions found in 
referred women (direct 
and indirect).
Participants
hrHPV cohort Number of CIN2+ 
lesions found in 




Table 1, Table 2
Cytology cohort Number of findings in 
referred women (direct 
and indirect). For 
cytology only group, 
women must have had 
an examination within 
150 days of primary 
screening (direct 
referrals) or within 150 
days of repeat cytology 
test (indirect referrals).
Participants
hrHPV cohort Number of findings in 
referred women (direct 
and indirect). For 
cytology only group, 
women must have had 
an examination within 
150 days of primary 
screening (direct 
referrals) or within 150 
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We aim to compare the cost-effectiveness of the old cytology programme with the new 
high-risk human papillomavirus (hrHPV) screening programme, using performance 






Dutch 30-year-old unvaccinated females followed up lifelong.
methods
We updated the microsimulation screening analysis (MISCAN) model using the most 
recent epidemiological and screening data from the Netherlands. We simulated both 
screening programmes, using the screening behaviour and costs observed in each 
programme. Sensitivity analyses were performed on screening behaviour, utility losses 
and discount rates.
main Outcome measures
Cervical cancer incidence and mortality rates, number of screening tests and repeat 
tests, colposcopy referrals by lesion grade, costs from a societal perspective, quality-
adjusted life-years (QALYs) gained and cost-effectiveness.
results
The new Dutch cervical cancer screening programme decreased the cervical cancer 
mortality by 4% and the incidence by 1% compared to the old programme. Colposcopy 
referrals of women without cervical intra-epithelial neoplasia grade 2 or worse increased 
by 172%, but 13% more QALY’s were still achieved. Total costs were reduced by 21%, 
mainly due to fewer screening tests. Per QALY gained, the hrHPV programme cost 46% 
less (€12,225) than the cytology programme (€22,678) and hrHPV-based screening 
remained more cost-effective in all sensitivity analyses.
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Conclusions
The hrHPV-based screening programme was found to be more effective and costeffec-
tive than the cytology programme. Alternatives for the current triage strategy should be 
considered to lower the number of unnecessary referrals.
Tweetable abstract
First results after implementation confirm that HPV screening is more cost-effective than 
cytology screening.
INTrODuCTION
In January 2017, the Dutch population-based cervical cancer screening programme 
switched the primary screening test from cytology to the high-risk human papillomavi-
rus (hrHPV) test. Women can now choose either to have a cervical smear taken by their 
general practitioner (GP) or to use a self-sampling kit. The latter option was added as 
an alternative screening method to increase attendance rates in women who feel un-
comfortable with taking a test at their GP. The implementation of this new programme 
was based on, amongst other considerations, cost-effectiveness analyses showing that 
primary hrHPV screening is more cost effective than primary cytology screening.1,2 How-
ever, as no other country had implemented primary hrHPV screening up to that time, 
many model inputs had to be based on assumptions, potentially biasing the results.1,2
The Dutch cervical cancer screening programme has been monitored for decades, us-
ing high-quality data.3 However, information on important performance indicators (such 
as the participation rate, use of self-sampling, positivity rates, referral rates, precancerous 
cervical intraepithelial neoplasia (CIN) detection rates and costs) of the primary hrHPV-
based screening programme has only recently been published.4 Some key indicators 
were found to be unfavourable for the effectiveness of the new programme, such as a 
drop of three percentage points in screening participation as well as a lower adherence 
to triage testing.4,5 This unique information from the implementation of hrHPV-based 
screening can now be used as reliable model input for a cost-effectiveness analysis to 
compare the new programme with the old cytology-based screening programme.
Using this newly available monitoring data, we aimed to answer the following research 
question: What are the costs, effects and cost-effectiveness of the newly implemented 
cervical cancer screening programme using primary hrHPV-testing compared to the old 
cytology-based screening programme? We will simulate scenarios where a 30-year-old 
cohort of unvaccinated women are offered either the full cytology-based programme 
or the full hrHPV-based programme and follow these women up until death. For these 
women, we will present costs per life-years gained and costs per quality-adjusted life-
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years (QALYs) gained as the main outcome. The number of referrals to a gynaecologist 
and detected CIN, most of which will not progress to cancer, will be presented, as these 
are considered to be important harmful effects of screening.6,7 These results are use-
ful for policymakers of similar countries to decide whether a switch to primary hrHPV 
screening is beneficiary for their country.
meTHODS
To estimate the effects of both the cytology screening programme and the hrHPV-based 
screening programme in The Netherlands, the MISCAN-Cervix (Microsimulation Screen-
ing Analyses-Cervix) model was used.1, 8-10 An extensive model description can be found 
in Appendix S1. In short, MISCAN-Cervix is a microsimulation model, coded in Borland 
Delphi 7, that simulates the natural history of cervical cancer in a hypothetical popula-
tion. Women have an age-specific risk to acquire one or multiple hrHPV infections which 
may or may not progress sequentially to CIN1, CIN2 and CIN3 or regress at any time. A 
CIN3 may progress to a micro-invasive cancer and later into more invasive cancer stages 
before it is clinically detected. Different screening strategies can be simulated in this 
population to quantify and compare the harms and benefits of each strategy (Appendix 
S1: Figures S1-S4, Table S1). As described in Appendix S1, many model assumptions are 
based on high quality data from the Netherlands Cancer Registry (NCR) and the na-
tionwide network and registry of histo- and cytopathology in the Netherlands (PALGA), 
both having a national coverage.11, 12 To reduce the impact of random variability on the 
predicted outcomes, the model simulates a large population of 10 million women and 
applies the same sequence of random numbers in each simulation.
model updates
For this analysis, we extended and recalibrated (Appendix S1: Figure S6-S9) the existing 
model using the most recent cancer and screening data from the NCR and PALGA11, 12 in 
order to incorporate three new features compared to the previously published model. 
First, hrHPV infections in the model are now type-specific, allowing for different progres-
sion probabilities per hrHPV type. Four groups of hrHPV types were defined based on 
their oncogenicity and their presence in different HPV vaccines.13, 14 HPV16, HPV18, other 
hrHPV types covered by the nonavalent vaccine (HPV-31/33/45/52/58), and the remain-
ing seven hrHPV types (HPV-35/39/51/56/59/66/68). Second, FIGO2+ cancers were split 
up into FIGO2, FIGO3 and FIGO4, as survival probabilities differ between those stages. 
Third, the test characteristics of both cytology and the hrHPV test were updated based on 
evidence from published literature and to be able to fit well to observed data on interval 
cancers and false positive rates by hrHPV status.15-18 In this updated version, 12% of exist-
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ing precancerous lesions are consistently missed by cytology, and the probability of an 
abnormal cytological result is higher in hrHPV-positive women (calibrated parameters, 
see Table S3 in Appendix S1). Multiple studies found the concordance between hrHPV 
tests from different manufacturers to be lower in lower grade lesions (≤ CIN1), suggesting 
that more hrHPV infections are missed.15, 19 Therefore, we now assume that for hrHPV-
positive women the sensitivity of the hrHPV test increases with the severity of their lesion.
Screening programmes
In the Dutch cytology programme, women aged 30–60 years were invited for screening 
every five years. Women with a high-grade squamous intraepithelial lesion (HSIL) or worse 
were directly referred to colposcopy, while women with a low-grade cytological abnor-
mality (i.e. atypical squamous cells of undetermined significance or low-grade squamous 
intraepithelial lesion) were invited for a repeat test after six months. The vast majority of 
the executive laboratories analysed those cervical smears using both cytology and hrHPV 
testing, although some still used cytology only.20 When an HSIL or worse was found at this 
co-test, the woman was referred to colposcopy. Women testing hrHPV-positive were also 
referred to colposcopy if they had low-grade cytological abnormalities result. Women 
testing negative on both tests were discharged from follow-up while the remaining 
women were invited for a repeat cytology test after 12 months (Appendix S1: Figure S5).
In the hrHPV-based screening programme, women are still invited every five years 
at the ages 30–60; however the screening interval has been extended to ten years for 
women testing hrHPV-negative at age 40 or 50 and there is an extra invitation at age 65 
for women testing hrHPV-positive at age 60. After a positive hrHPV test, the sample is 
analysed with cytology, after which women with abnormal cytology results are referred 
to a gynaecologist, while women with normal cytology are invited for a repeat cytology 
test after six months (Appendix S1: Figure S5). Women who are uncomfortable with tak-
ing a test at their GP can request a self-sampling kit, although if their test result is hrHPV-
positive, they still need a smear taken by their GP to test for cytological abnormalities.
In the Netherlands, primary screening and follow-up tests are fully paid for by the gov-
ernment. If a woman is referred for colposcopy, health insurance covers the diagnosis 
and treatment costs. Health insurance is obligatory in the Netherlands and each insured 
person is also liable for an excess.
model assumptions – Demographic characteristics, epidemiology and natural 
history
A cohort of ten million women was simulated and followed until death. This cohort 
represents 30-year old Dutch women in 2019 with regard to their remaining life expec-
tancy (54.3 years), hysterectomy probabilities, hrHPV epidemiology and progression 
probabilities to CIN and cancer as described in Appendix S1.
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model assumptions –screening behaviour
The screening behaviour of all women in The Netherlands is registered on an indi-
vidual level in PALGA. Based on these observations, we were able to accurately model 
the screening behaviour in both programmes. As described in more detail in Appendix 
S1, the screening behaviour during the cytology programme was based on all women 
invited in 2015 and the screening behaviour during the hrHPV programme was based 
on all women invited in 2017.
Participation by age
The age-specific attendance at the primary test differs between the programmes. Table 
1 shows the percentage of the female population without a hysterectomy that partici-
pates in screening; in the hrHPV-based programme this can either be the regular GP test 
or a self-sampling kit.
For most ages, the attendance rates could be directly observed in the first screening 
round after implementation of hrHPV screening. However, in this first screening round, 
all women aged 45 and 55 were invited for screening, whereas in future rounds only 
those that tested hrHPV-positive in the preceding round or did not participate the 
preceding round will be invited. Therefore, fewer women will participate at those ages 
than currently observed in the first screening round (calculations presented above Ap-
pendix S1: Table S2). Also, in this first screening round no women aged 65 were invited 
yet as they first had to test hrHPV-positive at age 60 first. Therefore, we assumed the 
participation rate for women at age 65, who tested hrHPV-positive at age 60, to be the 
same as age 60.
Distribution of screenings across the population
The chance that an individual woman participates in a screening round is not entirely 
random; the total attendance is assumed to be distributed among 90% of the female 
population that potentially participates in screening, while the remaining 10% never 
attends a GP test (‘never attenders’) and have a 2.6 times higher background risk for 
acquiring an hrHPV infection (calibrated parameter, see Appendix S1). Also, if a woman 
attends one screening round, she is more likely to attend the next round and vice versa.
Of all self-sampling users in the new screening programme, 10.6% were assumed to 
have been never attenders in the old screening programme, based on screening histo-
ries in the previous two screening rounds (calculations described in Appendix S1). Since 
women aged 30 or 35 were not invited at least twice before, the proportion of young 
women taking a self-sample that would otherwise be never attenders was assumed to 
be equal to the weighted average proportion of 40-60 year old women. For all ages, the 
total screening attendance was higher in the cytology-based programme than in the 
hrHPV-based programme (Table 1).
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GP test participation by age in all women of the population*
- 30 years 52.3% 43.4%
- 35 years 57.9% 49.3%
- 40 years 64.3% 56.4%
- 45 years 67.6% 15.6%**
- 50 years 70.4% 61.5%
- 55 years 69.6% 12.7%**
- 60 years 66.8% 60.3%
- 65 years NA 3.1%***
Self-sampling participation by age*
- 30 years NA 5.5%
- 35 years NA 4.8%
- 40 years NA 4.5%
- 45 years NA 0.9%**
- 50 years NA 4.6%
- 55 years NA 1.0%**
- 60 years NA 5.7%
- 65 years NA 0.2%***
Adherence to cytology after a positive self-sample NA 90.1%
Adherence to triage testing
- 6 months after primary test 92.2% 77.1%
- 6 months after primary self-sample NA 41.6%
- 18 months after primary test 67.3% NA
Adherence to a referral for colposcopy after a…
- Direct referral (ASC-US/LSIL) NA 88.4%
- Direct referral (HSIL) 97.0% 96.9%
- Referral at 6 months after primary test (ASCUS/LSIL) 97.5% 88.4%
- Referral at 6 months after primary test (HSIL) 97.5% 96.9%
- Referral at 18 months after primary test 52.4% NA
ASC-US, atypical squamous cells of undetermined significance; hrHPV, high-risk human papillomavirus; 
HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; NA, not 
applicable.
* Simulated participation rate in all women excluding those who have had a hysterectomy and those with 
a prevalent diagnosed cancer.
** Participation in the general population is much lower at ages 45 and 55 because significantly fewer 
women are invited for screening at these ages (i.e. only those who do not participate or test hrHPV-positive 
in the preceding screening round).
*** Participation in the general population is much lower at age 65 because significantly fewer women are 
invited for screening at this age (i.e. only those who test hrHPV-positive at age 65).
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Participation in triage testing and colposcopy
Adherence to triage testing and colposcopy was monitored in both programmes. In the 
hrHPV-based programme, the adherence to triage testing was lower in self-sampling 
users (41.6%) than in women who attended the primary test at their GP (77.1%). Also, 
adherence to colposcopy was higher in women with HSIL (96.1%) than in women with 
lower grade cytology results (88.4%). In the cytology-based programme, the adherence 
to triage testing at 18 months after the primary test (67.3%) was lower than at 6 months 
after the primary test (92.2%). The adherence to colposcopy at 18 months (52.4%) was 
considerably lower than after a direct referral or a referral 6 months after the primary 
test (97% and 97.5% respectively).
Model assumptions – test characteristics, costs and utilities
The sensitivity and specificity of both cytology and the hrHPV-test are presented in Table 
S3 of Appendix S1. The test characteristics of cytology were calibrated to observed data, 
whereas the test characteristics of the hrHPV-test were derived from literature15, 21 as 
described in Appendix S1.
All costs and utilities applied are presented in Table 2. The cost-effectiveness analysis 
was performed using a societal perspective. All costs presented are in euros (€) and are 
indexed to the year 2019.22, 23 The utilities for screening and disease are obtained from 
an empirical Dutch study by de Kok et al. using the SF-6D questionnaire.24 Costs and 
effects were discounted annually by 3% as suggested by Sanders and colleagues in their 
recommendations for cost-effectiveness analyses.25
Sensitivity analyses
Multiple univariate sensitivity analyses have been performed. First, we assumed the 
screening attendance and/or triage adherence as observed in the cytology-based 
programme (Table 1) to also hold for the hrHPV-based programme. Second, we used 
an alternative published disutility set.1 Last, we performed the analyses using discount 
rates of 4% for costs and 1.5% for effects as is the guideline of the National Health Care 
Institute in The Netherlands.26
Core outcomes
Outcomes of interest were total number of screening tests, referrals to colposcopy, 
cancer incidence, cancer mortality, costs, life-years gained and QALYs gained compared 
to a situation without screening. All outcomes will be presented per 100 000 30-year-old 
women followed for their remaining life.
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Ethics approval and patient involvement
Ethical approval by a medical ethical committee was not required under Dutch law as 
no patients were involved in the development of the research and only non-identifiable 
data was used for this study.
reSulTS
model calibration
After calibration, the model outcomes fitted the observed age-specific cervical cancer 
incidence rates, cervical cancer stage distribution, detection rates of CIN and cervical 








SCreeNING Dutch public health 
subsidy scheme22Primary cytology programme
Primary cytology test 0 0 70
Repeat cytology test 0.03 15 51
Reflex hrHPV test after cytology repeat test 0 0 139
Primary hrHPV-test programme Dutch public health 
subsidy scheme22Primary hrHPV-test 0 0 58
Primary hrHPV self-sampling kit 0 0 43
Reflex cytology after hrHPV-test 0 0 26
Repeat cytology after hrHPV self-sampling 0.03 1 52
Repeat cytology after 6 months 0.03 6 53
DIaGNOSIS aND TreaTmeNT Report on the effects 
and costs of cervical 
cancer screening in the 
Netherlands in 200623
No CIN detected 0.03 1 316
CIN1 0.03 1 986
CIN2 0.03 1 1,461
CIN3 0.03 1 1,710
FIGO1A 0.08 12 5,601
FIGO1B 0.08 12 13,283
FIGO2+ clinically detected 0.14 12 12,226
FIGO2+ screen detected 0.14 12 13,092
Cancer survivor 0.03 120 0*
Palliative care 0.5 12 29,745
CIN, cervical intraepithelial neoplasia; FIGO, International Federation of Gynaecology and Obstetrics; HPV, 
human papillomavirus.
*Costs included in treatment costs.
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cancer, hrHPV positivity rates and the hrHPV-type distribution by age and by lesion 
grade (Appendix S1, Figures S10-S15). The model also validated well with age-specific 
cervical cancer mortality rates observed in the Netherlands in 2004-2013 (Appendix S1: 
Figure S16).
Table 3. Base case results per 100 000 women simulated lifelong








Total screening tests 444,356 364,306 -18
- Primary screening tests (GP) - 422,959 281,710 -33
- Primary self-samples - - 25,797 NA
- Reflex cytology after positive GP test - - 33,906 NA
- Cytology smear after positive self-sample - - 3,384 NA
- Tests 6 or 18 months after primary test - 21,397 19,509 -9
Referrals to colposcopy - 7,746 12,841 +66
- No lesion present - 1,458 5,242 +260
- CIN 1 - 1,514 2,851 +88
- CIN 2 - 1,523 2,039 +34
- CIN 3 / AIS - 3,070 2,509 -18
- Screen detected cervical cancer - 181 200 +10
Clinically detected cervical cancers 1,157 522 496 -5
Total cervical cancers 1,157 704 697 -1
Cervical cancer mortality 440 215 206 -4
Life-years gained compared to no screening - 5,163 5,250 +2
QALY’s gained compared to no screening - 4,580 5,161 +13
Costs (€ millions, undiscounted)
Screening tests - 33 19 -41
Diagnosis and treatment of precancerous lesions and 
false-positive referrals
- 9 12 +24
Diagnosis and treatment of cervical cancer 14.7 8 8 -2
Palliative care 13.1 6 6 -4
Total costs 27.7 57 45 -21
Cost-effectiveness (in €, discounted yearly by 3% for both costs and effects)
Costs per life-year gained compared to no screening - 15,247 10,890 -29
Costs per QALY gained compared to no screening - 22,678 12,225 -46
AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; GP, general practitioner; hrHPV, high-risk 
human papillomavirus; NA, not available because this was not present in the cytology programme; QALY, 
quality adjusted life-year.
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effects, costs and cost-effectiveness
Table 3 presents the base-case results per 100 000 30-year-old women followed for their 
remaining life. The table includes the predicted effects, costs and cost-effectiveness of 
offering either no cervical cancer screening at all, the cytology screening programme 
or the hrHPV-based screening programme. Compared to the cytology programme, 
the hrHPV-based programme used fewer screening tests (-18%), referred more women 
to colposcopy (+66%), decreased the cancer incidence (-1%) and mortality (-4%) and 
reduced the total costs (-21%). The extra referrals to colposcopy were predominantly 
among women with ≤ CIN1 and the decrease in total costs was mainly due to the lower 
number of screening tests.
The cost-effectiveness of the hrHPV-based programme was more favourable than 
that of the cytology-based programme. When compared to no screening, the cytology 
programme cost €22,678 per QALY gained, while this was €12,225 (-46%) for the hrHPV-
based programme. Per life-year gained, the cytology programme cost €15,247, while 
this was €10,890 (-29%) for the hrHPV-based programme.
Sensitivity analyses
Figure 1 shows that when the attendance rates at primary screening in the hrHPV-
programme were assumed to be equal to those of the cytology programme, the 
cost-effectiveness of the hrHPV-based programme slightly deteriorated from €12,225 
to €12,951 per QALY gained. Assuming the same adherence in the triage across both 
programmes also slightly deteriorated the cost-effectiveness of the hrHPV-based pro-
gramme (€13,108 per QALY gained). When both equal screening attendance and equal 
triage adherence were assumed, the cost-effectiveness would deteriorate to €13,757. 
Nevertheless, under these assumptions, the hrHPV-based programme would still remain 
more cost effective than the cytology-based programme (€22,678 per QALY gained).
Using the alternative set of disutilities or discount rates improved the cost-effectiveness 
of both programmes substantially, however the hrHPV-based programme remained the 
most cost-effective option of the two in both cases.
DISCuSSION
main findings
According to our modelling analyses, the recent switch from cytology to hrHPV testing 
in the Dutch cervical cancer screening programme will improve its cost-effectiveness. 
Compared to the lifetime cytology-based screening programme, the lifetime hrHPV-
based programme is expected to incur considerably fewer costs (-21%) for a modestly 
higher number of life-years (+2%) gained and 13% more QALYs gained.
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The reduction in total costs by switching to the hrHPV-based screening programme 
is almost completely due to the reduction in screening costs. The predicted increase 
in life-years gained is explained by the lower cancer incidence and cancer mortality in 
the hrHPV-based programme, in which more precancerous lesions are detected and 
treated despite lower attendance rates. We found that the increase in detection of low 
grade precancerous lesions is substantial. As most low grade lesions will not progress 
to cancer, the number of women who are referred to a gynaecologist unnecessarily 
increases as well, causing anxiety for these women and potentially leading to overtreat-
ment. However, the reduction in QALYs resulting from unnecessary referrals does not 
outweigh the QALYs gained because of the lower cancer incidence and cancer mortality.
The number of detected CIN3 lesions does not increase with the switch to hrHPV 
screening. Although the HPV test is more sensitive for CIN3 lesions than cytology, fewer 
CIN3 lesions are prevalent at screening because more low-grade lesions are picked up 
Figure 1. Results of the sensitivity analyses. The red dots and blue diamonds indicate the base-case cost-ef-
fectiveness of the hrHPV-based programme and the cytology-based programme respectively. The horizon-
tal lines indicate how the cost-effectiveness of each programme would change when: (1) the attendance 
to primary screening in the hrHPV-based programme would be equal to that of the cytology programme; 
(2) the adherence to triage testing would be equal to that of the cytology programme; (3) both the at-
tendance to primary screening and the adherence to triage testing would be equal to that of the cytology 
programme; (4) an alternative published utility set was applied to the results of both programmes1; (5) 
costs would be discounted with 4% annually and utilities with 1.5% annually, as is recommended in The 
Netherlands.26
hrHPV, high-risk human papillomavirus; QALY, Quality adjusted life year.
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before progression towards CIN3. The number of cancers detected by screening does 
increase, which is caused by the introduction of the extended screening intervals, allow-
ing more lesions to progress to cancer before the next screening round.
Sensitivity analyses on screening behaviour and utilities consistently showed a more 
favourable cost-effectiveness of the hrHPV-based programme.
limitations and strengths
In the Netherlands, the first cohort of women vaccinated against HPV-16 and HPV-18 
will enter the screening programme in 2023. We compared the effects of hrHPV-based 
screening with those of cytology-based screening for unvaccinated women only. The 
results of both programmes are likely to be different for vaccinated and unvaccinated 
women in vaccinated cohorts.10, 27 Therefore, the cost-effectiveness of screening in vac-
cinated populations needs further investigation.
Also, the attendance for primary screening for women aged 45, 55 or 65 could not 
yet be observed in the first round of the hrHPV-based programme, as the eligibility for 
screening at those ages normally depends on the results of the preceding round.
Furthermore, we compared the cost-effectiveness between both programmes by di-
viding the total costs by the total QALYs gained. Although this method does capture the 
overall cost-effectiveness of each programme, different cost types might be allocated 
to different parties depending on how the programme is funded. Because of that, costs 
may rise for some parties, especially those paying for diagnosis and treatment of low 
grade lesions. If more costs would be allocated to participating women, this may lead to 
different screening behaviour.
To the authors’ knowledge, this is the first modelling study to use observed data from 
an implemented hrHPV-based organised screening programme as model inputs. The 
national pathology database, PALGA, which was the main source for calibrating the 
model and obtaining model inputs for this analysis, contains high-quality data on an 
individual level about results of both hrHPV-testing and cytology. Because this detailed, 
robust data could be used, the screening behaviour in both programmes could be mod-
elled very accurately, thereby reducing uncertainty of the outcomes.
Furthermore, univariate sensitivity analyses were performed varying several impor-
tant assumptions. The hrHPV-based screening programme remained more cost effective 
in all sensitivity analyses.
Interpretation
The main reason the hrHPV-based screening programme was found to be more cost 
effective than the cytology-based programme is because the hrHPV-based screening 
programme has lower screening costs while retaining the protection for cervical can-
cer. These screening costs are lower due to the reduced number of screening rounds 
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combined with lower unit costs for primary hrHPV testing versus cytology. The retained 
protection at longer intervals has also been demonstrated by follow-up studies of the 
POBASCAM trial and the ARTISTIC trial.28, 29 Therefore, reducing the number of screening 
rounds can be concluded to be a safe way to improve the cost-effectiveness of hrHPV-
based screening programmes.
The finding that the hrHPV-based screening programme is more cost effective than 
the cytology-based screening programme is in line with previous modelling studies 
assessing the cost-effectiveness of comparable cytology-based and hrHPV-based 
screening programmes.1, 2, 27, 30 Although the methods and assumptions used in previous 
studies vary widely, none of them used inputs that were observed after implementation 
of an hrHPV-based programme. Because of that, the same screening attendance was 
assumed for both programmes. When comparing the difference in effects between both 
programmes in this study with that of previous studies, one should be aware of this 
difference in assumptions on screening behaviour.
The lower observed attendance rate in the hrHPV-based screening programme might 
be directly related to specific organisational changes that were implemented next to the 
switch in screening protocol.4 For example, GPs are no longer able to personally invite 
women for screening. Therefore, the lower attendance rates in hrHPV-based screening 
might not be applicable to other countries implementing hrHPV-based screening.
Previous studies showed that offering hrHPV self-sampling could increase the par-
ticipation in women who would otherwise not attend screening.31 Now that the hrHPV 
self-sampling kit has been found to be non-inferior to a GP-test,19 offering hrHPV self-
sampling could improve the effectiveness of screening programmes.19, 32 This is depen-
dent on the proportion of regular attendees that would switch to self-sampling and the 
proportion of never attenders, with a higher background risk, that will now participate 
in self-sampling.32
We showed that the switch to the hrHPV-based screening programme leads to an 
increase in the detection rates of low-grade CIN lesions. Most of the detected low-grade 
lesions will not progress.7 Previous studies on triage strategies have shown that the 
number of unnecessary referrals to colposcopy could be reduced by the use of genotyp-
ing.33 Genotyping is not used in the current Dutch hrHPV-based screening programme, 
but should be considered to reduce the number of colposcopies.
CONCluSION
Even though lower participation in primary screening and lower adherence to triage 
testing were observed after the introduction of the hrHPV-based screening programme 
in the Netherlands, the cost-effectiveness is still estimated to be more favourable in the 
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hrHPV-based programme than in the old cytology-based programme. However, there is 
a substantial increase in the number of women who are unnecessarily referred to a gyn-
aecologist increases substantially, so alternatives for the currently used triage strategy 
should be investigated.
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Declining attendance in the Dutch cervical cancer screening programme was recently 
observed, coinciding with preparations for implementing primary hrHPV-based screen-
ing, which was implemented in January 2017. We aimed to investigate which factors 
were related to decreased attendance. We conducted a population-based cohort study 
including all women aged 30 to 60 years who were eligible for screening between 
2014 and 2018. Attendance was defined as participation in the screening programme 
within 15 months of the start of the invitation-eligible year. We used data from the 
Dutch pathology archive (PALGA) linked with data from Statistics Netherlands to 
investigate population characteristics (position in the household, household income, 
socio-economic status, number of people in the household, migration background, 
age) and data from the five Dutch screening organisations (SO) to investigate the ef-
fect of cessing self-inviting GP’s (‘inviting organisation’). SO’s were termed SO 1 to 5. 
Higher attendance rates were observed in women who were employed (60.8%), married 
(62.9%), Dutch (61.2%), in the highest income bracket (63.4%), living in households with 
four persons (65.3%) and women who were invited by their GP (69.8%). Differences in 
personal characteristics did not explain the decline in attendance rates. By adjusting 
for whether the GP or the SO sent the invitation, the differences in attendance rates 
between 2014-2015 and 2016 and between 2014-2015 and 2017-2018 were explained 
in some screening organisations. Removing the possibility for GPs to send invitations 
explains some of the decline in participation, although this did not account for the total 
change in attendance.
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Several studies have shown that there is an upward shift in the classification of cervical 
cytology when high-risk HPV (hrHPV) status is known to be positive. The Netherlands 
implemented primary hrHPV screening with reflex cytology as the primary screening 
test in 2017. Prior to implementation of the new programme, we aimed to investigate 
whether knowledge of hrHPV status influences cytology rating.
methods
Using a set of 200 cytology slides that had been previously tested, two pairs of cytotech-
nicians rated 100 slides per pair twice; first without knowledge of hrHPV status and then, 
after a wash-out period of two months, with knowledge of hrHPV status.
results
We found that hrHPV positive slides were more likely to be rated up over the referral 
threshold (i.e. from negative for intraepithelial lesion or malignancy to atypical squa-
mous cells of undetermined significance+) than hrHPV negative slides at the second 
review when hrHPV status was known (relative risk = 3.2; 95% CI: 1.3 – 7.9).
Conclusions
If the same upward shift in ratings were to be observed in the national programme, it 
may have implications for referrals of women with low-grade lesions.
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INTrODuCTION
In 2017, the Netherlands implemented primary high-risk HPV (hrHPV) screening in the 
national cervical cancer screening programme, replacing primary cytology. All eligible 
women (aged 30 to 60 years) are offered hrHPV screening every five years, with reflex 
cytology when hrHPV is found.
Several studies have found that knowledge of positive HPV status can result in 
upward rating of cervical cytology.1-6 In the renewed Dutch programme, all cytology 
slides reviewed will be hrHPV positive. An upward shift in cytology rating may result in 
more referrals. We aimed to investigate whether cytotechnicians would classify cytology 
slides higher when positive hrHPV status is known.
meTHODS
A set of 200 unmarked glass slides (~50% hrHPV positive), taken between August 2013 
and July 2014 and adjusted for age and expected proportion of cytological abnormali-
ties, was selected from the Dutch screening comparison study (DuSC).7 This set was di-
vided into two sets of 100, each allocated to a pair of cytotechnicians for review.
Four experienced cytotechnicians volunteered for this study and were grouped into 
two pairs. Prior to the implementation of the hrHPV screening programme, each pair 
reviewed 100 slides twice: once without hrHPV status, and after a two-month wash-out, 
with hrHPV status and reordered slides. Analysts were asked to rate slides in one of the 








There were 800 individual observations from the entire dataset; 400 observations from 
each review (100 paired observations per cytotechnician). Twenty slides (10% of sample; 
9 hrHPV positive, 11 hrHPV negative) were excluded due to the incorrect hrHPV status 
being accidentally provided at the second review, resulting in 360 paired observations 
from 180 slides. Switches in rating between review 1 and 2 were classified as upgrades 
(e.g. NILM to ASC-US), downgrades (e.g. LSIL to NILM), no change (e.g. NILM at both rat-
ings) or to/from inadequate. Ratings from NILM to ASC-US+ or vice versa were classified 
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as switches over or below the referral threshold. The net increase/decrease in referrals 
was calculated by subtracting the number of upgrades over the referral threshold at 
the second review from the number of downgrades below the referral threshold at the 
second review.
Data analysis was performed using SAS Base 9.4 and IBM SPSS Statistics v25. The high-
est classification was selected for three records categorised in multiple categories (e.g. 
‘Pap 0/1’). Risk estimates were calculated. Proportional risk difference was calculated us-
ing Wald asymptotic test of equality. Wald asymptotic confidence limits were calculated 
for proportions.
reSulTS
HrHPV positive slides were more likely to be upgraded over the referral threshold at the 
second review than hrHPV negative slides (relative risk (RR) = 3.2; 95% CI: 1.3 – 7.9). There 
was a net increase in ratings that would result in referral between the first and second 
review of 12 for hrHPV positive slides and a net decrease of 18 for hrHPV negative slides.
Overall, hrHPV negative slides were downgraded 29 times (15.9%; 95% CI: 10.6% - 
21.3%), compared with 15 times (8.4%; 95% CI: 4.3% – 12.5%) for hrHPV positive slides 
(p = 0.03). Conversely, hrHPV positive slides were upgraded 22 times (12.4%; 95% CI: 
7.8% - 17.2%), compared with seven times (3.8%; 95% CI: 1.0% - 6.7%) for hrHPV negative 
slides (p = 0.003). Results by Bethesda classification are shown in Figure 1.
DISCuSSION
This study suggests there may be an upward shift in the rating of cervical cytology slides 
when positive hrHPV status is known. Our results show that hrHPV positive slides were 
rated upwards more often than hrHPV negative slides, and more often over the referral 
threshold. This is consistent with previous literature.3,4 Upgrading cytology when hrHPV 
status is positive was previously observed in Dutch observational data. Between 2007 
and 2016, hrHPV testing was used in some laboratories as an additional test at six months 
for women with ASC-US/LSIL at primary screening. Under this policy, significantly fewer 
slides were rated NILM, and significantly more slides were rated ASC-US/LSIL at six-
month follow-up when hrHPV status was known.8 Similar results were also seen in the 
regular monitoring of the Dutch national screening programme, with more slides rated 
at ASC-US or higher when hrHPV testing was performed at six-month follow-up.9
Two studies1,2 found that prior knowledge of hrHPV status resulted in an increased 
sensitivity for CIN 2+ lesions, which points to an increase in true positive referrals. How-
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ever, first results of the new hrHPV screening programme show both increased CIN 2+ 
detection and more unnecessary referrals (<CIN 2) compared with the cytology-based 
programme,10 suggesting that there may be an influence of upward cytology ratings on 
the number of referrals of women with low-grade lesions. As all women with hrHPV posi-
tive, ASC-US+ primary screens are directly referred in the new hrHPV-based programme, 
Figure 1: Flowchart of switches in cytology ratings between slide review 1 and slide review 2 by hrHPV status, 
rounded percentages
NILM: Negative for intraepithelial lesion or malignancy
ASC-US: Atypical squamous cells of undetermined significance
LSIL: Low-grade squamous intraepithelial lesion
Numbers in the figure represent pairs of observations for one analyst, not the total count of slides; 360 pairs 
of observations are included in this figure.
Percentages are rounded to one decimal place. As such, totals may not sum to 100%.
Dashed black arrows represent upgrades and solid black arrows represent downgrades. Solid grey arrows 
represent changes to or from ‘inadequate’.
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an increase in slides rated as ASC-US may lead to more women with low-grade lesions 
being referred unnecessarily. This is concerning, as overtreatment of low-grade lesions 
also presents risks of harm. To mitigate the impact of potential cytology upgrading 
within the Dutch programme, training was provided at all five screening programme 
laboratories on morphological differences between Pap classifications (personal com-
munication, 28 February 2018) and professional education continues to be provided.
This study has several strengths. Because this study was conducted prior to imple-
mentation of the new hrHPV screening programme, cytotechnicians were still review-
ing both hrHPV positive and negative slides. The cytotechnicians in this study were 
experienced in evaluating cervical cytology. The distribution of age and abnormalities 
reflects the screened population, as slides were drawn from the screening programme. 
The study also has some limitations. The small sample size has an impact on statistical 
power. Additionally, 10% of slides were excluded, due to incorrect HPV status provided 
at the second review.
CONCluSION
Our study suggests that knowledge of hrHPV status may result in an upward shift in 
cytology ratings. While appropriate training is being provided to cytotechnicians, 
continued monitoring of unnecessary referrals will be essential, to mitigate risks of 
overtreatment following referrals of women with low-grade lesions.
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With the implementation of primary high-risk human papillomavirus (hrHPV) screening 
in the Netherlands, an increase was observed in the number of unnecessary referrals 
(<=Cervical Intraepithelial Neoplasia (CIN) 1) to colposcopy. We aimed to investigate 
which alternative triage strategies safely reduce unnecessary referrals in HPV-based 
cervical cancer screening programmes.
methods
Microsimulation model MISCAN was used to simulate an unvaccinated cohort of ten 
million 30-year old Dutch women. We calculated unnecessary referrals, cervical cancer 
incidence, mortality, costs and QALYs for 24 triage strategies. Condition for direct referral 
(atypical squamous cells of undetermined significance (ASC-US), low-grade squamous 
intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), condi-
tional on HPV-genotype 16/18/other high risk (OHR)), type of triage test (cytology alone 
or combined with hrHPV) and time to triage test (6 or 12 months) was varied.
results
The 24 triage strategies had varying effects on the number of unnecessary referrals 
ranging from -72% to +35%. Adjusting conditions for referral to ‘HPV16/18+ and ASC-
US+’ and ‘HPVOHR+ and HSIL+’ and extending the interval between tests to 12 months 
resulted in a reduction in unnecessary referrals of 40% (incidence +0%, mortality -1%). 
Reduction in unnecessary referrals without genotyping was achieved by adjusting con-
ditions for direct referral to LSIL (12 months to repeat test) (unnecessary referrals -37%, 
incidence +2%, mortality +0%).
Conclusions
To reduce the number of unnecessary referrals without increasing incidence and mortal-
ity by more than 2% in the Dutch cervical cancer screening programme, genotyping for 




Many high-income countries have recently made the transition from primary cytology 
screening to primary high-risk human papillomavirus (hrHPV) DNA screening in their 
cervical cancer screening programmes.1-3 In 2017, the Netherlands became the first 
country to implement a national cervical cancer screening programme based on primary 
hrHPV screening for all women, either by clinician-collected testing or self-sampling, 
and reflex cytology triage. Women aged 30 to 60 years are eligible for invitation. Women 
who test hrHPV-positive with cytological abnormalities (atypical squamous cells of 
undetermined significance (ASC-US) or higher) are referred to the gynaecologist, and 
hrHPV-positive women without cytological abnormalities are invited for a repeat cytol-
ogy test after six months.
Not all women who are referred from cervical cancer screening programmes require 
treatment because low-grade lesions (< CIN 2) can regress without intervention. These 
women are unnecessarily referred. The first results of the hrHPV screening programme 
showed that the number of unnecessary referrals to the gynaecologist increased after 
implementation,4 which confirmed model estimates from prior to the programme’s 
implementation.5 Increases in unnecessary referrals can lead to increased costs and 
colposcopy capacity problems.6 It can also be distressing and cause anxiety for women.7 
Additionally, unnecessary treatment of detected regressive or non-progressive pre-
invasive lesions can cause physical distress, such as pain, bleeding, and discharge, and 
has been associated with preterm births.8 Therefore, limiting unnecessary referrals and 
treatment can reduce harms related to treatment. Following the successful implementa-
tion of the programme in the real-life setting, reducing the number of unnecessary re-
ferrals was identified as the first opportunity to optimise the new screening programme.
Currently available technologies that can be used to optimise the triage algorithm as 
a fast and easy way to achieve a reduction in unnecessary referrals are 1) adding geno-
typing to the triage algorithm, 2) changing the cytology cut-off for direct referral (LSIL 
instead of ASC-US), and 3) lengthening the time to repeat cytology testing. The latter 
is based on the fact that most hrHPV infections regress within one to two years,9 which 
means that most infections are probably not yet regressed within 6 months (i.e. the cur-
rent repeat interval). However, the impact of these potential changes on unnecessary 
referrals and cervical cancer epidemiology has not yet been quantified.
We aimed, using microsimulation modelling, to identify a triage strategy which results in 
a quickly achievable reduction of the number of unnecessary referrals, without increasing 
cervical cancer incidence and mortality beyond what is considered acceptable. We calcu-
lated the effects of implementing the following possible options (or combinations thereof): 
adding genotyping on HPV16 or HPV16/18; adding a repeat hrHPV test; increasing time to 




In order to estimate the costs and health effects of different triage strategies, we 
conducted analysis using the MISCAN-Cervix microsimulation model. MISCAN-Cervix 
is a well-documented semi-Markov microsimulation software program. We used the 
recently calibrated version of MISCAN-Cervix described previously by Jansen and col-
leagues.6
mISCaN-Cervix model
MISCAN-Cervix generates a large hypothetical population with individual life histo-
ries. For this study, we simulated a cohort of ten million unvaccinated 30-year-old 
women based on Dutch demographic10 and hysterectomy data.11 Women in the 
simulated population can acquire one or more hrHPV infections during their life. 
These infections are categorised in four groups, based on their oncogenicity and 
their presence in different vaccine types (i.e. the bi-, quadri-, and nonavalent vaccine). 
These groups are (1) HPV-16, (2) HPV-18, (3) Other high risk HPV types (HPV-OHR; 
HPV-31/33/45/52/58/35/39/51/56/59/66/68). In MISCAN-Cervix, a distinction is made 
between HPV-31/33/45/52/58 and HPV-35/39/51/56/59/66/68, but results for these two 
groups are presented together in this study. The infection either clears or leads to the 
development of pre-invasive cervical lesions. These lesions can either regress or develop 
into invasive cervical cancer, classified in FIGO (International Federation of Gynecology 
and Obstetrics) stages 1A, 1B, 2, 3, and 4. In the model, death can occur from cervical 
cancer or from other causes. Multiple infections can occur at the same time, which are 
independent of each other. Interventions such as hysterectomy, treatment, and screen-
ing can affect these life histories. Pre-invasive stages and FIGO 1A cases can only be 
detected by screening, as these are assumed to be asymptomatic, whereas FIGO 1B or 
worse can also be clinically diagnosed.
Disease development
The model divides cervical disease into nine sequential stages: hrHPV infection, three 
pre-invasive stages (CIN grade 1, 2, and 3), and five invasive stages (FIGO stages 1A, 
1B, 2, 3, and 4). The risk of acquiring an hrHPV infection is age- and type-specific. In 
the model, most HPV infections are transient. Lesions in pre-invasive stages can also 
regress. While pre-invasive lesions can develop without an HPV infection (in which case 
they will always regress in our model), cervical cancer can only develop in the presence 
of a hrHPV infection. The durations of HPV infections as well as most pre-invasive and 
invasive cancer stages are modelled as exponential distributions with different average 
durations, as shown in Table 1.
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To account for different cancer risk levels for different HPV genotypes, the progression 
probabilities for the different health stages are dependent on the genotype of the HPV 
infection [see Appendix A]. The progression probabilities per group of HPV genotypes 
were found through calibration. Progression probabilities for an HPV-16 infection are 
higher than average for all lesion grades, whereas those for an HPV-35/39/51/56/59/66/68 
infection are lower for all lesion grades. For HPV-18 infections, the progression prob-
abilities are generally higher than those of HPV-31/33/45/52/58 infections, although this 
does depend on the lesion grade.6
Table 1: Average sojourn time until progression or regression and cytology/HPV test characteristics per stage.
HPV infection 
present
Disease status mean duration 
(Weibull 
distribution)








≥1 HPV infection no CIN present 1 year29,30 17.1% 0.0% 55.0%
≥1 HPV infection CIN1 1.5 years31 36.2% 2.6% 72.0%
≥1 HPV infection CIN2 2 years31 37.1% 10.7% 94.0%
≥1 HPV infection CIN3°ªº 14.3/5.7 years*ª 75.4% 51.6% 94.0%
≥1 HPV infection FIGO 1A 4 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 1B 2.2 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 2 1.7 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 3 1.7 yearsª 85.1% 64.7% 94.0%
≥1 HPV infection FIGO 4 0.7 yearsª 85.1% 64.7% 94.0%
No HPV no CIN present - 0.6% 0.04% 0.0%
No HPV CIN1 1.5 years31 36.2% 2.6% 0.0%
No HPV CIN2 2 years31 37.1% 10.7% 0.0%
No HPV CIN3 14.3/5.7 years*ª 75.4% 51.6% 0.0%
No HPV FIGO 1A 4 yearsª 85.1% 64.7% 0.0%
No HPV FIGO 1B 2.2 yearsª 85.1% 64.7% 0.0%
No HPV FIGO 2 1.7 yearsª 85.1% 64.7% 0.0%
No HPV FIGO 3 1.7 yearsª 85.1% 64.7% 0.0%
No HPV FIGO 4 0.7 yearsª 85.1% 64.7% 0.0%
ª Calibrated in MISCAN-cervix
* Progressive CIN 3/Regressive CIN 3
** Probability to test positive the first time a women with this lesion present attends screening. 12% of the 
CIN lesions will be missed systematically over time.
*** The same test characteristics are assumed for GP smears as for self-sampling kits
hrHPV = high-risk human papillomavirus; CIN = cervical intraepithelial neoplasia; ASC-US = Atypical squa-
mous cells of undetermined significance; LSIL = Low-grade squamous intraepithelial lesion; HSIL = High-




The test characteristics for cytology were calibrated based on CIN detection rates and 
interval cancers between 2004-2013 (Table 1). The test characteristics for the HPV test 
were based on literature.12, 13 The test characteristics for the HPV self-test were assumed 
to be equal to those of the regular HPV test. Furthermore, the sensitivity of colposcopy 
is assumed to be 100%.
Triage strategies
We estimated the costs and health effects of 24 different triaging strategies (including 
the current triage strategy; Figure 1)). These were subdivided into six categories. Table 2 
contains information about all 24 strategies. Visual representations of the six categories 
of strategies can be found in Appendix B. For each category of strategies, we estimated 
effects based on both a six-month period and a 12-month period to repeat testing.













Figure 1: Current HPV-based screening and triage algorithm.
HPV-/+: negative/positive result of HPV test
ASC-US: Atypical squamous cells of undetermined significance
NILM: Negative for intraepithelial lesion or malignancy
M/Y: months/years
NB: Primary screening could be conducted by a general practitioner or by using a self-sampling kit. Women 
who are hrHPV-negative at age 60 exit the programme and do not receive another screening invitation.
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The first alternative strategy is to extend the time to repeat cytology (TTR) from 6 
months to 12 months (Strategy name: ‘12mthTTR’). In the second category, we added 
an HPV test to the repeat test after six months. In this strategy, the repeat test for HPV 
positive, cytology negative women consists of an HPV test first and a cytology reflex 
test if the HPV test is positive. If both are positive, women are referred for colposcopy 
(Strategy names: ‘ExtraHPV’, ‘ExtraHPV-12mthTTR’).
For the third category of triage strategies, we increased the referral threshold after 
the reflex cytology to either low-grade squamous intraepithelial lesion (LSIL) or high-
grade squamous intraepithelial lesion (HSIL) (Strategy names: ‘CytLSIL’, ‘CytHSIL’, ‘CytLSIL-
12mthTTR’, ‘CytHSIL-12mthTTR’).
The fourth category is a combination of the second and third category: an HPV test 
was added to the repeat test after six months and the referral threshold after the initial 
reflex cytology was increased to LSIL or HSIL, respectively (Strategy names: ‘ExtraHPV-
CytLSIL’, ‘ExtraHPV-CytHSIL’, ‘ExtraHPV-CytLSIL-12mthTTR’, ‘ExtraHPV-CytHSIL-12mthTTR’.)
In the fifth category, the initial triage of hrHPV-positive women was based on both the 
cytology result and the hrHPV genotype. We simulated two scenarios in which women 
who were positive for HPV16 or HPV18 were referred as usual, but women who were 
HPV-OHR positive were only directly referred if they had at least an LSIL or HSIL cytology 
result. In two additional similar scenarios, only women with HPV16 were referred as usual 
(Strategy names: ‘16/18+ASC-US+/OHR+LSIL,’ ‘16/18+ASC-US+/OHR+HSIL’, ‘16/18+ASC-
Table 2: Strategies based on months to repeat test, repeat test type and direct referral conditions. Strategy 1.1 
is the current strategy.
Category Strategy Triage interval
(months)
Triage tests Direct referral conditions
1 1.1; 1.2 6; 12 Cytology HPV positive, ASC-US+
2 2.1; 2.2 6; 12 hrHPV, Cytology HPV positive, ASC-US+
3 3.1; 3.2 6; 12 Cytology HPV positive, HSIL+
3 3.3; 3.4 6; 12 Cytology HPV positive, LSIL+
4 4.1; 4.2 6; 12 hrHPV, Cytology HPV positive, HSIL+
4 4.3; 4.4 6; 12 hrHPV, Cytology HPV positive, LSIL+
5 5.1; 5.2 6; 12 Cytology HPV16/18 positive, ASC-US+ or
other hrHPV positive, HSIL+
5 5.3; 5.4 6; 12 Cytology HPV16/18 positive, ASC-US+ or
other hrHPV positive, LSIL+
5 5.5; 5.6 6; 12 Cytology HPV16 positive , ASC-US+ or
other hrHPV positive, HSIL+
5 5.7; 5.8 6; 12 Cytology HPV16 positive , ASC-US+ or
other hrHPV positive, LSIL+
6 6.1; 6.2 6; 12 Cytology HPV16/18 positive or other hrHPV positive, HSIL+




OHR+LSIL’, ‘16+ASC-US+/OHR+HSIL’, ‘16+ASC-US+/OHR+LSIL-12mthTTR’, ‘16+ASC-US+/
OHR+HSIL-12mthTTR’).
Finally, in the sixth category we simulated one scenario in which women who were 
positive for HPV16 were referred to the gynaecologist directly, without cytological 
testing. The remaining hrHPV-positive women were only referred if they had at least 
an HSIL cytology result. In another scenario, women with HPV18 were referred directly 
as well, irrespective of the cytology result (Strategy names: ‘16/18+/OHR+LSIL’, ‘16/18+/
OHR+HSIL’, ‘16/18+/OHR+LSIL-12mthTTR’, ‘16/18+/OHR+HSIL-12mthTTR’).
Key outcomes
Outcomes of interest are the number of unnecessary referrals, cervical cancer mortality, 
cervical cancer incidence, total costs and number of lost quality-adjusted-life-years (QA-
LYs). We defined clinically relevant lesions as being CIN 2 or higher, meaning all referrals 
resulting in a diagnosis of lower than CIN 2 were considered unnecessary. We calculated 
a woman’s QALYs by subtracting disutilities caused by either screening-related events 
or due to disease from the total number of life-years lived. The values of the disutilities 
are determined by the duration of the event and a weight reflecting the severity of the 
event. We used a similar approach to determine the total costs of screening; for each 
screening- or disease-related event, there are associated costs which are summed over 
the lifetime of all simulated women. The assumptions for QALYs and costs can be found 
in Appendix C. All outcomes are presented per 100,000 30-year-old women followed 
lifelong. Suitable strategies are defined as those which result in a decrease in unneces-
sary referrals and less than 2% increase in cervical cancer incidence or mortality. We 
allowed for an increase up to 2% to account for random variation in model outcomes.
base case analysis
In the base case analysis, we assumed attendance rates of primary screening and adher-
ence to repeat testing and colposcopy referral to be 100%. In this way, we tailor the 
triage strategy to women who attend the screening programme and we avoid unneces-
sary screening of these women. In addition, we applied disutilities from screening and 
colposcopy referrals as reported in the Dutch utility study by de Kok and colleagues.14
Sensitivity analyses
In univariate sensitivity analyses, we varied several uncertain parameters to investigate 
their influence on the model outcomes. For screening behaviour, we performed three 
different sensitivity analyses (details can be found in Appendix D). First, we assumed 
attendance and adherence as observed in 2017 in the Netherlands in order to get an 
estimate of how each strategy would perform in the context of current screening at-
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tendance rates.6 Secondly, we used the attendance and adherence as observed in 2017, 
but we decreased the adherence for the repeat test to 69% if the time to repeat test 
was increased to 12 months, based on the participation for triage cytology after 12 
months in the old Dutch cytology-based programme.15 As a third scenario, we applied 
the attendance rates as observed in 2014-2016 in the Netherlands, when a cytology-
based screening algorithm was used. In this period the attendance and adherence were 
somewhat higher than in 2017 (assuming that in the future the attendance will return to 
the previous rates again).4 In the second sensitivity analysis we used alternative disutility 
assumptions.16, 17 In the third sensitivity analysis, we increased sensitivity of the cytol-
ogy test after a positive HPV test by 50% for CIN 1 and CIN 2 as compared to the test 
characteristics in the base case analysis. Higher sensitivity has been measured when 
the cytology test is used as a reflex or repeat test as compared to use as a primary test.18 
Lastly, we considered the effect of a change in the outcome measure by increasing the 
threshold for clinically relevant lesions from CIN 2 to CIN 3.
Patient and public involvement
This research was done without patient involvement. Patients were not invited to com-
ment on the study design, interpret the results or contribute to writing or editing of this 




The current screening programme resulted in 361 cancer diagnoses, 74 cervical cancer 
deaths and 19,838 unnecessary referrals per 100,000 women (Table 3). The strategies 
with direct referral for HPV16 or HPV16/18 positive women (category 6) cause an increase 
in unnecessary referrals (Figure 2). Therefore, this category of strategies does not meet 
the defined criteria of a preferred strategy. Furthermore, all the strategies where the cy-
tology referral threshold is increased (‘(ExtraHPV-)CytLSIL/HSIL’, category 3 and 4) cause 
a relatively large increase in mortality and incidence. Therefore, these strategies are also 
not preferred. One exception is the strategy where the referral threshold is increased to 
LSIL and the time to repeat testing is extended to 12 months (‘CytLSIL-12mthTTR’, Table 
2 (3.4)). Lastly, the strategy where the referral threshold is increased to HSIL for all HPV-
positive women who do not have HPV-16 with six months to repeat test (‘16+ASC-US+/
OHR+HSIL’, Table 2 (5.5)), causes an increase in both incidence and mortality of slightly 
more than 2% and is therefore excluded from the preferred strategies.
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Figure 2 also shows that only extending the time to repeat test to 12 months (‘12mth-
TTR’, Table 2 (1.2)) does not increase the incidence of or mortality from cervical cancer. 
On the contrary, it decreases incidence and mortality (-1.2% and -1.7%, respectively, 
Table 3) while also reducing the number of unnecessary referrals. In general, strategies 
with 12 months to repeat test result in a larger reduction of unnecessary referrals than 
strategies with 6 months to repeat test without deteriorating mortality or incidence.
The largest reductions in unnecessary referrals without substantial increase in mortal-
ity or incidence are achieved by genotyping for HPV16 (-45%, ‘16+ASC-US+/OHR+HSIL-
12mthTTR’ (5.6)) or HPV16/18 (-40%, ‘16/18+ASC-US+/OHR+HSIL-12mthTTR’ (5.2)) while 
allowing direct referral for HPV-OHR with HSIL+ cytology, with time to repeat test set to 
12 months. Without genotyping, the largest reduction (-37%) in unnecessary referrals is 
achieved by increasing the threshold for direct referral from ASC-US to LSIL while setting 
time to repeat test to 12 months (‘CytLSIL-12mthTTR’ (3.4)).
As expected, we found that the total cost of the screening programme decreases 
linearly with the decrease in unnecessary referrals (Figure 3). Finally, the QALYs lost 
increase linearly with the decrease in unnecessary referrals, as the number of repeat 
tests increases (Figure 3).




































1.1 Current 19,838 74 361 61,458,537 2,591
1.2  12mthTTR % -7% -2% -1% -1% 28%
2.1  ExtraHPV % -12% 1% 1% -1% 1%
2.2  ExtraHPV-12mthTTR % -17% -1% -1% -2% 29%
3.4  CytLSIL-12mthTTR % -37% 0% 2% -5% 40%
5.1  16/18+ASC-US+/OHR+HSIL % -32% 1% 2% -4% 6%
5.2  16/18+ASC-US+/OHR+HSIL-12mthTTR % -40% -1% 0% -6% 39%
5.3 16/18+ASC-US+/OHR+LSIL % -19% 1% 1% -2% 3%
5.4  16/18+ASC-US+/OHR+LSIL-12mthTTR % -26% -2% -1% -3% 34%
5.6  16+ASC-US+/OHR+HSIL-12mthTTR % -45% 0% 2% -7% 42%
5.7  16+ASC-US+/OHR+LSIL % -21% 1% 1% -3% 4%
5.8  16+ASC-US+/OHR+LSIL-12mthTTR % -29% -1% 0% -4% 35%
* Strategies are only included if they increase cervical cancer incidence and mortality with at most 2%. The 
values of the current strategy are highlighted in bold.
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Figure 2: Reduction in unnecessary referrals plotted against incidence and mortality for all 24 strategies (per 
100,000 women).
The vertical and horizontal solid lines represent the current triage strategy. The dotted vertical line repre-
sents the 2% cut-off for mortality and incidence. Strategies on the left of this line and above the horizontal 
line are considered preferred.
Figure 3: Reduction in unnecessary referrals plotted against total costs and QALYs lost for all 24 strategies (per 
100,000 women).
The vertical and horizontal solid lines represent the current triage strategy. The dotted vertical line repre-




A detailed overview of the results of the sensitivity analyses can be found in Appendix 
E. We found that the results of the study are relatively robust for changes in attendance 
and adherence. None of the sensitivity analyses we have done for attendance and ad-
herence have caused a shift in the preferred strategies.
The number of QALYs lost decreased significantly when applying the alternative set of 
assumptions for disutilities due to screening and treatment.16, 17 This effect is especially 
large for strategies with twelve months to repeat testing.
We found that the results of this study are robust to the described increases in sensi-
tivity of the cytology test. The changes made have no substantial effect on the number 
of unnecessary referrals, mortality from or incidence of cervical cancer. Lastly, we found 
that the strategies based on genotyping result in a slightly larger reduction in unneces-
sary referrals, compared to the other strategies, when increasing clinical relevance from 
CIN2+ to CIN3+ due to the higher prevalence of HPV16 in this group. However, we did 
not find a change in preferred strategies.
DISCuSSION
The aim of this study was to identify a triage strategy that results in a quickly achiev-
able, safe reduction of the number of unnecessary referrals for colposcopy in the Dutch 
hrHPV-based cervical screening programme. We found that changing the conditions 
for referral based on HPV 16/18 genotyping resulted in a substantial reduction in un-
necessary referrals without increasing mortality or incidence. Similar results were also 
found by increasing the threshold for direct referral to LSIL for all HPV genotypes. For 
all strategies, 12 months to repeat test, compared to six months, resulted in the larg-
est reduction in unnecessary referrals. Univariate sensitivity analyses showed that the 
results are robust to changes in attendance, test characteristics, and clinical relevance 
threshold.
In the base case analysis, we found that the number of QALYs lost increases substan-
tially when the number of unnecessary referrals decreases. The reasons for this are two-
fold. Firstly, decreasing the number of referrals results in more women being advised to 
have repeat testing. In our base-case disutility set, repeat testing has a higher disutility 
weight than referral. Secondly, increasing the time to repeat testing from 6 months to 12 
months amplifies this effect while decreasing the number of referrals, since the disutility 
is applied for a longer period.14 When using a different set of disutility assumptions, the 
number of QALY’s lost were lower, because a longer period of uncertainty distressed 
women who were surveyed less.16, 17 Given the large variation in women’s preference, 
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we decided not to focus on QALYs lost as a main outcome measure, instead focusing on 
outcomes that could be measured more objectively.
The HPV16/18 genotyping strategies resulted in a large reduction in unnecessary re-
ferrals without increasing mortality or incidence. This is explained by the fact that 70 to 
76% of cervical cancers worldwide are caused by these two types of hrHPV infections.19 
By only raising the referral threshold for the remaining hrHPV types, the number of un-
necessary referrals decreases without a large increase in the risk of leaving progressive 
lesions undetected. An increase in the time to repeat test also has a positive impact on 
the unnecessary referrals. An explanation for this is that a longer time to repeat test al-
lows the HPV infection to clear, since cervical cancer is a relatively slow growing cancer.
Our study has several strengths. All simulations were done with a validated model, 
which used data directly observed from the new hrHPV-based screening programme as 
input. MISCAN-Cervix is a well-used, published microsimulation model, which is used 
in comparative modelling studies and uses input values taken from observed data and 
from the peer-reviewed literature. Moreover, we evaluated many strategies that are 
easy to implement. This makes the results of the study directly applicable and relevant 
for practice in many countries that consider implementing primary HPV screening. In 
addition, in sensitivity analyses we considered a wide range of different values for adher-
ence, two sets of disutility assumptions and two sets of test characteristics for cytology. 
As the conclusions of the study did not change with these sensitivity analyses, we can 
conclude that the results of this study are robust to changes in assumptions.
Our study also has some limitations. There are a few alternative triaging methods 
that we did not consider, such as personalised (based on previous screen test results) 
screening strategies, co-testing, and new technologies. A Dutch study found women 
are at higher risk of a CIN 3+ lesions in the years following a hrHPV-positive screen, 
even if they have a hrHPV-negative screen in the subsequent screening round,20 sug-
gesting that personalised screening strategies based on factors like screening history 
may be beneficial. This was not considered as a viable option for triage optimisation at 
this time due to logistical reasons. Although co-testing is common practice in several 
Western countries, it has been found to be inefficient in modelling studies21 and, thus, 
was not considered. New technologies such as methylation, dual staining for p16/Ki67 
or HPV E6/7 mRNA testing have been shown to be promising triage options, with better 
sensitivity and specificity than cytology only.22-25 However, these technologies are still 
under investigation and not ready to implement in a running programme. Furthermore, 
implementing these technologies would require infrastructural changes to be made, 
such as extra training for cytotechnicians and pathologists, as well as changing screen-
ing laboratory workflow. Given our aim was to find an alternative triage strategy that 
could be rapidly implemented, these technologies were not considered. Finally, the 
quality of a model is always dependent on the data used and the assumptions made. 
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However, in the Netherlands, we have a population-based registry that contains data 
on all screening-indicators that we use for development of the model. Still, the assump-
tions for participation, test characteristics and disutilities are less certain when making 
changes to the screening programme that are not implemented yet (i.e. no observed 
data yet). We performed sensitivity analysis on the parameters that are most uncertain, 
to show the robustness of the results and found that they did not change our conclu-
sions.
This is the first study to compare so many strategies for triaging hrHPV-positive women 
in order to investigate unnecessary referrals versus cancer incidence and mortality. A 
smaller study has previously been published, which focused on determining the optimal 
triage strategy for a smaller subgroup of HPV-OHR positive women.26 They found that, 
for HPV-OHR positive women who had low-grade cytology, 12 month follow-up was the 
most cost-effective triage option, as it balanced the benefits of surveillance with harms 
of unnecessary referrals. For the group with high-grade baseline cytology, on the other 
hand, it was found to be cost effective to advise direct referral to colposcopy. While di-
rect comparison with these results is difficult, our study also found that risk stratification 
by HPV type and cytology grade are important for finding the optimal triage strategy for 
different groups of women.
We found that genotyping based on HPV-16/18 can improve the efficiency of triaging 
HPV-positive women. The same conclusion was reached by a recent data study on the 
implementation phase of the hrHPV-based screening programme in Norway, where 
CIN3+ risk was estimated for cytology results and HPV genotypes. By inviting women 
with HPV-OHR and low-grade cytology for a repeat test instead of referring these women 
for colposcopy, the harms and benefits of the screening programme were found to be 
more balanced.27
Internationally, the reduction in unnecessary referrals that can be achieved by imple-
menting HPV 16/18 genotyping should encourage policymakers to consider hrHPV test-
ing systems that allow for this feature; at a minimum, screening programme managers 
should consider the availability of systems that can distinguish HPV16 and HPV18 from 
HPV-OHR. Of course, policymakers need to evaluate the needs and requirements of their 
own settings prior to implementing a test system, but in the decision-making process, 
hrHPV genotyping should be considered as a possible addition to new HPV-based cervi-
cal cancer screening programme algorithms.
From 2023, the first cohort of women that were eligible for HPV vaccination will en-
ter the screening programme in the Netherlands. Although our study did not include 
vaccinated women within the simulated cohort, this important change to the eligible 
population will necessitate reassessment of the triage algorithm in the coming decade. 
Women vaccinated with a bivalent vaccine are protected against HPV16 and HPV18 in-
fections, which has been shown in other countries to reduce risk of CIN lesions amongst 
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both vaccinated and unvaccinated women (protected by herd immunity effects).28 
Without a more efficient triage strategy, such as genotyping, vaccinated women may 
be more likely to be unnecessarily referred to the gynaecologist. The balance between 
harms and benefits of screening for vaccinated women could be improved by including 
genotyping on HPV16/18 in the triage strategy.
CONCluSION
This study aimed to identify a triage strategy that results in a quickly achievable reduc-
tion of the number of unnecessary referrals with the Dutch cervical cancer screening 
programme, without deteriorating mortality from and incidence of cervical cancer. It is 
the first study where such a wide range of strategies is modelled to find the best strategy 
for all HPV positive women. We found that adding genotyping for HPV16 and/or HPV18 
to the referral algorithm while increasing the referral threshold for HPV-OHR to HSIL 
substantially decreases the number of unnecessary referrals without increasing cervical 
cancer incidence or mortality. Extending the time to repeat testing from six to 12 months 
also reduced unnecessary referrals. Based on our findings, we recommend implement-
ing genotyping as a triage strategy for HPV-positive women in the Dutch cervical cancer 
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Supplement to: S Kaljouw, EEL Jansen, CA Aitken et al. Reducing unnecessary referrals for col-
poscopy in hrHPV-positive women within the Dutch cervical cancer screening programme: 
a modelling study
appendix a: Transition probabilities per HPV genotype and age group as 
defined in mISCaN-Cervix.
Table S1 Transition probabilities (regression and progression) per HPV type, age group and current state, as 
defined in MISCAN-Cervix.
HPV type age regression Probability Progression Probability
from To from To
HPV 16 15 HPV 16 No HPV 0.968 HPV 16 CIN 1 0.032
HPV 16 25 HPV 16 No HPV 0.978 HPV 16 CIN 1 0.022
HPV 16 35 HPV 16 No HPV 0.886 HPV 16 CIN 1 0.114
HPV 16 50 HPV 16 No HPV 0.762 HPV 16 CIN 1 0.238
HPV 16 75 HPV 16 No HPV 0.993 HPV 16 CIN 1 0.007
HPV 18 15 HPV 18 No HPV 0.943 HPV 18 CIN 1 0.057
HPV 18 25 HPV 18 No HPV 0.962 HPV 18 CIN 1 0.038
HPV 18 35 HPV 18 No HPV 0.801 HPV 18 CIN 1 0.199
HPV 18 50 HPV 18 No HPV 0.582 HPV 18 CIN 1 0.418
HPV 18 75 HPV 18 No HPV 0.988 HPV 18 CIN 1 0.012
HPV 9V 15 HPV 9V No HPV 0.975 HPV 9V CIN 1 0.025
HPV 9V 25 HPV 9V No HPV 0.983 HPV 9V CIN 1 0.017
HPV 9V 35 HPV 9V No HPV 0.913 HPV 9V CIN 1 0.087
HPV 9V 50 HPV 9V No HPV 0.817 HPV 9V CIN 1 0.183
HPV 9V 75 HPV 9V No HPV 0.995 HPV 9V CIN 1 0.005
HPVOHR 15 HPVOHR No HPV 0.975 HPVOHR CIN 1 0.025
HPVOHR 25 HPVOHR No HPV 0.983 HPVOHR CIN 1 0.017
HPVOHR 35 HPVOHR No HPV 0.913 HPVOHR CIN 1 0.087
HPVOHR 50 HPVOHR No HPV 0.818 HPVOHR CIN 1 0.182
HPVOHR 75 HPVOHR No HPV 0.995 HPVOHR CIN 1 0.005
HPV 16 20 CIN 1 HPV 16 0.556 CIN 1 CIN 2 0.444
HPV 16 35 CIN 1 HPV 16 0.038 CIN 1 CIN 2 0.962
HPV 16 50 CIN 1 HPV 16 0.519 CIN 1 CIN 2 0.481
HPV 16 65 CIN 1 HPV 16 0.869 CIN 1 CIN 2 0.131
HPV 18 20 CIN 1 HPV 18 0.880 CIN 1 CIN 2 0.120
HPV 18 35 CIN 1 HPV 18 0.741 CIN 1 CIN 2 0.259
HPV 18 50 CIN 1 HPV 18 0.870 CIN 1 CIN 2 0.130
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Table S1 Transition probabilities (regression and progression) per HPV type, age group and current state, as 
defined in MISCAN-Cervix. (continued)
HPV type age regression Probability Progression Probability
from To from To
HPV 18 65 CIN 1 HPV 18 0.965 CIN 1 CIN 2 0.035
HPV 9V 20 CIN 1 HPV 9V 0.736 CIN 1 CIN 2 0.264
HPV 9V 35 CIN 1 HPV 9V 0.427 CIN 1 CIN 2 0.573
HPV 9V 50 CIN 1 HPV 9V 0.714 CIN 1 CIN 2 0.286
HPV 9V 65 CIN 1 HPV 9V 0.922 CIN 1 CIN 2 0.078
HPVOHR 20 CIN 1 HPVOHR 0.877 CIN 1 CIN 2 0.123
HPVOHR 35 CIN 1 HPVOHR 0.732 CIN 1 CIN 2 0.268
HPVOHR 50 CIN 1 HPVOHR 0.866 CIN 1 CIN 2 0.134
HPVOHR 65 CIN 1 HPVOHR 0.964 CIN 1 CIN 2 0.036
NoHPV 20 CIN 1 No HPV 0.762 CIN 1 CIN 2 0.238
NoHPV 35 CIN 1 No HPV 0.485 CIN 1 CIN 2 0.515
NoHPV 50 CIN 1 No HPV 0.743 CIN 1 CIN 2 0.257
NoHPV 65 CIN 1 No HPV 0.930 CIN 1 CIN 2 0.070
HPV 16 20 CIN 2 CIN 1 0.518 CIN 2 CIN 3 0.482
HPV 16 35 CIN 2 CIN 1 0.459 CIN 2 CIN 3 0.541
HPV 16 50 CIN 2 CIN 1 0.766 CIN 2 CIN 3 0.234
HPV 16 65 CIN 2 CIN 1 0.704 CIN 2 CIN 3 0.296
HPV 18 20 CIN 2 CIN 1 0.815 CIN 2 CIN 3 0.185
HPV 18 35 CIN 2 CIN 1 0.792 CIN 2 CIN 3 0.208
HPV 18 50 CIN 2 CIN 1 0.910 CIN 2 CIN 3 0.090
HPV 18 65 CIN 2 CIN 1 0.886 CIN 2 CIN 3 0.114
HPV 9V 20 CIN 2 CIN 1 0.657 CIN 2 CIN 3 0.343
HPV 9V 35 CIN 2 CIN 1 0.615 CIN 2 CIN 3 0.385
HPV 9V 50 CIN 2 CIN 1 0.833 CIN 2 CIN 3 0.167
HPV 9V 65 CIN 2 CIN 1 0.789 CIN 2 CIN 3 0.211
HPVOHR 20 CIN 2 CIN 1 0.729 CIN 2 CIN 3 0.271
HPVOHR 35 CIN 2 CIN 1 0.696 CIN 2 CIN 3 0.304
HPVOHR 50 CIN 2 CIN 1 0.868 CIN 2 CIN 3 0.132
HPVOHR 65 CIN 2 CIN 1 0.833 CIN 2 CIN 3 0.167
NoHPV 20 CIN 2 CIN 1 0.609 CIN 2 CIN 3 0.391
NoHPV 35 CIN 2 CIN 1 0.561 CIN 2 CIN 3 0.439
NoHPV 50 CIN 2 CIN 1 0.810 CIN 2 CIN 3 0.190
NoHPV 65 CIN 2 CIN 1 0.760 CIN 2 CIN 3 0.240
HPV 16 20 CIN 3 CIN 2 0.930 CIN 3 CC 0.070
HPV 16 35 CIN 3 CIN 2 0.882 CIN 3 CC 0.118
HPV 16 50 CIN 3 CIN 2 0.865 CIN 3 CC 0.135
HPV 16 65 CIN 3 CIN 2 0.090 CIN 3 CC 0.910
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Table S1 Transition probabilities (regression and progression) per HPV type, age group and current state, as 
defined in MISCAN-Cervix. (continued)
HPV type age regression Probability Progression Probability
from To from To
HPV 18 20 CIN 3 CIN 2 0.561 CIN 3 CC 0.439
HPV 18 35 CIN 3 CIN 2 0.254 CIN 3 CC 0.746
HPV 18 50 CIN 3 CIN 2 0.147 CIN 3 CC 0.853
HPV 18 65 CIN 3 CIN 2 0.090 CIN 3 CC 0.910
HPV 9V 20 CIN 3 CIN 2 0.970 CIN 3 CC 0.030
HPV 9V 35 CIN 3 CIN 2 0.949 CIN 3 CC 0.051
HPV 9V 50 CIN 3 CIN 2 0.942 CIN 3 CC 0.058
HPV 9V 65 CIN 3 CIN 2 0.090 CIN 3 CC 0.910
HPVOHR 20 CIN 3 CIN 2 0.981 CIN 3 CC 0.019
HPVOHR 35 CIN 3 CIN 2 0.968 CIN 3 CC 0.032
HPVOHR 50 CIN 3 CIN 2 0.963 CIN 3 CC 0.037
HPVOHR 65 CIN 3 CIN 2 0.090 CIN 3 CC 0.910
No HPV 20 CIN 3 CIN 2 1.000 CIN 3 CC 0.000*
No HPV 35 CIN 3 CIN 2 1.000 CIN 3 CC 0.000*
No HPV 50 CIN 3 CIN 2 1.000 CIN 3 CC 0.000*
No HPV 65 CIN 3 CIN 2 1.000 CIN 3 CC 0.000*
hrHPV = high-risk human papillomavirus; CIN = cervical intraepithelial neoplasia; CC = cervical cancer
* CIN 3 lesions can never transition to cervical cancer without an HPV infection
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appendix b Visual representation of triage strategies
Figure S1: Category 1 - Extend time to repeat test to 12 months
HPV-/+: negative/positive result of HPV test
ASC-US: Atypical squamous cells of undetermined significance
NILM: Negative for intraepithelial lesion or malignancy
M/Y: months/years
NB: The part of the triage algorithm that has been changed is highlighted in red text. Primary screening can 
be conducted by a general practitioner or via self-sampling, Women who are hrHPV-negative at age 60 exit 
the programme and do not receive another screening invitation.
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Figure S2: Category 2 - Add HPV test to repeat test
HPV-/+: negative/positive result of HPV test 
ASC-US: Atypical squamous cells of undetermined signifi cance 
NILM: Negative for intraepithelial lesion or malignancy 
M/Y: months/years 
NB: The part of the triage algorithm that has been changed is highlighted in red text. Primary screening can 
be conducted by a general practitioner or via self-sampling. Women who are hrHPV-negative at age 60 exit 
the programme and do not receive another screening invitation.
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Figure S3: Category 3 - Increase referral threshold to LSIL/HSIL (two strategies)
HPV-/+: negative/positive result of HPV test 
ASC-US: Atypical squamous cells of undetermined significance 
NILM: Negative for intraepithelial lesion or malignancy 
M/Y: months/years 
NB: The part of the triage algorithm that has been changed is highlighted in a red box. Primary screening 
can be conducted by a general practitioner or via self-sampling. Women who are hrHPV-negative at age 60 
exit the programme and do not receive another screening invitation.
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Figure S4: Category 4 - Combination of categories 2 and 3 (two strategies)
HPV-/+: negative/positive result of HPV test 
ASC-US: Atypical squamous cells of undetermined significance 
NILM: Negative for intraepithelial lesion or malignancy 
M/Y: months/years 
NB: The part of the triage algorithm that has been changed is highlighted in red text and a red box. Primary 
screening can be conducted by a general practitioner or via self-sampling. Women who are hrHPV-negative 
at age 60 exit the programme and do not receive another screening invitation.
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Figure S5: Category 5 - HPV genotyping and increase referral threshold to LSIL/HSIL (four strategies)
HPV-/+: negative/positive result of HPV test 
ASC-US: Atypical squamous cells of undetermined significance 
NILM: Negative for intraepithelial lesion or malignancy 
M/Y: months/years 
NB: The part of the triage algorithm that has been changed is highlighted in a red box. Primary screening 
can be conducted by a general practitioner or via self-sampling. Women who are hrHPV-negative at age 60 
exit the programme and do not receive another screening invitation.
Figure S6: Category 6 - HPV genotyping and direct referral (two strategies)
HPV-/+: negative/positive result of HPV test
ASC-US: Atypical squamous cells of undetermined significance
NILM: Negative for intraepithelial lesion or malignancy
M/Y: months/years
NB: The part of the triage algorithm that has been changed is highlighted in a red box. Primary screening 
can be conducted by a general practitioner or via self-sampling. Women who are hrHPV-negative at age 60 
exit the programme and do not receive another screening invitation.
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appendix C: assumptions for costs and quality-adjusted life years
Table S2: Assumptions for costs and quality-adjusted life years (QALYs) lost in the base case analysis





Primary hrHPV-test 58 0 0
Primary hrHPV selftest 43 0 0
Reflex cytology after hrHPV-test 26 0 0
Repeat cytology after hrHPV selftest 52 0.03 1
Repeat cytology after 6 months 53 0.03 6
DIaGNOSIS aND TreaTmeNT
No CIN 316 0.03 1
CIN1 986 0.03 1
CIN2 1 461 0.03 1
CIN3 1 710 0.03 1
FIGO1A 5 601 0.08 12
FIGO1B 13 283 0.08 12
FIGO2+ clinically detected 12 226 0.14 12
FIGO2+ screen-detected 13 092 0.14 12
Cancer survivor 0* 0.03 120
Palliative care 29 745 0.5 12
* Costs are included in treatment
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appendix D: assumptions for attendance and adherence in sensitivity analyses








GP-test participation by age in all women of the 
population*
     
30 43.4% 43.4% 52.3%
35 49.3% 49.3% 57.9%
40 56.4% 56.4% 64.3%
45 58.6%/15.6%** 58.6%/15.6%** 67.6%
50 61.5% 61.5% 70.4%
55 62.7%/12.7%** 62.7%/12.7%** 69.6%
60 60.3% 60.3% 66.8%
65 NA/3.1%***  NA/3.1%***  NA
Self-sampling participation by age*      
30 5.5% 5.5% NA
35 4.8% 4.8% NA
40 4.5% 4.5% NA
45 4.4%/0.9%** 4.4%/0.9%** NA
50 4.6% 4.6% NA
55 4.8%/1.0%** 4.8%/1.0%** NA
60 5.7% 5.7% NA
65 NA/0.2%***  NA/0.2%***  NA
Adherence to cytology after a positive self-sample 90.1% 90.1% NA
Adherence to triage testing (6/12m)      
- after primary office-based test 77.1% 69.0% 92.2%
- after primary self-sampling test 41.6% 69.0% NA
Adherence to a referral for colposcopy after a      
- direct referral (ASC-US/LSIL) 88.4% 88.4% NA
- direct referral (HSIL) 96.9% 96.9% 97.0%
- referral at 6 months after primary test  (ASCUS/LSIL) 88.4% 88.4% 97.5%
- referral at 6 months after primary test (HSIL) 96.9% 96.9% 97.5%
* Simulated participation rate in all women excluding those who have had a hysterectomy and those with 
a prevalent diagnosed cancer.
** Participation in the general population is much lower at ages 45 and 55 from the second screening 
round, because significantly fewer women are invited for screening at these ages (i.e. only those who do 
not participate or test hrHPV-positive in the preceding screening round). 
*** Participation in the general population is much lower at age 65 because significantly fewer women are 
invited for screening at this age (i.e. only those who test hrHPV-positive at age 65).
HPV = human papillomavirus; NA = not applicable; ASC-US = Atypical squamous cells of undetermined 




appendix e: results from sensitivity analyses
Table S4: Results of sensitivity analysis on attendance and compliance rates (per 100,000 women).
ATTENDANCE




12 6 12 12 6 12 6 12 12 6 12
Value
(base case)
% % % % % % % % % % %
Base case analysis
Unnecessary referrals 19,838 -7% -12% -17% -37% -32% -40% -19% -26% -45% -21% -29%
Mortality 74 -2% 1% -1% 0% 1% -1% 1% -2% 0% 1% -1%
Incidence 361 -1% 1% -1% 2% 2% 0% 1% -1% 2% 1% 0%
Costs (€) 61,458,537 -1% -1% -2% -5% -4% -6% -2% -3% -7% -3% -4%
QALYs lost 2,591 28% 1% 29% 40% 6% 39% 3% 34% 42% 4% 35%
Current screening programme
Unnecessary referrals 8,077 -6% -10% -14% -37% -35% -43% -17% -24% -49% -20% -27%
Mortality 192 -1% 1% 0% 1% 0% 0% 0% -1% 1% 0% 0%
Incidence 652 0% 0% 0% 1% 0% 0% -1% -1% 1% 0% -1%
Costs (€) 43,963,363 -1% 0% -1% -3% -3% -4% -1% -2% -4% -1% -2%
QALYs lost 5,073 5% 0% 6% 8% 1% 8% 0% 6% 9% 1% 7%
Current screening programme, low attendance for 12 months to repeat test
Unnecessary referrals 8,077 -8% - -15% -39% - -45% - -25% -51% - -29%
Mortality 192 0% - 0% 1% - 0% - 0% 2% - 0%
Incidence 652 -1% - 0% 1% - 0% - -1% 1% - 0%
Costs (€) 43,963,363 5% - -1% -3% - -4% - -2% -5% - -2%
QALYs lost 5,073 -8% - 5% 8% - 7% - 6% 9% - 7%
Cytology screening programme
Unnecessary referrals 10,096 -7% -12% -17% -39% -34% -43% -20% -28% -48% -23% -31%
Mortality 187 -1% 0% 0% 0% 0% -1% 0% -1% 0% 0% 0%
Incidence 627 0% 0% 0% 1% 1% 0% 0% 0% 1% 1% 0%
Costs (€) 46,575,467 -1% 0% -1% -3% -3% -4% -2% -3% -5% -2% -3%
QALYs lost 4,987 7% 0% 7% 11% 2% 10% 1% 9% 11% 1% 9%
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Table S5: Results of sensitivity analysis on disutility assumptions (per 100,000 women).
DISUTILITIES




12 6 12 12 6 12 6 12 12 6 12
Value
(base case)
% % % % % % % % % % %
Normal1
Unnecessary referrals 19,838 -7% -12% -17% -37% -32% -40% -19% -26% -45% -21% -29%
Mortality 74 -2% 1% -1% 0% 1% -1% 1% -2% 0% 1% -1%
Incidence 361 -1% 1% -1% 2% 2% 0% 1% -1% 2% 1% 0%
Costs (€) 61,458,537 -1% -1% -2% -5% -4% -6% -2% -3% -7% -3% -4%
QALYs lost 2,591 28% 1% 29% 40% 6% 39% 3% 34% 42% 4% 35%
Alternative2 3
Unnecessary referrals 19,838 -7% -12% -17% -37% -32% -40% -19% -26% -45% -21% -29%
Mortality 74 -2% 1% -1% 0% 1% -1% 1% -2% 0% 1% -1%
Incidence 361 -1% 1% -1% 2% 2% 0% 1% -1% 2% 1% 0%
Costs (€) 61,458,537 -1% -1% -2% -5% -4% -6% -2% -3% -7% -3% -4%
QALYs lost 2,843 3% 1% 3% 5% 0% 3% 0% 3% 4% 0% 4%








12 6 12 12 6 12 6 12 12 6 12
Value
(base case)
% % % % % % % % % % %
Normal
Unnecessary referrals 19,838 -7% -12% -17% -37% -32% -40% -19% -26% -45% -21% -29%
Mortality 74 -2% 1% -1% 0% 1% -1% 1% -2% 0% 1% -1%
Incidence 361 -1% 1% -1% 2% 2% 0% 1% -1% 2% 1% 0%
Costs (€) 61,458,537 -1% -1% -2% -5% -4% -6% -2% -3% -7% -3% -4%
QALYs lost 2,591 28% 1% 29% 40% 6% 39% 3% 34% 42% 4% 35%
Higher sensitivity (+50% for CIN 1 and CIN 2)
Unnecessary referrals 21,957 -5% -11% -14% -34% -29% -37% -17% -24% -42% -20% -26%
Mortality 72 -1% 1% -1% 0% 1% -2% 0% -2% -1% 1% -1%
Incidence 342 -1% 1% 0% 1% 1% 0% 0% -1% 1% 1% 0%
Costs (€) 63,781,599 -1% -1% -2% -4% -4% -5% -2% -3% -6% -2% -3%
QALYs lost 2,472 28% 1% 29% 40% 6% 40% 3% 34% 43% 4% 36%
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Table S7: Results of sensitivity analysis on assumptions for clinical relevance threshold (per 100,000 women).
CLINICAL RELEVANCE




12 6 12 12 6 12 6 12 12 6 12
Value % % % % % % % % % % %
>=CIN2
Unnecessary referrals 19,838 -7% -12% -17% -37% -32% -40% -19% -26% -45% -21% -29%
Mortality 74 -2% 1% -1% 0% 1% -1% 1% -2% 0% 1% -1%
Incidence 361 -1% 1% -1% 2% 2% 0% 1% -1% 2% 1% 0%
Costs (€) 61,458,537 -1% -1% -2% -5% -4% -6% -2% -3% -7% -3% -4%
QALYs lost 2591 28% 1% 29% 40% 6% 39% 3% 34% 42% 4% 35%
>=CIN3
Unnecessary referrals 24,206 -6% -10% -14% -32% -28% -35% -16% -23% -40% -18% -25%
Mortality 74 -2% 1% -1% 0% 1% -1% 1% -2% 0% 1% -1%
Incidence 361 -1% 1% -1% 2% 2% 0% 1% -1% 2% 1% 0%
Costs (€) 61,458,537 -1% -1% -2% -5% -4% -6% -2% -3% -7% -3% -4%
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Atypical glandular cells (AGC) are rare abnormalities found on cervical cytology associ-
ated with a range of lesions of the female reproductive system. We compared the risk of 
cervical and other gynaecological cancers following AGC on cervical cytology with the 
risk following squamous cell abnormalities of comparable severity.
methods
We used data from the Dutch Pathology Archive (PALGA) from 2000-2015 to categorise 
cervical cytology tests into groups based on most severe cytological abnormality and 
correlated follow-up advice (normal cytology and ‘no follow-up’ advice, squamous-cell 
based-, AGC-based, and combined AGC/squamous-cell based each with either repeat 
testing or referral advice). Cancer data were linked from the Netherlands Cancer Reg-
istry. Cox proportional hazard models were calculated stratified by age (younger (<50 
years) and older (50+ years)), adjusted for number of previous primary cytology tests.
results
8,537,385 cytology smears and 9,061 cancers were included. When repeat cytology test-
ing was advised, hazard ratios (HR) of cervical cancer (younger women – HR: 6.91, 95% 
CI: 5.48 – 8.71; older– HR: 3.98, 95% CI: 2.38 - 6.66) or other gynaecological cancer diag-
nosis in younger women (HR: 2.82, 95% CI: 1.39 - 5.74) were significantly higher after an 
AGC-based abnormality compared with squamous-based abnormalities. Hazards were 
also significantly higher for ‘referral’ advice cytology, except for cervical cancer amongst 
older women (HR: 0.88, 95% CI: 0.63 – 1.21).
Conclusions
AGC indicates an increased risk of gynaecological cancer compared to squamous-based 
abnormalities of comparable severity.
Impact
Gynaecologists should be alert for cervical and endometrial cancers when examining 
women referred following AGC.
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The aim of this study was to describe trends in diagnosis and treatment of women 
referred from screening with cervical intraepithelial neoplasia (CIN) in the Netherlands, 
compare this to national guidelines and identify potential areas for improvement for the 
new primary high-risk HPV screening programme.
material and methods
We conducted a population-based cohort study using data from Dutch pathology 
archive. Women aged 29-63 years who took part in the Dutch cervical screening pro-
gramme between 1 January 2005 to 31 December 2014 were selected. Three referral 
groups were identified: direct referrals and those referred after either one (first indirect 
referrals) or two (second indirect referrals) repeat cytology tests, totaling 85,239 referrals 
for colposcopy. The most invasive management technique and most severe diagnosis of 
each screening episode were identified. Rates of management techniques were calcu-
lated separately by referral type, highest CIN diagnosis and age group.
results
In all, 85.1% of CIN 3 lesions were treated with excision (either large excision or hysterec-
tomy) and 26.4% of CIN 1 lesions were treated with large excision. Rates of overtreatment 
(CIN 1 or less) in see-and-treat management were higher for indirect referrals than for 
direct referrals and increased with age. Large excision rates increased with CIN diagnosis 
severity.
Conclusions
Despite guideline recommendation not to treat, CIN 1 lesions were treated in just over 
25% of cases and approximately 15% of CIN 3 lesions were possibly undertreated. Given 
the expected increase in CIN detection in the new primary high-risk HPV screening 
programme, reduction in CIN 1 treatment and CIN 2 treatment in younger women is 
needed to avoid an increase in potential harm.
Key meSSaGe
Both over- and undertreatment of cervical intraepithelial neoplasia occurs after referral 
from organized cervical screening, despite treatment guidelines being available.
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INTrODuCTION
In the Netherlands, cervical intraepithelial neoplasia (CIN) detection rates have increased 
over the last decade, largely independent of socio-economic and demographic factors.1 
The replacement of conventional cytology by high-risk human papillomavirus (hrHPV) 
DNA testing as primary screening test in the Dutch Cervical Cancer Screening Program 
in 2017 will likely further increase CIN detection, given the higher sensitivity of hrHPV 
testing for CIN 2+ lesions.2 Recent Dutch modeling estimated that the number of de-
tected CIN lesions would increase by 196% for CIN 1 and 54% for CIN 2 over the lifetime 
of women entering the program in 2017 due to primary hrHPV screening.3
As more CIN lesions are detected, there is concern about overtreatment, which could 
result in increased harm associated with screening.4 Evidence suggests that there is 
an association between excisional treatments for CIN and adverse obstetric outcomes 
including preterm birth and low birthweight.5,6 Increasing excision volume has been 
associated with increased risk.6,7 Additionally, a robust randomized controlled trial con-
cluded that immediate side-effects of excisional treatments such as discharge and pain 
occur more frequently, more severely and for longer in women treated with large loop 
excision of the transformation zone (LLETZ) compared with both colposcopy-only and 
biopsy-diagnosed women.8
The Dutch Association of Obstetrics and Gynecology has published consensus-based 
guidelines for CIN treatment and management which detail the recommended treat-
ment practices, including recommending no treatment of CIN 1 and excisional treatment 
of CIN 2+.9 However, compliance with these guidelines has never been evaluated. The 
lack of evaluation of CIN management in the Dutch setting has been recognized by oth-
ers4 as a knowledge gap in an otherwise closely monitored program. Our study intends 
to objectify current clinical management of CIN to understand discrepancies between 
guideline recommendations and observed interventions. By doing so, we aim to identify 
potential areas for improvement for the new primary hrHPV screening program.
maTerIal aND meTHODS
National organized cervical screening has taken place in the Netherlands since the 1980s. 
Women are invited for cytology screening every five years from ages 30 to 60. Screening 
takes place within primary care. Women are referred to a gynecologist when colposcopy 
is required. Details of clinical guidelines for management of CIN are given in Table 1. Since 
1998, the recommendations for management of abnormal cytology have been fairly 
stable, allowing for more reliable measurement of procedural parameters after colpos-
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copy. In 2017, hrHPV testing replaced cytology as the primary screening test within the 
program.10
Our study is a population-based cohort study. Women aged 29 to 63 years who partici-
pated in the national screening program and received referral advice between 1 January 
2005 and 31 December 2014 were included. Possible referral pathways within the Dutch 
screening program can be found in Figure 1. Three groups of referrals were identified:
•	 Direct	referrals:	Women	who	received	referral	advice	after	primary	cytology	of	high-
grade squamous intraepithelial lesion (HSIL)/adenocarcinoma in situ (AIS)/atypical 
endometrial glandular cells (AGC)/AGC favoring neoplasia/cancer. The classification 
ASC-H (atypical squamous cells cannot exclude HSIL) is not utilized in the Netherlands.
•	 First	 indirect	 referrals:	Women	 who	 received	 referral	 advice	 for	 repeat	 testing	 six	
months after primary cytology of atypical squamous cells of undetermined sig-
nificance (ASC-US)/low-grade squamous intraepithelial lesion (LSIL) or endocervical 
AGC.
Table 1: Summary of Dutch CIN treatment guidelines




Targeted biopsies are 
required only with an 
atypical transformation 
zone.
Biopsy can be omitted if there is slight cytological dysplasia and 
no visible colposcopic abnormalities, in situations when the whole 
transformation zone can be seen.
At least two random biopsies should be taken where there are severe 
cytological abnormalities with no colposcopic abnormalities.
In the case of severe cytological and colposcopic abnormalities, 
either two targeted biopsies can be taken or ‘see-and-treat’ 
management can be used.
CIN 1 Generally not treated. In principle, should not be treated. In the case of persistent low-grade 
cytology outside of reproductive age, treatment options may be 
discussed with the patient.
CIN 2 Should be treated, 
preferably by LLETZ*
Individual assessment is required, particularly in younger women, 
weighting up the risks and benefit of treatment. If treatment is 
decided on, LLETZ* is recommended.
CIN 3 Should be treated, 
preferably by LLETZ*
Should always be treated. Women with high-grade cytology 
(moderate dyskaryosis/dysplasia or worse) and colposcopy are 




Conization is preferred if 
there is suspicion of AIS
It should be discussed with the patient whether she wants an 
excisional treatment or hysterectomy, provided that invasive 
carcinoma is excluded as far as possible.
Conization is preferred for AIS as it allows for better assessibility of 
the endocervical area and margins. If LLETZ is chosen, the pathologist 
must be notified for a better assessment of the margins.
* Large loop excision of the transformation zone
CIN: Cervical intraepithelial neoplasia; AIS: adenocarcinoma in situ.
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•	 Second	 indirect	 referrals:	Women	who	received	referral	advice	after	 two	triage	cy-
tology tests (at six and 18 months), with the first repeat cytology being negative, 
hrHPV-negative with endocervical ASC-US/LSIL/AGC or hrHPV positive with negative 
cytology, and second triage cytology being ASC-US or higher.
We excluded women with primary smears taken by a gynecologist, as women under the 
care of a gynecologist in the Netherlands are usually already receiving specialist care. 
Indirect referrals must have been referred within four years of primary screening to be 
included, in line with the definitions used in the monitoring of the national screening 
program. Repeat cytology testing at six months could be performed either with or with-
Figure 1: Pathways to referral within the Dutch Cervical Cancer Screening Program, adapted from Bekkers et 
al.31 and Rozemeijer32
* Includes HSIL, AGC endometrial, AGC favor neoplasia, adenocarcinoma in situ and cancer irrespective of 
hrHPV status.
** Includes ASC-US, LSIL, AGC endometrial and HSIL or worse* cytology results.
ASC-US/LSIL: Atypical squamous cells of undetermined significance/ low-grade squamous intraepithelial 
lesion
AGC: Atypical glandular cells
HSIL: High-grade squamous intraepithelial lesion
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out hrHPV triage. As hrHPV triage was not standard practice in all pathology labs during 
the study period, we did not include hrHPV status information in our study.
There is no national registry of gynecological treatments in the Netherlands. Therefore, 
we used an extract of all cervical cytology and histology records from the nationwide 
network and registry of histo- and cytopathology in the Netherlands (PALGA). PALGA 
has a nationwide coverage of all pathology labs.11 Women are identified by the first eight 
letters of their surname (maiden name is used for married women) and date of birth. 
Information about primary screening as well as up to five follow-up cytology and/or 
histology samples were selected. Follow-up of primary smears was included until the 
end of the database – 31st March 2016. We defined ‘episode of screening’ as the period 
starting with the primary screening test, possibly followed by follow-up tests and/or 
treatment and ending with the next primary cytology in the database. We only analyzed 
information recorded during this window (see Appendix S1). As PALGA is not a registry 
of treatments, we validated our results with two expert groups and with clinical data 
from one gynecology clinic (see Appendix S2).
Our primary outcome measure was the proportion of the most invasive diagnostic 
tests and therapeutic treatments by the most severe CIN diagnosis within a screening 
episode. Our secondary outcome measure was the proportion of overtreatment in see-
and-treat management. The most severe diagnosis within the screening episode was 
identified from all diagnostic codes recorded after referral advice as follows: most to 
least severe – cancer, CIN 3, CIN 2, CIN 1, benign/reactive, cytology only, no diagnosis 
recorded.
Diagnostic tests and therapeutic treatments are pre-coded by PALGA. The most ag-
gressive test/treatment of the episode after referral was ranked as follows: most to least 
aggressive - hysterectomy, large excision [including cone biopsy, LLETZ, other excisional 
treatments], polypectomy, endometrial curettage, endocervical curettage, punch bi-
opsy [excluding cone biopsy], cytology only, other techniques. This ranking was verified 
by gynecologists and pathologists.
See-and-treat management involves combining colposcopy and treatment in the 
same outpatient visit.12 A large excision in the next record after referral was considered 
indicative of see-and-treat management. We estimated possible overtreatment in see-
and-treat management as the proportion of women with CIN 1 or lower histological 
diagnosis as the highest diagnosis of the episode who were treated with large excision 
at the first contact with a gynecologist divided by all women who were treated with 
large excision at the first contact with a gynecologist (definition from Ebisch et al12). Age 
at primary screening was grouped into 5-year age groups.
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Statistical analysis
Chi-squared tests were performed to compare differences between proportions. Analy-
sis of variance was used to compare mean ages across referral types. For one-way tables, 
a chi-square goodness of fit test was applied. Confidence intervals for proportions were 
calculated using a binomial distribution. All analyses were performed using SAS Base 
v9.4 (SAS Institute Inc., Cary, NC, USA).
ethical approval
We used a retrospective, anonymized dataset from PALGA, which is exempt from ethi-
cal approval by a Medical Ethical Testing Committee. We obtained anonymized clinical 
data (only women referred from screening) for validation as part of the evaluation of 
the national cervical screening program (evaluation of national screening programs 
is legislated in the Population Screening Act in the Netherlands). We received written 
approval from the Medical Director of the specialist outpatient clinic to use their clinical 
data for research purposes.
reSulTS
From the 5,450,148 primary cytology smears taken within the screening program from 
women aged 29–63 years between 2005–2014, 98.9% were taken by a non-gynecologist 
and eligible for inclusion (n = 5,389,342). Of these smears, 44,209 (0.8%) resulted in a 
direct referral to a gynecologist, 34,282 (0.6%) resulted in a first indirect referral and 
6,748 (0.1%) resulted in a second indirect referral (Table 2). The majority of referrals were 
within reproductive age range (29-43 years: 65.5%). The number of referrals was higher 
in the period 2010 - 2014 than in the period 2005 - 2009 for all referral types (Table 2).
Of all women directly referred, 81.1% were diagnosed with a CIN lesion (that is CIN 1, 
2 or 3) within the episode of screening (Table 2). The proportion of indirectly referred 
women diagnosed with a CIN lesion was lower, 64.9% for first indirect referrals and 
39.9% for second indirect referrals (Table 2). When restricted to only referrals that re-
sulted in a histological diagnosis (i.e. excluding episodes with no recorded diagnosis or 
no histology taken), there were still differences in the proportion of episodes diagnosed 
with a CIN lesion between the referral groups (direct: 88.7%; first indirect: 78.1%; second 
indirect: 67.0%) and the differences were statistically significant (X2 (2, N = 72,902) = 
2,161.98, p < 0.001) (figures not presented). Among direct referrals, there was a higher 
proportion of women with a CIN 3 diagnosis (53.5%) than among indirect referrals (first 
indirect: 17.5%; second indirect: 8.8%) (Table 2).
The highest proportion of CIN lesions were diagnosed in women aged 29-33 years; 
79.8% of all referrals in this age group were diagnosed with a CIN lesion (Figure 2). The 
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proportion of episodes with no recorded diagnosis or no histology increased with age 
(Figure 2). In women aged 44 years and older, 61.3% of the no recorded diagnosis and 
55.3% of the no histology group had no further primary screening episodes after refer-
ral, and the remainder had further cytology and/or histology tests taken in the next 
primary episode, which were excluded from analysis (figures not presented).
The more severe the CIN diagnosis, the higher the proportion of women treated with 
large excision (Table 3). Women who were directly referred and diagnosed with CIN 1 
Table 2: Demographic characteristics of women referred for colposcopy following participation in the Dutch 










Total referrals 44 209 34 282 6 748









29–33 12 452 (28.2%) 9 086 (26.5%) 1 352 (20.0%) < 0.001
34–38 9 373 (21.2%) 6 661 (19.4%) 1 117 (16.6%)
39–43 8 151 (18.4%) 6 351 (18.5%) 1 250 (18.5%)
44–48 6 027 (13.6%) 5 448 (15.9%) 1 196 (17.7%)
49–53 3 944 (8.9%) 3 567 (10.4%) 1 005 (14.9%)
54–58 2 527 (5.7%) 2 022 (5.9%) 513 (7.6%)
59–63 1 735 (3.9%) 1 147 (3.4%) 315 (4.7%)
Period
2005–2009 20 630 (46.7%) 14 400 (42.0%) 2 803 (41.5%) < 0.001
2010–2014 23 579 (53.3%) 19 882 (58.0%) 3 945 (58.5%)
Highest diagnosis of the episode after referral
No recorded diagnosis 1 770 (4.0%) 1 275 (3.7%) 835 (12.4%) < 0.001
Cytology only 2 023 (4.6%) 4 540 (13.2%) 1 894 (28.1%)
Benign/Other† 3 019 (6.8%) 6 072 (17.7%) 1 306 (19.4%)
CIN 1 4 039 (9.1%) 9 024 (26.3%) 1 411 (20.9%)
CIN 2 8 152 (18.4%) 7 219 (21.1%) 688 (10.2%)
CIN 3 23 649 (53.5%) 5 996 (17.5%) 594 (8.8%)
Cancer‡ 1 557 (3.5%) 156 (0.5%) 20 (0.3%)
* Some IDs have more than one referral within the same referral type. The number of unique IDs represents 
the number of individual women referred within the referral type.
†Benign/Other includes histological results that are lower grade than CIN 1.
‡ Includes micro-invasive and invasive disease
SD: Standard deviation; CIN: Cervical intraepithelial neoplasia
See Figure 1 for description of referral types.
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had higher rates of large excision treatment compared with women who were indirectly 
referred: 34.4% compared with 23.9% [fi rst indirect] and 19.7% [second indirect]; X2 (2, 
N = 14,474) = 193.1, p < 0.001). No age-dependency was seen in the percentage with 
large excision treatment of CIN 3 (fi gures not shown). For CIN 1 lesions, the proportion of 
treatment with large excision increased with age. Rates of treatment with large excision 
diff ered signifi cantly between referral types across all age groups for CIN 1 lesions (from 
13.1% to 50.4%) and for the four youngest age groups for CIN 2+ lesions (Figure 3).
See-and-treat management was observed more often in direct referrals than indirect 
referrals and was performed mostly in women with severe CIN lesions (Figure 4). Treat-
ment of CIN 1 or lower in see-and-treat management increased with age across all refer-
ral types and were higher for indirect referrals in all age groups (Figure 5).
Figure 2: Highest diagnosis of the screening episode within age groups, all women referred, rounded percent-
ages
* Includes micro-invasive and invasive disease




Despite recommendations not to treat CIN 1 lesions, we found that 26.4% of the 
diagnosed CIN 1 lesions underwent an excisional procedure, ranging from 13.2% to 
50.4% depending on age and referral type. Compared to the European guidelines for 
clinical management of abnormal cervical cytology,13 the Dutch CIN 1 advice in the 2004 
Guidelines were quite conservative. Despite this, the proportion of CIN 1 treated with 
large excision is slightly higher than previously reported figures from Italian colposcopy 
audits14,15 with the latest reporting 16% of CIN 1 lesions were treated and that increase 
in the proportion of CIN 1 that was not treated was observed between audit periods. 
However, compared with the European Federation for Colposcopy guidelines16 that 
state 85% of excisional treatments should have a definitive histology of CIN 2+, our data 
shows the Dutch program exceeds this benchmark at 87%. To our knowledge, no other 
Table 3: Most invasive management technique of the screening episode by most severe CIN diagnosis of the 
screening episode, rounded percentages
CIN I (%) CIN 2 (%) CIN3 (%) p
Direct referrals
Hysterectomy 1.2 1.8 3.4 < 0.001
Large excision* 34.4 69.4 82.0
Biopsy† 62.5 28.2 14.3
Other techniques‡ 1.9 0.6 0.3
first indirect referrals
Hysterectomy 0.9 1.7 2.9 < 0.001
Large excision* 23.9 66.9 81.3
Biopsy† 73.2 30.8 15.4
Other techniques‡ 1.9 0.6 0.4
Second indirect referral
Hysterectomy 0.6 2.2 1.9 < 0.001
Large excision* 19.7 61.8 80.3
Biopsy† 77.5 35.3 17.3
Other techniques‡ 2.2 0.7 0.5
all referrals
Hysterectomy 1.0 1.8 3.3 < 0.001
Large excision* 26.4 68.0 81.8
Biopsy† 70.7 29.7 14.6
Other techniques‡ 1.9 0.6 0.3
* Large excision includes cone biopsy, LLETZ and other excisional therapies
† Includes all types of biopsies (exc. cone biopsy).
‡ Includes polypectomy, endometrial and endocervical curettage and histology not otherwise specified.
See Figure 1 for description of referral types
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European countries have published CIN treatment rates by diagnosis in peer-reviewed 
journals, though Danish researchers have recommended monitoring of CIN treatment 
trends in light of increasing CIN treatment rates in Denmark.17
Monitoring of treatment rates can have a positive eff ect on compliance with guide-
lines by making practitioners cognizant of recommendations. A study from one US 
hospital found that active monitoring of excisional treatments led to an increase in 
guideline compliance and an decrease in inappropriate excisional treatments.18 Regular 
monitoring should be implemented given the expected rise in CIN 1 diagnoses, due to 
the new, more sensitive hrHPV primary test. Modeling estimated that CIN 1 diagnoses 
will approximately double in the new screening program.3 In the old cytology screening 
program, if CIN 1 treatment rate were 5% during the period of our study, rather than 
26.4%, this would have resulted in approximately 300 fewer CIN 1 lesions treated with 
large excision per year. Under the new hrHPV screening program, the impact of reduced 
CIN 1 treatment rates could be even larger.
Figure 3: Proportion of episodes with large excision as most aggressive treatment for CIN 1 and CIN 2+ (denomi-
nator: total episodes within each age group with the same highest diagnosis), by age group and referral type
* Pearson’s chi-squared test signifi cantly diff erent between referral types.
See Figure 1 for description of referral types
CIN: Cervical intraepithelial neoplasia
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It is unrealistic to expect no CIN 1 treatment, as there will always be women with 
persistent or recurring low-grade abnormalities for whom treatment may be favor-
able or reassuring.19 Guidelines are only one factor in clinical decision making for CIN; 
gynecologists consider information about colposcopy, cytology, hrHPV status, family 
planning, age, women’s preferences and other factors when advising about treatment. 
Communication between pathologists and gynecologists also infl uences treatment 
decisions.18 There may be situations where CIN 1 was preceded by HSIL cytology, hrHPV 
positivity and CIN 2+ colposcopic impression or biopsies. Additionally, in women with 
transformation zone type 3, diagnostic LLETZ after high-grade cytology is indicated in 
IARC guidelines.20 In such situations, performing LLETZ may be a justifi able, appropriate 
treatment. Clarifi cation of a reasonable rate of treatment for CIN 1 should be given in 
future guideline revisions, preferably accompanied by intuitive nomograms to assist in 
Figure 4: Proportion of episodes managed with see-and-treat* within each CIN diagnosis group and referral 
type, 2005-2014
* See-and-treat management is defi ned as episodes where the fi rst treatment after referral advice is large 
excision.
See Figure 1 for description of referral types
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decision making, for example, that hrHPV negative biopsies can be observed rather than 
treated.
The treatment guidelines were revised in 201521 and now advise see-and-treat for a 
subcategory of women. Although this approach has advantages (reduced loss to follow-
up, convenience for women, lower costs),22 overtreatment is a risk.23 See-and-treat needs 
careful implementation to reduce overtreatment risks. We found that treatment of CIN 
1 or lower was more frequent in indirect referrals than direct referrals, and increased 
with age. These fi ndings are similar to those of other Dutch studies.24 Given the higher 
number of CIN 1 and lower diagnoses in the two indirect referral groups, this fi nding is 
unsurprising. Our results are consistent with Ebisch and colleagues, who found women 
with low-grade cytology had higher overtreatment rates than women with high-grade 
cytology.12 Restricting see-and-treat to women with concordant high-grade cytology 
and colposcopy could minimize overtreatment, as could the use of a grading system, 
such as the Swede score, which has shown to have high specifi city for CIN 2+ lesions.25
Figure 5: Proportion of overtreatment* in see-and treat management by age group and referral type
* Overtreatment in see-and-treat management is defi ned as the proportion of women with CIN 1 or lower 
histological diagnosis who were treated with large excision at the fi rst contact with a gynecologist divided 
by all women who were treated with large excision at the fi rst contact with a gynecologist.
See Figure 1 for description of referral types
CIN: Cervical intraepithelial neoplasia
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It is not surprising that rates of treatment with large excision for CIN 2+ lesions vary 
little by age within referral types. Up until 2015, treatment guidelines for CIN 2 were not 
age-specific. However, the 2015 Guidelines21 state that women with CIN 2 lesions should 
be individually assessed as to whether benefits of treatment outweigh the risks, largely 
related to future childbearing. Active surveillance of young women allows time for CIN 2 
lesions to regress, which is likely to occur in most CIN 2 cases.26 However, active surveil-
lance also comes with the risk of loss to follow-up or progression to a higher-grade le-
sion. Going forward, we expect CIN 2 treatment will vary by age, as more young women 
are conservatively managed. As such, both the treatment and outcomes for women with 
CIN 2 lesions should be monitored to ensure that clinical practice reflects guidelines.
As expected, women diagnosed with CIN 3 had the highest rates of treatment with 
excisional techniques. This is consistent across referral types with no differences by age 
(figures not shown). On the other hand, between 14.6% and 17.8% of women diagnosed 
with CIN 3 were not managed with an excisional treatment (large excision or hyster-
ectomy). This apparent undertreatment may be the result of several factors. Although 
uncommon in the Netherlands, these women may have been treated non-invasively 
using electrocoagulation, cryotherapy or imiquimod prescription and these procedures 
are not recorded in PALGA. Undertreatment may be overestimated due to data issues, 
such as records belonging to one woman not being properly linked. Finally, a clinician 
can decide to use an expectant management strategy if diagnostic biopsy removed 
most of the lesion. Regardless, guidelines state that CIN 3 should always be treated 
given the risks of progression; long-term follow-up of women in an unethical study in 
which treatment was delayed or withheld from women with high-grade lesions showed 
the cumulative incidence of cervical or vaginal vault cancer was 31.3% at 30 years, with 
a higher cumulative incidence (50.3%) amongst women with persistent high-grade le-
sions.27 Timely and effective treatment of CIN 3 is therefore necessary to avoid the risk 
of disease progression. Communication of these results directly with gynecologists is 
essential, emphasizing that the benefits of treatment for these women greatly outweigh 
the risks.
Our study is the first to use a national database to investigate CIN treatment practices 
in the Netherlands. Analysis in this study was split by referral type, allowing us to inves-
tigate women with different risk profiles separately, as the severity of the initial cytology 
influences follow-up. Reflective of this, we found that women who are directly referred 
have a much higher proportion of CIN 3 diagnoses.
Our study has some limitations. We did not include information about hrHPV status in 
our analysis, as the practice of hrHPV testing was not universally conducted during the 
study period. However, knowledge of hrHPV status may have resulted in more aggres-
sive treatment for women who were hrHPV positive. We were also unable to evaluate 
conization and large loop excisions separately, or analyze by depth of excision or lesion 
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size. This is not coded in PALGA. This information would be useful for stratification of 
results, as depth of excision can have implications for both the risk of adverse obstetric 
outcomes5,6,28 and the risk of recurrent or progressive disease.29 Furthermore, we do not 
have information about results of colposcopy. If a woman is referred to a gynecologist 
and examined with colposcopy, but has no accompanying test or treatment, no informa-
tion is reported to PALGA.
Validation of our results with clinical data found that PALGA may slightly overestimate 
CIN 1 treatments (Appendix S2), although these clinical data came from a highly spe-
cialized clinic with physicians who almost exclusively treat cervical dysplasia. As such, 
treatment of CIN 1 with excision at this clinic is likely to occur less often than average. 
One Dutch study compared the impact of different CIN management strategies (more or 
less aggressive) in two hospital facilities in the same city and found that 68% less CIN 1 
lesions were found with the less aggressive strategy.30 As PALGA has national coverage, 
the treatment rates we observed were not influenced by policies or practices of any 
single clinic.
PALGA does not have a unique identification code to track women’s screening history; 
women are identified by the first eight letters of their surname and date of birth. It is 
possible that tests of multiple women are attributed to a single identification code. In 
such cases, it is possible that follow-up was censored early for some women, leading to 
a misclassification of the highest diagnosis or most invasive treatment of the episode.
CONCluSION
Our study shows that both under- and overtreatment takes place, despite guidelines 
being available. Regular monitoring of national trends and reviews of treatment rates 
should be implemented at each clinic that treats women for CIN, to make both gynecolo-
gists and pathologists aware of the guidelines and their own performance in relation 
to them. This may lead to greater compliance with the guidelines, reducing potential 




CIN – Cervical intraepithelial neoplasia
hrHPV – high-risk human papillomavirus
LLETZ – Large loop excision of the transformation zone
PALGA – Nationwide network of cyto- and histopathology in the Netherlands
ASC-US – atypical squamous cells of undetermined significance
LSIL – low-grade squamous intraepithelial lesion
HSIL – high-grade squamous intraepithelial lesion
AIS – adenocarcinoma in situ
AGC – atypical glandular cells
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aPPeNDIx S1: DaTa uSeD IN THIS STuDy
Data from the nationwide network and registry of histo- and cytopathology in the Neth-
erlands (PALGA) was used to identify referrals from the Dutch National Cervical Cancer 
Screening Programme. This appendix explains which data was used in our results. Figure 
S1 outlines five fictitious example cases to demonstrate case- and data selection for this 
analysis. Explanation of these cases can be found in Supplementary Table 1.








a Direct CIN 3 Large excision The algorithm used in this analysis selects 
treatment and diagnosis variables from all 
secondary treatments regardless of chronological 
order, so the highest diagnosis and most invasive 
treatment in this screening episode are from 
different secondary tests.
b Indirect CIN 1 Biopsy The secondary tests that are included in the 
analysis from this episode are two, three and four. 
The first secondary test results in referral advice, 
indicating the start of care by a gynaecologist.
C Indirect No histology Cytology This episode is counted in the total number of 
indirect referrals, but there is no CIN diagnosis, so 
this episode is not included in the main analysis 
in this study.
D Direct None None This woman may not have attended her referral 
appointment, or the colposcopy did not result in 
a histological or cytological examination. As such, 
there is no information for diagnosis or treatment 
for this screening episode.
e None None None This record is excluded as an indirect referral 
because the record that contains the referral 
advice after the primary cytology smear is in 
the next primary cytology episode. There are 
421 records that are excluded from indirect 




Legend for Figure S1
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aPPeNDIx S2: ValIDaTION Of reSulTS
Validation with experts
We consulted two expert groups and used clinical data from one specialist clinic to 
validate our results. Data experts at PALGA were consulted about quality of coding. 
The data in PALGA is based on information in pathologist reports. Reviews of histology 
records have previously been conducted by experts at PALGA to ensure that records are 
appropriately classified and have been found to be largely concordant with pathology 
reports.
Following this, three practicing Dutch gynaecologists (RB, BtH, JB) were asked whether 
the PALGA results were broadly reflective of the clinical practice in the Netherlands, 
in order to assess the face validity of our results. This assessment was based on their 
extensive knowledge of clinical practice in the Netherlands. They agreed that the results 
were broadly reflective of clinical practice.
Validation with clinical data
We compared a subset of our dataset with 2012 data from a specialist gynaecology 
outpatient clinic. This clinic has specialist physicians that primarily work with cervical 
dysplasia. To do this comparison, we created a subset of our PALGA data that matched 
the same year (2012) and same screening region that the clinic is located in.
The proportion of treatments (figure not shown) and diagnoses (Figure S2) were com-
parable in both datasets (with the exception of hysterectomies, which are not performed 
at the specialist outpatient clinic), as well as the rates of the use of large excision and 
biopsy in episodes with a CIN 2 or 3 diagnosis (figures not shown). Rates of treatment 
of CIN 1 lesions were lower at specialist clinic than in PALGA (Figure S3), however these 
differences may be explained by differences in policies and practices in various clinics in 
screening region covered by the PALGA dataset.
Conclusion of validation
Results of our validation found that PALGA reflects the distribution of diagnoses and 
treatments as found in a clinical dataset. Quality of coding was found to be good and 
face validity was checked by practicing gynaecologists. Based on the comparison with 
clinical data, the treatment rates for CIN 1 may be slightly overestimated, however the 
clinical data came from a highly specialised clinic. As such, CIN 1 treatment practices at 
this clinic are likely to be lower than average.
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Figure S2: Proportion of highest diagnosis of the episode by diagnosis and dataset, only CIN and cancer diag-
noses shown, 95% confi dence intervals
SC: Specialist gynaecology outpatient clinic
CIN: Cervical intraepithelial neoplasia
Figure S3: Proportion of CIN 1 cases with large excision or biopsy as the most invasive technique used by data 
source, 95% confi dence intervals
SC: Specialist gynecology outpatient clinic
CIN: Cervical intraepithelial neoplasia
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Striking a balance: Complete evaluation of organised 
cervical cancer screening programmes is not possible 
until harms of screening are better quantified
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Organised cervical cancer screening programmes need to achieve a careful balance be-
tween benefits and harms to maximum effectiveness. Harms of screening can be psycho-
logical or physical and can occur at screening, during follow-up or during diagnosis and 
treatment. We aimed to outline potential harms in each phase of screening, synthesise a 
list of indicators for quantifying harms and explore why harms are not quantified more 
regularly. We reviewed three European indicator sets to identify indicators for harms and 
supplemented this list with additional indicators based on the literature. We identified 
16 indicators that cover physical and psychological harms across the whole screening 
process. Despite multiple organisations identifying indicators measuring harms in their 
indicator sets, these indicators are not regularly reported. Challenges in quantifying 
indicators due to difficulties with data collection and lack of organisation should be 
addressed to facilitate more comprehensive reporting. Quantifying harms will become 
increasingly important as the underlying population risk for cervical lesions changes. 
The combination of hrHPV vaccination and hrHPV screening is driving this change in risk, 
and will necessitate a re-optimisation of organised screening programmes. Complete 
information about both benefits and harms is required for programme optimisation.
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This thesis aimed to evaluate each stage of the Dutch cervical cancer screening pro-
gramme, from invitation to clinical care, as well as the overall screening programme 
with a focus on the transition from cytology-based screening to hrHPV-based screening.
Overall screening process
On the whole, the implementation of hrHPV-based screening in the Netherlands has 
been successful; our research presented in this thesis indicates that, following imple-
mentation, the programme performed as expected based on modelling. The implemen-
tation of the new hrHPV-based screening programme required substantial change to 
many processes and procedures in the programme and coordination of many different 
organisations. The switch to hrHPV-based screening across the first quarter of 2017 in all 
screening organisations should be seen as a success for all parties involved. Monitoring 
and evaluation of the transition from cytology-based screening to hrHPV-based screen-
ing has been able to provide insights to policymakers and health services managers 
about areas in which the programme could be further optimised.
What was the impact of implementation of the hrHPV-based screening programme 
on short-time programme indicators?
In Chapter 2.1, we investigated what the impact of implementation of the hrHPV-based 
screening programme was on short-time programme indicators. The implementation of 
hrHPV-based screening has led to an increase in CIN 2+ detection, with an correspond-
ing increase in unnecessary referrals. The increased CIN 2+ detection rate was achieved 
by a higher positivity rate (increased from 5% in the cytology-based programme to 
9% in the hrHPV-based programme; p < 0.001) and higher referral rate (from 1% in the 
cytology-based programme to 3% in the hrHPV-based programme; p < 0.001). However, 
more women who were referred did not have a clinically significant lesion. Our analysis 
found that the driver of unnecessary referrals was increased referrals amongst women 
with ASC-US/LSIL cytology, with an approximately 60% increase in the number of refer-
rals needed to detect one CIN 2+/CIN 3+ lesion in this group. This indicates that too 
many women with low-grade lesions that are not clinically significant are being referred 
to the gynaecologist in the new hrHPV-based programme.
The increase in referral rates has also been seen in the Australian hrHPV-based screen-
ing programme. Australia also implemented nationwide hrHPV-based screening in 2017. 
Although there are differences between the Dutch and Australian programmes, both in 
programme dynamics (number of lifetime screens, included ages, triage algorithms) and 
background risk (as Australia implemented hrHPV vaccination in 2007), analysis of the 
first results of the Australian programme (though not based on nationwide data) also 
found that the direct referral rate (2.6%) was substantially higher than in the previous 
cytology-based programme (0.8%).1 While, in both screening programmes, this was not 
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unexpected based on modelling, it is an area of possible optimisation for the Dutch 
programme now that implementation is complete. We explored this further in Chapter 
4.2.
Is the new hrHPV programme still considered to be more cost-effective than the 
cytology-based screening when using the results of the first year of the hrHPV-
based screening programme to calculate cost-effectiveness?
In Chapter 2.2, we found that the cost-effectiveness of the hrHPV-based screening pro-
gramme is still superior to cytology-based screening even when taking into account the 
lower-than-expected participation rates observed in Chapter 2.1. Our results show that 
hrHPV-based primary screening is estimated to decrease cervical cancer mortality (-4%) 
and incidence (-1%) compared to the old programme. Despite an increase in unneces-
sary referrals (+172%), hrHPV-based screening still results in more QALY’s gained (+13%). 
The hrHPV-based programme was more cost-effective than cytology-based programme, 
costing 46% less per QALY gained; €12,225 per QALY gained for hrHPV-based screen-
ing versus €22,678 per QALY gained for cytology-based screening. Our results support 
modelling done prior to implementation of the programme.2 3
Chapter 2.2 showed that the total costs of the hrHPV-based programme were 21% 
lower than the old programme, which is mainly driven by lower costs of primary screen-
ing. This is due to a lower number of lifetime screening tests – from seven per woman 
in the cytology-based programme to as low as five per woman in the hrHPV-based pro-
gramme. Extending the screening interval from five to ten years for hrHPV-based screen-
ing is considered to be safe for women aged 40 years and older who test hrHPV negative, 
based on analysis of the POBASCAM trial.4 However, it is still unclear how women will 
respond to extended screening intervals once they are implemented. Various studies of 
acceptability of extending screening intervals have found that women are more likely 
to accept extended intervals if they are recommended by their healthcare provider5 6 or 
if more information and education is provided about the rationale for extending inter-
vals.7 8 These studies investigated the willingness of women to have screening intervals 
extended up to five years. A screening interval of 10 years is considerably longer, and the 
feasibility of implementing extended screening intervals will partly depend on whether 
Dutch women will find this extension acceptable.
Also related to extended screening intervals, the differences seen between the 
clinician-collected test and self-sampling may impact on the implementation of the 10 
year screening interval. Although the exact impact of the differences in hrHPV positivity 
on the test characteristics is still unclear, if self-sampling has a lower sensitivity for CIN 
2+ than clinician-collected testing, extending the screening interval for women who 
used self-sampling and tested hrHPV-negative may not be advisable. This may impact 
the cost-effectiveness of the hrHPV-based programme, as more women would need to 
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be re-invited at ages 45 and 55. Further cost-effectiveness modelling should investigate 
this issue.
What factors (both personal and organisational) are related to attendance, and 
which factors are related to the drop in attendance rates between the old and new 
screening programmes?
We saw in Chapter 2.1 that attendance in the new hrHPV-based screening programme 
was in 2017 lower than in the old cytology-based programme. In 2018,9 attendance rates 
were still lower than in the old programme. We aimed in Chapter 3.1 to investigate the 
decline in participation rates further, particularly focusing on whether the decline in 
participation could be explained by personal characteristics of women in the eligible 
cohort or by organisational factors.
Attendance rates did vary by personal characteristics of women; women who were 
employed (60.8%), married (62.9%), Dutch (61.2%), in the highest income bracket 
(63.4%), living in households with four persons (65.3%) and women who were invited 
by their GP (69.8%) had the highest attendance rates. Like in other organised European 
screening programmes, we found that attendance in the Dutch programme was lower 
amongst women with a migration background,10-13 women in lower income brackets11 14 
and women who live alone or are not married.12 14 15 However, our analysis found that 
personal characteristics were not associated with the decline in attendance in the 
programme. By adjusting for the organisation that sent the invitation (i.e. the GP or 
the screening organisation), the differences in attendance rates between 2014-2015 
and 2016 and between 2014-2015 and 2017-2018 were explained in some screening 
organisations, indicating that removing self-inviting GPs from the programme has had 
some impact on attendance rates.
Targeted strategies for increasing attendance rates
Bongaerts and colleagues identified that targeted strategies for subpopulations had 
been shown to impact on participation in the cervical cancer screening programme in 
the Netherlands.16 Women who do not attend screening are not a homogenous group, 
and therefore, multiple strategies may need to be adopted to reach all women. Marlow 
and colleagues used the Precaution Adoption Process Model to propose five categories 
of cervical cancer screening non-attenders: women unaware of screening, women unen-
gaged by screening, women who were undecided, women who had decided not to be 
screened and women who intended to participate, but did not.17
Women who are unaware, unengaged or undecided about cervical cancer screening 
may not have received, or engaged with, the relevant information materials to make 
an informed choice about participation. Korfage and colleagues found that providing 
women with an information leaflet about cervical cancer screening increased knowl-
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edge and informed decision making.18 Women in the Netherlands already receive a leaf-
let about the cervical cancer screening programme with their invitation, but ensuring 
women engage with, and understand, the material is challenging.
Women who do not participate despite intending to may require different interven-
tions to motivate attendance. Interviewing non-attenders in the English cervical cancer 
screening programme, Marlow and colleagues found that practical barriers, such as 
being busy with work, caring responsibilities or inconvenient clinic opening hours pre-
vented women who intended to participate from acting on their intentions.19 Forgetting 
to make an appointment was the primary reason given for non-attendance in a sample 
of Dutch non-participants.20 Offering more convenience for these women could help 
reduce the so-called ‘intention-behaviour gap’.21 Barriers to making an appointment, 
such as finding it difficult to get through to one’s general practice by phone, are possibly 
experienced by Dutch women who wish to be screened. Employing new technologies, 
such as online booking systems, could help facilitate participation. One study found that 
women who reported more barriers to participation were more likely to want to book 
their screening using an app or website.22 Another possible way to reduce barriers would 
be for general practices to offer after-hours walk-in clinics for screening that could be 
accessed without an appointment. Although these would be difficult to implement in 
the Netherlands on a national level, general practices could be encouraged to offer such 
services.
The ideal participation rate for cervical cancer screening will never be 100%, because 
some women make an informed choice that screening is not beneficial for them. Women 
who actively choose not to participate in cervical cancer screening have been shown to 
decline screening for several reasons. Bennett and colleagues found that active decliners 
were more likely than intenders to: a) perceive that their risk of cervical cancer was low 
due to sexual behaviour, b) report that they had more important things to worry about 
than screening, and c) to have weighed up the risks and benefits and decided screening 
is not relevant for them.23 Oscarsson and colleagues found that although many reasons 
were found for non-attendance, these could be grouped into three themes; ‘I do not 
need to’, ‘I do not want to’ and ‘I do not give it priority’.24 As with the intenders, some 
active decliners may respond to making screening more convenient. Self-sampling is 
one possible intervention to reduce barriers. Being sent a unsolicited self-sampling kit 
increased participation amongst Dutch non-attenders25 and was identified as preferable 
to the current English screening programme in a study of non-attending young English 
women.26
However, as discussed in Chapter 3.1, the availability of self-sampling has not resulted 
in increased participation in the Dutch screening programme. This is likely a result of the 
need to order a kit, which adds additional steps (which could be barriers) from invitation 
to participation. Sending self-sampling kits directly to women who do not respond to 
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the initial screening invitation may increase attendance. However, the impact of this 
change would need to be carefully tested, perhaps in a small pilot, prior to implementa-
tion in order to evaluate if it would increase participation and what the impact on cost 
and waste would be.
Impact of definition of attendance
One limitation of our study in Chapter 3.1 was that we used a standard definition of 
attendance (15-month attendance rates). This definition has been used in the annual 
short-term monitoring of the programme. However, it may be that this period was too 
short to capture participation in the new programme, given the phased implementation 
in 2017 and the delay period of four months between ordering the self-sampling kit 
and receiving it. We did an additional analysis aimed at investigating whether the de-
cline in participation is due to delayed participation in the new hrHPV-based screening 
programme. We did this by exploring different definitions of attendance. We aimed to 
investigate if extending the number of months included in the calculation of the partici-
pation rate would result in comparable participation rates in 2014-2015 and 2017-2018.
We used the same ScreenIT/CIS dataset described in Chapter 3.1 and defined atten-
dance as participation in the screening programme at any date from the start of the year 
of invitation to a censor date, starting at 12 months (1 January up to, and including ,31 
December), increasing the inclusion period in three-month increments to 36 months. 
Exact dates for each increment and invitation year can be found in Table 1.
Figure 1 shows attendance rates for periods 2014-2015, 2016 and 2017-2018 with ex-
tending inclusion periods for primary screens. Even after 36 months from the start of the 
invitation year, the attendance rate in 2017-2018 does not catch up with the attendance 




2014 2015 2016 2017 2018
12 months 31/12/2014 31/12/2015 31/12/2016 31/12/2017 31/12/2018
15 months 31/03/2015 31/03/2016 31/03/2017 31/03/2018 31/03/2019
18 months 30/06/2015 30/06/2016 30/06/2017 30/06/2018 30/06/2019
21 months 30/09/2015 30/09/2016 30/09/2017 30/09/2018 30/09/2019
24 months 31/12/2015 31/12/2016 31/12/2017 31/12/2018 31/12/2019*
27 months 31/03/2016 31/03/2017 31/03/2018 31/03/2019 *
30 months 30/06/2016 30/06/2017 30/06/2018 30/06/2019 *
33 months 30/09/2016 30/09/2017 30/09/2018 30/09/2019 *
36 months 31/12/2016 31/12/2017 31/12/2018 31/12/2019* *
* Last screen recorded in the dataset was 20 November 2019, therefore these cells are censored.
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rate in 2014-2015. This analysis suggests that using 15-month attendance rates did not 
aff ect the results in Chapter 3.1 and shows that participation in the new hrHPV-based 
programme remains lower over time than in the last years of the old cytology-based 
programme.
Other possible organisational factors
There were other changes to programme policies and procedures that we were unable 
to include in our study that could also have contributed to a declining participation 
rate. Another possible driver of the drop in attendance rates is the fact that gynaecolo-
gists are also no longer able to take screens within the screening programme, although 
the impact of making this change may be small. Having to take the invitation letter to 
the screening appointment, as discussed in Chapter 3.1, may also act as a barrier to 
screening. One reason that the letter is required is that it contains personalised stickers 
that need to be attached to the ThinPrep vial, making it easier to process the screening 
test in the laboratory. A possible solution would be to allow GPs to print these stickers 
themselves or obtain a unique identifi cation number that could be written on the vial 
from a secure online portal. This would still allow the women to be screened within the 
programme without their letter and would not interrupt the processes in the screening 
labs.
Figure 1: Attendance rate by increasing inclusion period by year of invitation
NB. Attendance rates in 2017-18 after 24 months are based only on data from 2017. Last date of screening 
in the dataset is in November 2019.
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Untangling the reasons for non-participation to increase uptake
The dynamics driving participation in organised cancer screening programmes are com-
plex. While there have been some studies conducted in the Netherlands looking at the 
characteristics of non-attenders (including Chapter 3.1) and the reasons for not attend-
ing, there has been no research published on whether the reasons for non-attendance 
have changed since the implementation of hrHPV-based primary screening. Future 
research should be conducted to understand the reasons for non-attendance within 
the hrHPV-based programme. This type of information could help guide programme 
managers to select interventions that would have the greatest impact on the participa-
tion rate.
Test and referral
are ratings of cytology slides by cytotechnicians influenced by the knowledge of 
hrHPV status?
Our small study, described in Chapter 4.1, into the potential impact of the knowledge 
of HPV status by cytotechnicians indicates that the knowledge of hrHPV status has 
some influence on the rating of cytology slides with low-grade abnormalities. If these 
slides are, in fact, normal, then ‘upwards ratings’ of slides may further contribute to the 
increased number of unnecessary referral in the new hrHPV-based programme. The 
reason this phenomenon was important to investigate is that all cytology slides that 
are now analysed in the new hrHPV-based programme are hrHPV-positive. As such, 
cytotechnicians are indirectly aware of the HPV status of every slide.
It seems that when slides are known to be hrHPV positive, cytotechnicians may err 
on the side of caution when reading slides. This results in them rating slides with fea-
tures not related to cervical dysplasia as ASC-US, when without knowledge of hrHPV 
status, the slide may have been rated as normal. Such errors may be, in part, caused 
by cognitive biases. Confirmation bias, which is the tendency to seek out informa-
tion that supports a belief or hypothesis that one already holds,27 may be influencing 
decision-making in these cases. Making these judgements with the knowledge of hrHPV 
status is understandable, especially with knowledge of the natural history of cervical 
cancer and the causal role of hrHPV in cervical dysplasia. Interpreting cytology slides, 
by nature, is somewhat subjective, meaning good training and quality control are vital. 
Therefore, ongoing training and assessment of the accuracy of cytology ratings by both 
cytotechnicians and pathologists has been conducted since the implementation of the 
new programme, as well as monitoring the quality of cytology. These activities should 
continue in order to ensure quality remains high.
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What are the options for optimising the triage algorithm of the hrHPV-based 
screening programme within the current parameters of the programme?
Given the high number of unnecessary referrals from the new hrHPV-based screening 
programme, optimisation of the triage algorithm may be required to minimise potential 
harms. Any new triage algorithm would need to reduce unnecessary referrals with little 
to no impact on cervical cancer incidence and mortality and be easy to implement within 
the current laboratory procedures. In Chapter 4.2, we found that the most effective way 
to reduce unnecessary referrals with the technology and expertise available now is to 
implement HPV 16/18 genotyping and possibly to increase the interval to repeat test-
ing from six to 12 months. Specifically, we found a reduction in unnecessary referrals of 
45% by adjusting the conditions for referral to ‘HPV16+ and ASC-US+’ and ‘HPV18+/HPV 
other high-risk types+ and HSIL+’, while also extending the interval between the cytol-
ogy negative primary test and the repeat test from six to 12 months. This was achievable 
with an estimated 2% increase in cervical cancer incidence and no increase in mortality.
Recent observational data further supports implementation of HPV 16 genotyping 
at a minimum, due to the increased risk of CIN 3+ following a HPV 16 infection.28 As the 
HPV test system that is currently used in the Dutch programme is already capable of 
HPV 16/18 genotyping, there would be few costs and almost no infrastructure changes 
required for such a change. Given the number of key events on the horizon for the Dutch 
programme (including the second screening round, extended screening intervals, entry 
of partly vaccinated cohorts and re-tendering of tests), making large-scale changes to 
the triage algorithm involving new technologies is inadvisable at the moment. More 
needs to be known about test performance and the underlying disease risk in the 
population to make more complex changes to the triage algorithm. Because of this, 
implementation of HPV16/18 genotyping is the most logical step for optimising the 
triage algorithm on the short-term.
What is the risk of cervical and other gynaecological cancers following aGC 
on cervical cytology and is this higher than the risk following squamous cell 
abnormalities of comparable severity?
Results from our study in Chapter 4.3 suggest that women who have AGC on cervical 
cytology are at higher risk of both cervical and other gynaecological cancers compared 
to squamous cell abnormalities of comparable severity. This suggests that women who 
have an AGC on cervical cytology need to be referred directly. In the new hrHPV-based 
screening programme, this is already occurring for women who are hrHPV-positive with 
AGC on cervical cytology.
The detection of endometrial and ovarian cancers through cervical cancer screening 
in the Netherlands is not monitored. These incidental findings could be seen as a harm 
of screening (as we put forward in Chapter 6.1) for a number of reasons. Firstly, women 
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are not giving informed consent for being tested for these cancers when participat-
ing in cervical cancer screening. Secondly, incidentally-detected cancers may lead to 
overdiagnosis, especially in older women. However, incidental findings may also benefit 
women, allowing them to receive diagnosis and treatment for a cancer that may have 
otherwise been detected at a later stage. In women aged over 50 years with AGC, the 
risk of an endometrial cancer cancer after a severe AGC abnormality was particularly 
high. These cancers are not associated with hrHPV infections. One study found that HPV 
positivity of AGC cytology differed depending on the type of AGC abnormality detected; 
AGC cytology with a concurrent squamous abnormality had the highest HPV positivity 
rate (84%), with AGC cytology with atypical endometrial cells having a 0% HPV positivity 
rate.29 Because of this, we anticipate that the implementation of hrHPV-based screening 
will lead to a reduction in the number of AGC cytology smears seen every year. This will 
be driven by a reduced number of AGC diagnoses related to non-HPV-related malignan-
cies in older women.
Other issues with testing and referrals
Differences between self-sampling and clinician-collected sampling
The availability of self-sampling for all women who wish to request a kit is one of the 
most unique aspects of the hrHPV-based programme in the Netherlands. In most set-
tings, self-sampling is used as a strategy for encouraging participation in non-responders 
only. In Chapter 2.1, we observed that the hrHPV positivity rate was different between 
the self-sampling test and the clinician-collected test, and amongst women directly 
referred and followed-up, there was a higher proportion of CIN 2+ detected amongst 
self-test users. These results were surprising given the previous studies conducted in 
the Netherlands found the hrHPV positivity rate to be either comparable30 or higher31 in 
self-samples compared with clinician-collected testing. Both of these studies were con-
ducted within the screening programme, so were expected to provide a good indication 
of how the test would perform in the real-life setting. The results in Chapter 2.1 may be 
due to differences in the types of women using the self-sampling test in the screening 
programme compared to previous studies or may be due to differences in the technical 
work-up of the tests within the programme completed to previous studies.
It is possible that differences exist between women using self-sampling and women 
who are screened by their GP. However, the fact that the overall participation rate is 
actually lower in the new screening programme32 and the results of Chapter 3.1 sug-
gest the characteristics of women did not impact on the decline in participation rates, 
it can be speculated that self-sampling is largely reaching the population of potential 
attenders (i.e. women who would have attended the screening programme with or 
without the offer of self-sampling). Modelling suggests that a gain in health benefits 
by implementing self-sampling depends on increasing overall participation, particularly 
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amongst women who were high-risk never-attenders, and on limiting the number of 
‘switchers’, i.e. women who have previously been screened by the GP.33 To maximise the 
benefits of self-sampling in the programme, more active approaches may be needed 
to reach non- and never-attenders, as previously discussed in Chapter 3.1 and section 
“Targeted strategies for increasing attendance rates”. However, it is still unclear if women 
using self-sampling are potential attenders (i.e. women who would have otherwise at-
tended by being screened by their GP) or non-attenders (i.e. women who would not 
have attended without the offer of self-sampling).
An alternative explanation for the difference between the two tests is that there is a 
difference in the way the tests are used within the screening programme versus previ-
ous studies of PCR self-sampling. The IMPROVE trial used a different clinician-collected 
test than is used in the screening programme,30 which could explain why there is a dif-
ference between the results of the trial and the screening programme. The VERA study, 
which tested the concordance between self-sampling and the clinician-collected test 
in a sample of screening programme responders, used the same tests as used in the 
screening programme. This study showed that self-sampling resulted in a higher hrHPV 
positivity than in the clinician-collected samples.31 The results in Chapter 2.1 in a com-
parable population show the exact opposite result. It is possible that, although the test 
and the technology are the same, processes within the screening laboratories result in 
the difference between the two tests. In the VERA study, the self-sampling dry brushes 
were processed in 4.5mL of ThinPrep medium, whereas in the screening programme, 
self-samples are processed in 20mL of ThinPrep medium. Dilution with 20mL of medium 
may have resulted in a lower sensitivity for hrHPV in self-samples. Investigating possible 
differences should be a priority for further research.
Diagnosis and treatment
What are the trends in CIN management and treatment following referral following 
the Dutch cervical cancer screening programme, and are these trends in line with 
the clinical guidelines?
In Chapter 5.1, we investigated CIN management and treatment following referral 
from the Dutch cervical cancer screening programme, and whether these were in line 
with the clinical guidelines. Our study showed that both over-and under-treatment was 
occurring following referral from the old cytology-based screening programme. Of par-
ticular concern was the overtreatment observed amongst certain groups who received 
see-and-treat management following referral. Our analysis suggests that there is room 
for improvement with compliance to the practice guidelines.
Our findings have been supported by an independent report on treatment and man-
agement of CIN in the ‘Sensible care’ (Zinnige Zorg) programme run by Zorginstituut 
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Nederland. Researchers at Zorginstituut Nederland also found overtreatment of CIN 1 
lesions and substantial variation in the follow-up of women who were referred. They 
concluded that the clinical guidelines should be followed more closely. Estimates from 
their report suggest that there could be substantial savings for the Dutch healthcare 
system (€1.3 million in direct costs and €1 million in indirect costs) if the following issues 
were addressed: fewer women unnecessarily treated for CIN 1 and CIN 2; more women 
treated for CIN 3; clarity and uniformity of the follow-up pathways for women with CIN; 
variations in these pathways reduced, and; improvements in patient information to 
facilitate shared decision-making.34 Ensuring that the CIN 1 and CIN 2 treatment guide-
lines are more closely followed is of more importance since the implementation of the 
new programme, as more women with low grade lesions are referred. Early indications 
reassuringly suggest that this increase in unnecessary referrals has led to an increase 
in overdiagnosis, but not overtreatment.35 However, given that many of the potential 
harms of screening identified in Chapter 6.1 can occur in the diagnosis and treatment 
stage of screening, regular monitoring of compliance with guidelines remains essential.
Improving programme monitoring with colposcopy data
In Chapter 2.1, we observed an increase in the rates of women who are referred, but 
do not comply with this referral advice, in the new hrHPV-based screening programme. 
In cases where women are referred from the screening programme with low-grade 
lesions and are found to have a normal colposcopic image, there is no indication to 
have any further tests at the initial colposcopy appointment. The increase we observed 
may not be a true increase in non-compliance, but caused by a lack of information in 
the current database used for monitoring and evaluation (PALGA). For these women, 
their colposcopy attendance is not recorded in PALGA because there was no cytological 
or histological test taken. Therefore, these women appear as lost-to-follow-up in the 
monitoring of the programme. Information about attendance at colposcopy, as well as 
detailed information about diagnostic or therapeutic procedures (including motivations 
for deviating from clinical guidelines), would add great value to both short-term moni-
toring of the programme and longer-term evaluation of changes in clinical practice. In 
the Dutch colorectal cancer screening programme, information about each colonos-
copy performed in the programme is recorded in a gastroenterology clinical database 
and combined with data on invitations from the screening programme and pathology 
information from PALGA, amongst other data, to ensure that there is a comprehensive 
overview of all aspects of the programme.36 A clinical database for colposcopy does not 
exist in the Netherlands. Building and implementing a national registry of colposcopy 
information that could be linked back to the ScreenIT system would provide more com-




future challenges and opportunities in the Dutch cervical cancer screening 
programme
Second screening round in 2022
In 2022, women who were invited for, and participated in, the first screening round in 
2017 will be invited for their second round of hrHPV-based screening. We expect that 
in the second round of screening, there will be fewer CIN 2+ lesions detected (as seen 
in the POBASCAM trial37), as the first screening round detects prevalent disease and 
subsequent rounds detect incident disease. Monitoring of the results from the second 
round will be important for assessing if the sensitivity of clinician-collected sampling 
and self-sampling are equivalent to one another. CIN 2+ detection in the second round 
amongst women who participated in both screening rounds should be compared by the 
test type used in the first round. Additionally, the first opportunity to investigate interval 
cancers will occur following the second screening round. Interval cancers are a proxy for 
lack of sensitivity in the programme, as interval cancers indicate a missed premalignant 
lesion in the prior screening round. Most interval cancers in the Dutch programme are 
diagnosed at or shortly following the next screening round.38 Comparing this indica-
tor by test type will also be important for understanding the performance of each test 
within the programme.
Vaccinated populations entering the screening programme
In 2023, the first partly-vaccinated cohort of women will enter the Dutch cervical cancer 
screening programme. In the Dutch vaccination programme, two doses of the bivalent 
vaccination are offered to 12/13-year-old girls. Girls who are 15 years and wish to be 
vaccinated are offered three doses. In Scotland, the effect of HPV vaccination on CIN de-
tection has already been observed, with an 88% reduction in CIN 2+ detected in partly 
vaccinated cohorts compared with unvaccinated cohorts.39 There were also herd im-
munity effects observed, although the Scottish vaccination coverage rates were higher 
than observed in the Netherlands. In Sweden, the cumulative incidence of cervical 
cancer amongst young vaccinated women was found to be significantly lower than in 
young unvaccinated women ( Adjusted IRR: 0.37 (95% CI: 0.21–0.57)).40 With similar dras-
tic reductions in disease prevalence expected in the Netherlands as well, the landscape 
for cervical cancer screening and prevention will shift, necessitating a rethink of the 
current screening paradigm. Modelling by Naber and colleagues found that the number 
of lifetime screens that are cost-effective depends on herd immunity rates. In a situation 
in which there is 50% herd immunity or higher, a less intense screening strategy (three 
instead of eight lifetime screens) was optimal.41 Careful consideration needs to be given 
to what the most optimal screening strategy will be in the coming decades, and changes 
should be made to the programme to prevent over-screening where necessary.
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elimination of cervical cancer in the Netherlands
The WHO announced in 2018 that it would draft a global strategy for the elimination of 
cervical cancer in the Netherlands. Elimination of cervical cancer is defined as less than 
four cases per 100,000 women. The WHO strategy covers primary, secondary and tertiary 
prevention strategies (as discussed in Chapter 1), defining the following targets that 
every country must reach by 2030:
• 90%	coverage	of	HPV	vaccination	of	girls;
• 70%	 coverage	 of	 screening	 (70%	 of	 women	 are	 screened	with	 high-performance
tests by the ages of 35 and 45 years) and 90% treatment of precancerous lesions;
• Management	of	90%	of	invasive	cancer	cases.42
In the Netherlands, there is still more work to do to meet these targets for both screen-
ing and vaccination coverage. HPV vaccination coverage in the 2004 cohort was 45.5%,43 
far below the target set of 90% by the WHO. In one large modelling study looking at the 
impact of these strategies in low- and middle-income countries, high HPV vaccination 
coverage was required for elimination over the long-term.44 As such, increasing vaccina-
tion coverage is essential to elimination of cervical cancer in the Netherlands. Increasing 
participation in cervical cancer screening is also important to expediting elimination. 
The current attendance rate (57.6% in 20189) is also lower than the WHO targets, but the 
difference between the target and the attendance rate is narrower than that for HPV vac-
cination coverage. An association between vaccination of daughters and the screening 
behaviour of mothers has been shown in a Dutch cohort, which found that girls’ vac-
cination status was positively associated with the mothers’ screening attendance.45 This 
association can be seen in regional participation rates; the provinces of North Brabant, 
Gelderland and parts of Overijssel and North Limburg have high participation rates in 
both screening and HPV vaccination (Figures 2 and 3).
Many of the factors have been shown to influence participation in the HPV vaccination 
programme in the Netherlands are regionally specific, suggesting that a more tailored, 
regional approach to increasing participation in both programmes may be beneficial. 
One of the main predictors of vaccination uptake is religion and faith. Conservative Prot-
estants often live in specific geographical regions in the Netherlands and tend to refuse 
vaccinations on religious grounds.45 Identifying as religious was found to be a strong 
predictor of declining the HPV vaccination.47 Areas with active anti-HPV vaccination 
groups also had lower rates of vaccine uptake.48 Paradoxically, increased use of local me-
dia by the community health services (in Dutch: gemeenschappelijke gezondheidsdienst 
or GGD) was associated with lower participation rates compared with no media use.48 
Collaboration between GGD’s and local schools and clinicians (GPs or gynaecologists) 
has shown to have a positive influence on participation.48 Just as discussed in Chapter 
3.1, GPs seem to play an important role in both screening and vaccination in the Nether-
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lands, and should continue to be involved in both programmes. Local collaborations to 
build trust and understanding between those eligible for screening and vaccination and 




expectations based on modelling.
•	 HrHPV-based	primary	screening	results	in	higher	CIN	2+	detection	in	round	one	of	
screening, at the expense of more unnecessary referrals.
Figure 2: HPV vaccination coverage, girls in birth cohort 2004, by city council region and province, 2019. Image 
source: Volksgezondsheidenzorg.info.46 Data source: RIVM- Dienst Vaccinvoorziening en Preventieprogramma’s. 
Grey lines denote city council regions, black boundaries denote borders of provinces.
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• Despite	higher	than	expected	hrHPV	positivity	 rates	and	 lower	participation	rates,
the new hrHPV-based screening programme is more cost-effective than the old
cytology-based screening in the Netherlands.
• The	fall	in	the	participation	rate	in	the	new	hrHPV-based	programme	is	partly	due	to
removing self-inviting GPs from the invitation policy.
• The	number	of	unnecessary	referrals	could	be	reduced	by	implementing	HPV16/18
genotyping to the triage algorithm and extending the interval to triage cytology
from six to 12 months.
Figure 3: Participation in the Dutch cervical cancer screening programme by city council region, 2012. Image 
source: Volksgezondsheidenzorg.info. Data source: Regional screening organisation. Colours denotes the at-





gynaecological cancers than women with squamous-cell abnormalities of compa-
rable severity.
•	 Knowledge	of	 the	hrHPV	status	of	a	cytology	slide	may	 lead	to	‘upwards	rating’	of	





be done without adding new technologies to the current programme infrastructure.
•	 The	 possibility	 of	 re-introducing	 the	 use	 of	 self-inviting	 general	 practices	 to	 the	
programme should be investigated.
•	 Further	research	should	be	conducted	to	understand	why	women	do	not	participate	
in the new hrHPV-based screening programme. Findings from these studies should 
be used to inform strategies aimed at increasing participation.
•	 Implementing	a	colposcopy	data	collection	system	should	be	considered.	This	infor-
mation should be linked to the national programme monitoring system to ensure 
complete monitoring of clinical care following referral from screening.
•	 Regular	monitoring	of	harms	of	the	screening	process	should	be	done	by	integrating	
datasets for clinically-reported issues (under- and overtreatment, incidental findings, 
obstetric complications) and implementing a ‘patient experience’ survey programme 
to measure the incidence of self-reported physical and psychological harms follow-
ing screening.
•	 The	 differences	 in	 hrHPV	 positivity	 between	 hrHPV	 self-sampling	 and	 clinician-
collected screening should be investigated, and this information should be used to 
inform any future changes to the implementation of self-sampling in the programme.
•	 Care	should	be	taken	to	implement	changes	to	the	current	programme	one-by-one.	
Changing multiple aspects of the programme at once will make it challenging to 
monitor the programme, as the cause of any changes in outcomes will be more dif-
ficult to clarify.
•	 Short-term	monitoring	and	in-depth	evaluation	should	continue	to	be	made	a	prior-
ity, given the number of key events (second screening round of the new programme, 
extended screening intervals, entry of partly vaccinated cohorts, re-tendering of 
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ParT 1: GeNeral INTrODuCTION
Human papillomavirus (HPV) is a common sexually transmitted infection. The majority 
of sexually active individuals are likely to acquire an HPV infection at some time in their 
lives. There are more than 200 HPV types that infect humans; twelve types (HPV 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are classified as carcinogenic to humans. These types 
are referred to as high-risk HPV (hrHPV). A persistent, transforming hrHPV infection 
can cause changes to the squamous and/or glandular cells of the uterine cervix. These 
changes can lead to cervical intraepithelial neoplasia (CIN), which are premalignant le-
sions of the cervix, or to invasive cervical cancer. HPV 16 and 18 are responsible for the 
majority of cervical cancers, in the range of 70%. 
Prevention strategies for cervical cancer aim to reduce incidence of, and mortality 
from the disease. This thesis focuses on cervical cancer screening in the Netherlands. In 
the Netherlands, organised cervical cancer screening has been implemented for more 
than 30 years. Up until 2017, primary cytology-based screening was conducted. Primary 
hrHPV-based screening has been shown to provide better long-term protection against 
high-grade CIN lesions and be more cost-effective than cytology-based screening. Based 
on this evidence, primary hrHPV-based screening replaced cytology-based screening 
in the Dutch programme in January 2017. Transition to primary hrHPV-based cervical 
cancer screening involved the following changes:
· Use of hrHPV tests as the primary screening test;
· The introduction of hrHPV self-sampling as an available screening modality;
· Cytology triage after hrHPV positive screening;
· Changes to the triage and referral algorithm;
· Reduced number of screening rounds by offering an extended screening interval of 
10 years to women aged 40 and 50 years who are hrHPV negative;
· Consolidation of the screening laboratories from approximately 40 labs to five labs;
· Standardisation of policies and procedures related to invitation.
The studies described in this thesis aimed to evaluate the Dutch cervical cancer screen-
ing programme as a whole (Part 2), as well as each stage of the screening process: 
attendance (Part 3), test and referral (Part 4) and diagnosis and treatment (Part 5).
ParT 2: OVerall SCreeNING PrOCeSS
Following the initial implementation of the primary hrHPV-based programme, it was 
critical to understand if the programme was performing as expected and how the new 
screening programme performed in comparison to the old cytology-based screening 
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programme. In Chapter 2.1, we found that the hrHPV-based screening programme 
resulted in higher screen positivity (9% vs. 5%) and higher direct referral rates (3% vs. 
1%) compared to the old cytology-based programme. CIN2+ detection also increased in 
the hrHPV-based programme from 11 to 14 per 1,000 women screened. However, there 
was also an increase in unnecessary referrals; this difference was due to an increase in 
referrals of women with low-grade cytological abnormalities. In the hrHPV-based pro-
gramme, the hrHPV positivity rate was higher in clinician-collected samples (9.2%) than 
in self-samples (7.6%). Participation in the hrHPV-based programme was significantly 
lower than in the cytology-based programme, despite the availability of self-sampling. 
In Chapter 2.2, we found that the cost-effectiveness of the hrHPV-based screening 
programme is still better than cytology-based screening programme, even when tak-
ing into account the lower-than expected participation rates observed in Chapter 2.1. 
Our results found that hrHPV-based primary screening is estimated to decrease cervical 
cancer mortality (-4%) and incidence (-1%) compared to the old programme. Despite 
an increase in unnecessary referrals (+172%), hrHPV-based screening still resulted in 
more QALY’s gained (+13%) The hrHPV-based programme was more cost-effective than 
cytology-based programme, costing 46% less per QALY gained.
ParT 3: aTTeNDaNCe
Cancer screening programmes can only be effective if a high proportion of people within 
the target population make an informed choice to participate. Short-term monitoring of 
the new hrHPV-based programme found that participation in the new programme was 
lower than the old cytology-based programme. This was unexpected, especially given 
the availability of self-sampling. In Chapter 3.1, we investigated the decline in par-
ticipation further, particularly focusing on whether the decline in participation could be 
explained by personal characteristics of women or by changes to invitation policies. We 
found that attendance rates did vary by personal characteristics of women; women who 
were employed (60.8%), married (62.9%), Dutch (61.2%), in the highest income bracket 
(63.4%), living in households with four persons (65.3%) and women who were invited by 
their GP (69.8%) had the highest attendance rates. However, personal characteristics did 
not explain the decline in attendance rates. By adjusting for the organisation that sent 
the invitation (i.e. the GP or the screening organisation), the differences in attendance 
rates were explained in some screening organisations, indicating that removing self-
inviting GPs from the programme has had some impact on attendance rates.
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ParT 4: TeST aND referral
In the new hrHPV-based screening programme, all cytology slides that are examined by 
cytotechnicians and pathologists are hrHPV positive. Previous research has indicated 
that when the professional reading the slide is aware of the hrHPV positivity of a cytol-
ogy smear, there is an upward bias in the rating of the slide. Whether this was likely 
to happen in the Dutch setting was unknown. Our study, described in Chapter 4.1, 
indicated that the knowledge of hrHPV status has some influence on the rating of cytol-
ogy slides with low-grade abnormalities. HrHPV positive slides were more likely to be 
upgraded over the referral threshold at the second review than hrHPV negative slides. 
If these HPV positive slides, in fact, have no cell abnormalities, then ‘upwards ratings’ 
of slides may further contribute to the increased number of unnecessary referral in the 
new hrHPV-based programme. 
Given the high number of unnecessary referrals from the new hrHPV-based screening 
programme, optimisation of the triage algorithm may be required to minimise potential 
harms from unnecessary referrals. We modelled potential options in Chapter 4.2 to 
study whether HPV genotyping or extending the time to triage cytology would reduce 
unnecessary referrals without increasing cervical cancer incidence and mortality by 
more than 2%. We found that the most effective way to reduce unnecessary referrals 
with the currently available technologies is to implement HPV 16/18 genotyping and 
to increase the interval to repeat testing from six to 12 months. Specifically, we found 
a reduction in unnecessary referrals of 45% by adjusting the conditions for referral to 
‘HPV16+ and ASC-US+’ and ‘HPV18+/HPV other high-risk types+ and HSIL+’, while also 
extending the interval between the cytology negative primary test and the repeat test 
from six to 12 months.
Atypical glandular cells (AGC) are a rare but high-risk cytological abnormality. Evidence 
suggests that women with AGC are at higher risk of cervical and other gynaecological 
cancers. In the old cytology-based programme, depending on the severity of the abnor-
mality, some women with AGC smears were advised to have repeat cytology rather than 
a direct referral. The risk of a cancer diagnosis in these groups has not been investigated 
previously using Dutch data. Results from our study in Chapter 4.3 suggest that women 
who have AGC on cervical cytology are at higher risk of both cervical and other gynae-
cological cancers compared to squamous cell abnormalities of comparable severity. In 
the hrHPV-based screening programme, women with AGC on cervical cytology after a 
positive HPV test are directly referred to gynaecologists. As some cancers indicated by 
an AGC cytology are not related to HPV (e.g. endometrial cancer), the number of AGC 
screens is likely to reduce over time.
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ParT 5: DIaGNOSIS aND TreaTmeNT
Despite the risks associated with overtreatment following cervical screening, there was 
previously little evidence published about adherence to the published CIN treatment 
guidelines. If there were gaps between the guidelines and clinician practice in the old 
screening programme, these could be used to identify areas for potential improvement. 
In Chapter 5.1, we investigated CIN management and treatment following referral from 
the Dutch cervical cancer screening programme, and whether these trends were in 
line with the clinical guidelines. Despite guideline recommendations not to treat, we 
found CIN 1 lesions were treated in just over 25% of cases and approximately 15% of 
CIN 3 lesions were possibly undertreated. Our analysis suggests that there is room for 
improvement with compliance to the practice guidelines. 
ParT 6: GeNeral DISCuSSION
Organised cervical cancer screening programmes need to achieve a careful balance 
between benefits and harms to maximise effectiveness. In Chapter 6.1, we argued 
that harms of cervical cancer screening should be more regularly quantified as part of 
monitoring and evaluation of organised cervical cancer screening. Challenges in quanti-
fying indicators due to difficulties with data collection should be addressed to facilitate 
more comprehensive reporting. In Chapter 6.2, the results of Chapters 2.1 to 5.1 were 
discussed in a broader context. Based on the findings of this thesis, we have drawn eight 
conclusions and put forward eight recommendations:
Conclusions
· The first results of the new hrHPV-based screening programme were consistent with
expectations based on modelling.
· HrHPV-based primary screening results in higher CIN 2+ detection in one round of
screening, at the expense of more unnecessary referrals.
· Despite higher than expected hrHPV positivity rates and lower participation, the new
hrHPV-based screening programme is more cost-effective than the old cytology-
based screening in the Netherlands.
· The fall in the participation rate in the new hrHPV-based programme is partly due to
removing self-inviting GPs from the invitation policy.
· The number of unnecessary referrals could be reduced by implementing HPV16/18
genotyping to the triage algorithm and extending the interval to triage cytology
from six to 12 months.
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· Women with AGC on cervical cytology have a higher risk of both cervical and other 
gynaecological cancers than women with squamous-cell abnormalities of compa-
rable severity.
· Knowledge of the hrHPV status of a cytology slide may lead to ‘upwards rating’ of 
slides, particularly from NILM to ASC-US.
· Following referral from the old cytology-based programme, both over- and under-
treatment occurred.
recommendations
· HPV genotyping should be implemented to reduce unnecessary referrals. This could 
be done without adding new technologies to the current programme infrastructure.
· The possibility of re-introducing the use of self-inviting general practices to the 
programme should be investigated.
· Further research should be conducted to understand why women do not participate 
in the new hrHPV-based screening programme. Findings from these studies should 
be used to inform strategies aimed at increasing participation.
· Implementing a colposcopy data collection system should be considered. This infor-
mation should be linked to the national programme monitoring system to ensure 
complete monitoring of clinical care following referral from screening.
· Regular monitoring of harms of the screening process should be done by integrating 
datasets for clinically-reported issues (under- and overtreatment, incidental findings, 
obstetric complications) and implementing a ‘patient experience’ survey programme 
to measure the incidence of self-reported physical and psychological harms follow-
ing screening.
· The differences in hrHPV positivity between hrHPV self-sampling and clinician-
collected screening should be investigated, and this information should be used to 
inform any future changes to the implementation of self-sampling in the programme.
· Care should be taken to implement changes to the current programme one-by-one. 
Changing multiple aspects of the programme at once will make it challenging to 
monitor the programme, as the cause of any changes in outcomes will be more dif-
ficult to clarify.
· Short-term monitoring and in-depth evaluation should continue to be made a prior-
ity, given the number of key events (second screening round of the new programme, 
extended screening intervals, entry of partly vaccinated cohorts, re-tendering of 






Deel 1: alGemeNe INleIDING
Humaan papillomavirus (HPV) infectie is een veel voorkomende aandoening, die seksu-
eel overdraagbaar is. De meeste seksueel actieve mensen lopen op enig moment in hun 
leven waarschijnlijk een HPV-infectie op. Er zijn meer dan 200 HPV-typen die mensen 
infecterenwaarvan twaalf typen (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) geclas-
sificeerd zijn als kankerverwekkend voor de mens. Deze typen worden hoog-risico HPV 
(hrHPV) genoemd. Een aanhoudende hrHPV-infectie kan veranderingen in de plavei-
sel- en/of glandulaire cellen van de baarmoederhals veroorzaken. Deze veranderingen 
kunnen leiden tot cervicale intra-epitheliale neoplasie (CIN), dit zijn premaligne laesies 
van de baarmoederhals, of tot invasieve baarmoederhalskanker. HPV 16 en 18 zijn 
verantwoordelijk voor de meeste vormen van baarmoederhalskanker, ongeveer 70%.
Preventiestrategieën voor baarmoederhalskanker zijn gericht op het verminderen van 
de incidentie van en de mortaliteit door de ziekte. Dit proefschrift richt zich op screening 
op baarmoederhalskanker in Nederland. In Nederland wordt al meer dan 30 jaar ge-
organiseerde baarmoederhalskankerscreening uitgevoerd. Tot 2017 werd screening 
op basis van cytologie uitgevoerd. Het is aangetoond dat primaire hrHPV-gebaseerde 
screening een betere langdurige bescherming biedt tegen hooggradige CIN-laesies 
en kosteneffectiever is dan screening op basis van cytologie. Daarom heeft primaire 
hrHPV-screening in januari 2017 de cytologie-gebaseerde screening vervangen in het 
Nederlandse bevolkingsonderzoek. De overgang naar primaire hrHPV-gebaseerde 






10 jaar aan te bieden aan vrouwen van 40 en 50 jaar die hrHPV-negatief zijn;
•	 Reductie	in	het	aantal	screeningslaboratoria	van	circa	40	labs	tot	vijf	labs;
•	 Standaardisatie	uitnodigingsbeleid	en	procedures.
De studies beschreven in dit proefschrift hadden tot doel het Nederlandse bevolkings-
onderzoek naar baarmoederhalskanker als geheel te evalueren (deel 2), evenals elke 
fase van het screeningsproces: opkomst (deel 3), test en verwijzing (deel 4) en diagnose 
en behandeling (deel 5).
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Deel 2: alGeHeel SCreeNINGPrOCeS
Na de implementatie van het primaire hrHPV-programma was het van cruciaal belang 
om te begrijpen of het programma presteerde zoals verwacht en hoe het nieuwe 
screeningsprogramma presteerde in vergelijking met het oude op cytologie gebaseerde 
screeningsprogramma. In Hoofdstuk 2.1 ontdekten we dat het hrHPV-gebaseerde 
screeningsprogramma resulteerde in hogere screentest-positiviteit (9% vs. 5%) en 
hogere directe verwijzingspercentages (3% vs. 1%) in vergelijking met het oude op 
cytologie gebaseerde programma. De CIN2+ detectie nam ook toe in het op hrHPV 
gebaseerde programma, van 11 naar 14 per 1.000 gescreende vrouwen. Er was echter 
ook een toename van onnodige verwijzingen; dit verschil was vooral een toename van 
het aantal verwijzingen van vrouwen met laaggradige cytologische afwijkingen. In 
het hrHPV-programma was het hrHPV-positiviteitspercentage hoger voor uitstrijkjes 
(9,2%) dan voor de zelfafnameset (7,6%). De deelname aan het hrHPV-programma was 
significant lager dan aan het cytologie-programma, ondanks de beschikbaarheid van de 
zelfafnameset. In Hoofdstuk 2.2 ontdekten we dat de kosteneffectiviteit van het hrHPV-
gebaseerde screeningprogramma nog steeds beter is dan het op cytologie gebaseerde 
programma, zelfs als we rekening houden met de lager dan verwachte deelnamegraad 
die we in Hoofdstuk 2.1 vonden. Onze resultaten toonden aan dat op hrHPV gebaseerde 
screening naar schatting de sterfte aan baarmoederhalskanker (-4%) en incidentie (-1%) 
verlaagt in vergelijking met het oude programma. Ondanks een toename van onnodige 
verwijzingen (+ 172%), leidde screening op basis van hrHPV nog steeds tot meer QALY’s 
(+ 13%). Het op hrHPV gebaseerde programma was kosteneffectiever dan het op cyto-
logie gebaseerde programma en kostte 46% minder per gewonnen QALY.
Deel 3: OPKOmST
Kankerscreeningsprogramma’s kunnen alleen effectief zijn als een groot deel van de 
mensen binnen de doelgroep een geïnformeerde keuze maakt om deel te nemen. 
Monitoring liet zien dat de deelname in het nieuwe hrHPV-programma lager was dan bij 
het oude op cytologie gebaseerde programma. Dit was onverwacht, zeker gezien de be-
schikbaarheid van zelfafnametests. In Hoofdstuk 3.1 onderzochten we de afname van 
de deelname verder, in het bijzonder of de afname in deelname kan worden verklaard 
door persoonlijke kenmerken van vrouwen of door veranderingen in het uitnodigingsbe-
leid. We ontdekten dat de opkomstpercentages verschilden naargelang de persoonlijke 
kenmerken van vrouwen; vrouwen die werken (60,8% deelname), gehuwd zijn (62,9%), 
Nederlands zijn (61,2%), tot de hoogste inkomensgroep behoren (63,4%), woonachtig 
zijn in huishoudens met vier personen (65,3%) en vrouwen die waren uitgenodigd door 
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hun huisarts (69,8%) hadden de hoogste opkomstpercentages. Persoonlijke kenmerken 
verklaarden echter niet de daling van de opkomstcijfers. Door te corrigeren voor de 
organisatie die de uitnodiging heeft gestuurd (de huisarts of de screeningsorganisatie), 
werden de verschillen in opkomstpercentages bij sommige screeningsorganisaties 
verklaard, wat aangeeft dat het verwijderen van zelfuitnodigende huisartsen uit het 
programma enige impact heeft gehad op de opkomst.
Deel 4: TeST eN VerWIjzING
In het nieuwe hrHPV-gebaseerde screeningsprogramma zijn alle cytologie testen die 
door cytologisch analist en pathologen worden onderzocht hrHPV-positief. Eerder 
onderzoek heeft aangetoond dat wanneer de professional die het cytologie preparaat 
beoordeelt zich bewust is van de hrHPV-positiviteit, deze het preparaat eerder als 
niet-normaal aanduidt. Het was niet bekend of dit in de Nederlandse setting ook zou 
gebeuren. Onze studie, beschreven in Hoofdstuk 4.1, toonde aan dat de kennis van 
de hrHPV-status enige invloed heeft op de beoordeling van cytologie preparaten met 
laaggradige afwijkingen. HrHPV-positieve cytologie preparaten werden bij de tweede 
beoordeling (waarbij de HPV status bekend was) vaker opgewaardeerd boven de ver-
wijzingsdrempel dan hrHPV-negatieve cytologie preparaten. Als deze HPV-positieve 
vrouwen geen baarmoederhalsafwijkingen hebben, kunnen ‘opgewaardeerde beoorde-
lingen’ van testen verder bijdragen aan het toegenomen aantal onnodige verwijzingen 
in het nieuwe op hrHPV gebaseerde programma. 
Gezien het grote aantal onnodige verwijzingen van het nieuwe op hrHPV gebaseerde 
screeningsprogramma, is optimalisatie van het triage-algoritme nodig om mogelijke 
schade door onnodige verwijzingen te minimaliseren. In Hoofdstuk 4.2 hebben we 
mogelijke opties gemodelleerd om te onderzoeken of HPV-genotypering of het ver-
lengen van de tijd tot triage cytologie onnodige verwijzingen zou verminderen zonder 
de incidentie en mortaliteit van baarmoederhalskanker met meer dan 2% te verhogen. 
We ontdekten dat, met de momenteel beschikbare technologieen, is om HPV 16/18 
genotypering te implementeren en het interval voor herhaalde tests te verlengen van 
zes naar twaalf maanden,  de meest effectieve manier om onnodige verwijzingen te 
verminderen. Concreet vonden we een vermindering van onnodige verwijzingen met 
45% door de voorwaarden voor verwijzing naar ‘HPV16 + en ASC-US +’ en ‘HPV18 + / 
HPV andere hoogrisicotypes + en HSIL +’ aan te passen, en tegelijkertijd ook het interval 
tussen de cytologie-negatieve primaire test en de herhalingstest van zes naar twaalf 
maanden te verlengen.
Atypische glandulaire cellen (AGC) zijn een zeldzame maar risicovolle cytologische 
afwijking. Er zijn aanwijzingen dat vrouwen met AGC een hoger risico lopen op 
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baarmoederhalskanker en andere gynaecologische kankers. In het oude op cytologie 
gebaseerde programma kregen sommige vrouwen met AGC-uitstrijkjes, afhankelijk van 
de ernst van de afwijking, het advies om de cytologie-test te herhalen in plaats van 
een directe verwijzing. Het risico op een kankerdiagnose bij deze groepen is niet eerder 
met Nederlandse gegevens onderzocht. Resultaten van onze studie in Hoofdstuk 
4.3 laat zien dat vrouwen met AGC op cervicale cytologie een hoger risico lopen op 
zowel baarmoederhalskanker als andere gynaecologische kankers in vergelijking met 
plaveiselcelafwijkingen van vergelijkbare ernst. In het op hrHPV gebaseerde screenings-
programma worden vrouwen met AGC op cervicale cytologie na een positieve HPV-test 
direct doorverwezen naar gynaecologen. Echter, aangezien sommige kankers die door 
een AGC-cytologie worden aangetoond niet gerelateerd zijn aan HPV (bijv. endome-
trium carcinoom), zal het aantal vrouwen met een AGC uitslag dalen.
Deel 5: DIaGNOSe eN beHaNDelING
Het is belangrijk dat de CIN-behandelrichtlijnen nageleefd worden, om de risico’s van 
overbehandeling na cervicale screening te verminderen. In het verleden was er echter 
weinig bewijs voor het naleven van deze richtlijnen. Als er verschillen zijn tussen de 
richtlijnen en de huidige praktijk van de arts, zouden deze kunnen worden gebruikt 
om te identificeren waar verbeteringen mogelijk zijn. In Hoofdstuk 5.1 onderzochten 
we CIN management en behandeling na verwijzing vanuit het Nederlandse bevolkings-
onderzoek baarmoederhalskanker, en of deze trends overeenkwamen met de klinische 
richtlijnen. Ondanks aanbevelingen om niet te behandelen, vonden we dat CIN 1-laesies 
in iets meer dan 25% van de gevallen werden behandeld en dat ongeveer 15% van de 
CIN 3-laesies niet behandeld werd. Onze analyse suggereert dat er enige ruimte voor 
verbetering is bij het naleven van de praktijkrichtlijnen, wat belangrijk is om de nadelen 
van baarmoederhalskankerscreening te verlagen.
Deel 6: alGemeNe DISCuSSIe
Bij georganiseerde screeningprogramma’s voor baarmoederhalskanker moet een zorg-
vuldige balans worden gevonden tussen voordelen en nadelen om de effectiviteit te 
maximaliseren. In Hoofdstuk 6.1 hebben we beargumenteerd dat de schade van baar-
moederhalskankerscreening regelmatiger moet worden gekwantificeerd als onderdeel 
van monitoring en evaluatie van georganiseerde baarmoederhalskankerscreening. Het 
gebrek aan gegevens moeten worden aangepakt om een beter inzicht in de nadelen 
van screening te verkrijgen. In Hoofdstuk 6.2 worden de resultaten van de Hoofdstuk-
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ken 2.1 t/m 5.1 in een bredere context besproken. Op basis van de bevindingen van dit 
proefschrift trekken we acht conclusies en doen we acht aanbevelingen:
Conclusies
•	 De	eerste	 resultaten	van	het	nieuwe	op	hrHPV	gebaseerde	 screeningsprogramma	
waren in overeenstemming met de verwachtingen op basis van modellen.
•	 Op	hrHPV	gebaseerde	primaire	screening	resulteert	in	hogere	CIN	2+	detectie	in	de	
eerste ronde van screening, ten koste van meer onnodige verwijzingen.
•	 Ondanks	hoger	dan	verwachte	hrHPV-positiviteitspercentages	en	lagere	deelname,	
is het nieuwe op hrHPV gebaseerde screeningsprogramma kosteneffectiever dan de 
oude op cytologie gebaseerde screening in Nederland.
•	 De	daling	van	de	deelname	aan	het	nieuwe	hrHPV-programma	wordt	mede	veroor-
zaakt door het verwijderen van zelfuitnodigende huisartsen uit het uitnodigingsbe-
leid.
•	 Het	 aantal	 onnodige	 verwijzingen	 zou	 kunnen	worden	 verminderd	 door	HPV16	 /	
18-genotypering in het triage-algoritme te implementeren en het interval naar 
triagecytologie te verlengen van zes naar twaalf maanden.
•	 Vrouwen	met	AGC	op	cervicale	cytologie	hebben	een	hoger	risico	op	zowel	cervicale	
als andere gynaecologische kankers dan vrouwen met plaveiselcelafwijkingen van 
vergelijkbare ernst.
•	 Kennis	 van	de	hrHPV-status	 van	 een	 cytologie	preparaat	 kan	 leiden	 tot	 het	 vaker	




· HPV-genotypering moet worden geïmplementeerd om onnodige verwijzingen te 
verminderen. Dit zou kunnen worden gedaan zonder nieuwe technologieën toe te 
voegen aan de huidige programma-infrastructuur.
· De mogelijkheid om het gebruik van huisartsenpraktijken die zelf uitnodigen op-
nieuw in het programma op te nemen, moet worden onderzocht.
· Er moet verder onderzoek worden gedaan om te begrijpen waarom vrouwen niet 
deelnemen aan het nieuwe op hrHPV gebaseerde screeningsprogramma. De bevin-
dingen van deze onderzoeken moeten worden gebruikt om strategieën te ontwik-
kelen die gericht zijn op het vergroten van de deelname.
· Het implementeren van een dataverzamelingssysteem voor colposcopiegegevens 
moet worden overwogen. Deze informatie moet worden gekoppeld aan het monito-
ringsysteem van het nationale programma om volledige monitoring van de klinische 
zorg na doorverwijzing door screening te garanderen.
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· Regelmatige monitoring van de schade van het screeningproces moet worden ge-
daan door datasets voor klinische problemen (onder- en overbehandeling, inciden-
tele bevindingen, obstetrische complicaties) te integreren en een patiëntervaring-
onderzoeksprogramma te implementeren om de incidentie van zelfgerapporteerde
lichamelijke en psychische schade na screening te meten.
· De verschillen in hrHPV-positiviteit tussen de zelfafnameset en het uitstrijkje moeten
worden onderzocht, en deze informatie moet worden gebruikt als input voor toe-
komstige wijzigingen in de implementatie van zelfafname in het programma.
· Wijzigingen in het huidige programma moeten één voor één worden doorgevoerd.
Als meerdere aspecten van het programma tegelijk wijzigen dan wordt het een
uitdaging om het programma te monitoren, omdat de oorzaak van eventuele veran-
deringen in de uitkomsten moeilijker te achterhalen is.
• Monitoring	op	korte	termijn	en	diepgaande	evaluatie	moeten	een	prioriteit	blijven,
gezien het aantal belangrijke gebeurtenissen (tweede screeningsronde van het
nieuwe programma, verlengde screeningsintervallen, deelname van gedeeltelijk
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